Evotec SE (EVO) 20-F12 May 232022 FY Annual report (foreign)Financial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	12 Months Ended
Document and Entity Information - shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-34041
Entity Registrant Name	Evotec SE
Entity Incorporation, State or Country Code	2M
Entity Address, Address Line One	Essener Bogen 7
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Entity Address, Postal Zip Code	22419
Title of 12(b) Security	Ordinary shares, no par value per share*
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	176,952,653
ICFR Auditor Attestation Flag	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Central Index Key	0001412558
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	BDO AG Wirtschaftsprüfungsgesellschaft	BDO AG Wirtschaftsprüfungsgesellschaft	Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft
Auditor Location	Frankfurt am Main, Germany	Frankfurt am Main, Germany	Munich, Germany
Auditor Firm ID	1010	1010	1251
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Dr. Werner Lanthaler
Entity Address, Address Line One	Essener Bogen 7
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Entity Address, Postal Zip Code	22419
City Area Code	49
Local Phone Number	40 560810
American Depositary Shares, each representing one-half of one ordinary share
Document Information [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing one-half of one ordinary share
Trading Symbol	EVO
Security Exchange Name	NASDAQ

Consolidated income statement

Consolidated income statement - EUR (€) € in Thousands	12 Months Ended
Consolidated income statement - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	[1]
Consolidated income statement
Revenues	€ 751,448	€ 618,034	€ 500,924
Costs of revenue	(577,383)	(466,491)	(375,181)
Gross profit	174,065	151,543	125,743
Operating income and (expenses)
Research and development expenses	(76,642)	(72,200)	(63,945)
Selling, general and administrative expenses	(156,190)	(105,445)	(77,205)
Impairment of intangible assets		(683)	(3,244)
Impairment of goodwill	0	0
Other operating income	81,582	73,472	72,175
Other operating expenses	(1,965)	(5,691)	(4,968)
Total operating income and (expenses)	(153,215)	(110,547)	(77,187)
Operating income	20,850	40,996	48,556
Non-operating income (expense)
Interest income	8,336	2,272	1,339
Interest expense	(13,150)	(9,254)	(8,465)
Measurement result from investments	(172,159)	223,791	1,500
Share of the result of associates accounted for using the equity method	(15,964)	(16,570)	(10,434)
Reversal of impairment (impairment) of investments using the equity method	866	(11,863)
Gain from bargain purchase	4,908
Other income from financial assets		24	70
Other expense from financial assets		(198)	(43)
Foreign currency exchange gain (loss), net	13,083	7,843	(6,935)
Other non-operating income	143	84	683
Other non-operating expense	(870)	(145)	(431)
Total non-operating income (expense)	(174,807)	195,984	(22,716)
Income before taxes	(153,957)	236,980	25,840
Current tax expense	(13,976)	(16,404)	(12,065)
Deferred tax income (expense)	(7,722)	(5,066)	(7,497)
Total taxes	(21,698)	(21,470)	(19,562)
Net income (loss)	(175,655)	215,510	6,278
thereof attributable to:
Shareholders of Evotec SE	€ (175,655)	€ 215,510	€ 6,278
Weighted average shares outstanding	176,674,341	166,405,926	153,752,241
Net income per share (basic)	€ (0.99)	€ 1.30	€ 0.04
Net income per share (diluted)	€ (0.99)	€ 1.30	€ 0.04

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Consolidated statement of compr

Consolidated statement of comprehensive income - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated statement of comprehensive income
Net income (loss)	€ (175,655)	€ 215,510	€ 6,278	[1]
Accumulated other comprehensive income
Remeasurement of defined benefit obligation	1,420	664	(580)
Revaluation of investments	(11,729)
Taxes	(357)	7	149
Foreign currency translation	(598)	26,091	(17,655)
Revaluation and disposal of investments	(13,500)	(1,878)	126
Other comprehensive income	(24,764)	24,884	(17,960)
Total comprehensive income	(200,419)	240,394	(11,682)
Shareholders of Evotec SE	€ (200,419)	€ 240,394	€ (11,682)

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Consolidated statement of finan

Consolidated statement of financial position - EUR (€) € in Thousands		Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents		€ 415,155	€ 699,326
Investments		303,334	158,908
Trade accounts receivable		168,653	132,078
Accounts receivable from associated companies and other long-term investments		3,146	2,643
Inventories		29,825	25,793
Current tax receivables		54,422	23,419
Contract assets		30,516	18,614
Other current financial assets		11,494	264
Prepaid expenses and other current assets		57,126	39,895
Total current assets		1,073,671	1,100,940
Non-current assets:
Long-term investments		131,042	268,793
Long-term investments accounted for using the equity method		16,043	13,068
Property, plant, and equipment		650,201	484,597
Intangible assets, excluding goodwill		23,819	30,851
Goodwill		274,819	257,569
Deferred tax assets		10,327	17,359
Non-current tax receivables		70,293	55,966
Other non-current financial assets		3,247	5,148
Other non-current assets		3,785	870
Total non-current assets		1,183,576	1,134,221
Total assets		2,257,247	2,235,161
Current liabilities:
Current loan liabilities		1,556	36,136
Current portion of lease obligations		14,825	14,473
Trade accounts payable		97,277	72,598
Provisions		54,410	39,260
Contract liabilities		122,922	112,061
Deferred income		13,748	14,718
Current income tax payables		8,987	10,596
Other current financial liabilities		7,087	12,115
Other current liabilities		16,894	12,559
Total current liabilities		337,706	324,516
Non-current liabilities:
Non-current loan liabilities		328,295	326,344
Long-term lease obligations		161,998	135,964
Deferred tax liabilities		18,524	17,688
Provisions		16,427	18,021
Contract liabilities		206,136	33,476
Deferred income			1,000
Other non-current financial liabilities		977	467
Total non-current liabilities		732,357	532,960
Stockholders' equity:
Share capital	[1]	176,953	176,608
Additional paid-in capital		1,440,010	1,430,136
Accumulated other comprehensive income		(37,402)	(12,638)
Accumulated deficit		(392,377)	(216,421)
Equity attributable to shareholders of Evotec SE		1,187,184	1,377,685
Total stockholders' equity		1,187,184	1,377,685
Total liabilities and stockholders' equity		€ 2,257,247	€ 2,235,161

[1]176,952,653 and 176,608,195 shares issued outstanding

Consolidated statement of fin_2

Consolidated statement of financial position (Parenthetical) - shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated statement of financial position
Number of shares issued	176,952,653	176,608,195	163,915,000	150,903,000
Number of shares outstanding	176,952,653	176,608,195

Consolidated statement of chang

Consolidated statement of changes in stockholders' equity - EUR (€) € in Thousands	Share capital	Additional paid-in capital	Foreign currency translation	Revaluation reserve	Accumulated deficit	[1]	Stockholders' equity attributable to shareholders of Evotec SE	Total
Beginning balance at Dec. 31, 2019	€ 150,903	€ 786,865	€ (24,127)	€ 4,565	€ (439,593)		€ 478,613	€ 478,613
Beginning balance (Shares) at Dec. 31, 2019	150,902,578							150,903,000
Capital increase	€ 11,478	238,495					249,973	€ 249,973
Capital increase (Shares)	11,478,315							11,478,000
Exercised stock options	€ 1,534	58					1,592	€ 1,592
Exercised stock options (shares)	1,533,848							1,534,000
Stock option plan		5,284					5,284	€ 5,284
Deferred and current tax on future deductible expenses					676		676	676
Other comprehensive income			(17,655)	(305)			(17,960)	(17,960)
Net income (loss) for the period					6,278		6,278	6,278	[2]
Total comprehensive income (loss)			(17,655)	(305)	6,278		(11,682)	(11,682)
Ending balance at Dec. 31, 2020	€ 163,915	1,030,702	(41,782)	4,260	(432,639)		724,456	€ 724,456
Ending balance (Shares) at Dec. 31, 2020	163,914,741							163,915,000
Capital increase	€ 11,497	391,629					403,126	€ 403,126
Capital increase (Shares)	11,497,500							11,497,000
Exercised stock options	€ 1,196						1,196	€ 1,196
Exercised stock options (shares)	1,195,954							1,196,000
Stock option plan		7,805					7,805	€ 7,805
Deferred and current tax on future deductible expenses					708		708	708
Other comprehensive income			26,091	(1,207)			24,884	24,884
Net income (loss) for the period					215,510		215,510	215,510
Total comprehensive income (loss)			26,091	(1,207)	215,510		240,394	240,394
Ending balance at Dec. 31, 2021	€ 176,608	1,430,136	(15,691)	3,053	(216,421)		1,377,685	€ 1,377,685
Ending balance (Shares) at Dec. 31, 2021	176,608,195							176,608,195
Exercised stock options	€ 345						345	€ 345
Exercised stock options (shares)	344,458							345,000
Stock option plan		9,919					9,919	€ 9,919
Transaction costs		(45)					(45)	(45)
Deferred and current tax on future deductible expenses					(301)		(301)	(301)
Other comprehensive income			(598)	(24,166)			(24,764)	(24,764)
Net income (loss) for the period					(175,655)		(175,655)	(175,655)
Total comprehensive income (loss)			(598)	(24,166)	(175,655)		(200,419)	(200,419)
Ending balance at Dec. 31, 2022	€ 176,953	€ 1,440,010	€ (16,289)	€ (21,113)	€ (392,377)		€ 1,187,184	€ 1,187,184
Ending balance (Shares) at Dec. 31, 2022	176,952,653							176,952,653

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”[2]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Consolidated statement of cash

Consolidated statement of cash flows - EUR (€) € in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash flows from operating activities:
Net income (loss)		€ (175,655)	€ 215,510		€ 6,278	[1]
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation of property, plant and equipment		72,677	55,596		42,122	[2]
Amortization of intangible assets		8,982	12,012		13,936	[2]
Depreciation of current assets		1,537	2,791		160	[2]
Impairment of intangible assets			683		3,244	[2]
Stock compensation expense		9,919	7,805		5,285	[2]
Non-cash foreign exchange loss		(9,423)	8,565
Interest income/expense		10,831	9,827		6,269	[2]
Loss on sale of financial assets			198		43	[2]
Gain on sale of financial assets			(24)		(70)	[2]
Share of the result and impairment of investments of associates accounted for using the equity method		15,098	28,433		17,274	[2]
Purchase price adjustments of associates accounted for using the equity method	[2]				(6,839)
Fair value adjustments on long-term investments		172,159	(223,791)		(1,500)	[2]
Gain from bargain purchase		(4,908)
Loss on sale of property, plant and equipment		178	147		50	[2]
Gain on sale of property, plant and equipment			(5)		(51)	[2]
Deferred tax expense (benefit)		7,722	5,066		7,497	[2]
Decrease (increase) in:
Accounts receivables		(38,429)	(48,032)		(4,178)	[2]
Inventories		(4,410)	(11,653)		(3,631)	[2]
Other assets		(81,328)	(28,999)		(25,851)	[2]
Other tax assets		(15,251)	(18,932)		(13,836)	[2]
Increase (decrease) in:
Accounts payable		24,549	31,341		2,165	[2]
Contract liabilities and deferred income		181,736	63,083		(14,618)	[2]
Provisions		13,708	(8,060)		4,879	[2]
Current income taxes payable		29,392	18,850		15,486	[2]
Other liabilities		9,294	121		2,677	[2]
Cash received during the year for:
Interest		3,026	1,106		1,191	[2]
Taxes		12,351	17,644		11,428	[2]
Cash paid during the year for:
Interest		(9,798)	(5,429)		(3,465)	[2]
Taxes		(30,851)	(11,616)		(21,224)	[2]
Net cash provided by operating activities		203,106	122,237		44,721	[2]
Cash flows from investing activities:
Purchase of current investments		(355,817)	(123,696)		(70,932)	[2]
Purchase of investments in affiliated companies net of cash acquired		(20,859)			(10,929)	[2]
Purchase of investments in associated companies and other long-term investments		(58,832)	(20,680)		(22,703)	[2]
Purchase of property, plant and equipment		(181,354)	(118,943)		(99,072)	[2]
Issue of convertible loan		(4,127)	(7,376)		(6,242)	[2]
Payment of subsequent contingent considerations			(410)
Proceeds from sale of current investments		205,166	27,250		54,789	[2]
Net cash used in investing activities		(415,823)	(243,855)		(155,089)	[2]
Cash flows from financing activities:
Proceeds from capital increase		355	403,126		249,972	[2]
Proceeds from option exercise		344	1,196		1,592	[2]
Proceeds from loans			30,791		21,539	[2]
Repayment of lease obligation		(19,046)	(20,665)		(20,174)	[2]
Repayment of loans		(34,067)	(16,018)		(6,520)	[2]
Net cash provided by (used in) financing activities		(52,414)	398,430		246,409	[2]
Net increase (decrease) in cash and cash equivalents		(265,131)	276,812		136,041	[2]
Exchange rate difference		(19,040)	(66)		9,505	[2]
Cash and cash equivalents at beginning of year		699,326	422,580	[2]	277,034	[2]
Cash and cash equivalents at end of the period		415,155	699,326		422,580	[2]
Supplemental schedule of non-cash activities:
Additions to leases		€ 42,716	€ 14,292		€ 68,044	[2]

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”[2]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Business description and basis

Business description and basis of presentation	12 Months Ended
Business description and basis of presentation	Dec. 31, 2022
Business description and basis of presentation
Business description and basis of presentation	(1) Business description and basis of presentation Evotec SE (“Evotec” or the “Company”) is a drug discovery and development company, continuously driving innovative approaches to develop new pharmaceutical products through discovery alliances and development partnerships with leading pharma and biotechnology companies as well as academic institutions, patient advocacy groups and venture capital partners. Evotec SE, located in Hamburg (Essener Bogen 7, 22419 Hamburg), is registered in the Commercial Registry of Hamburg with HRB 156381. Evotec was founded on 8 December 1993 and is listed on Frankfurt Stock Exchange, Segment Prime Standard, under the trading symbol “EVT” as well as on Nasdaq, New York, United States since 8 November 2021 under the trading symbol “EVO”. Evotec SE, being the ultimate parent entity, presents its consolidated financial statements in its functional currency of Euro. All amounts in the notes are shown in thousands of Euros (k€), unless indicated otherwise. The consolidated financial statements of Evotec were prepared under the going concern premises. The Executive Board prepared the consolidated financial statements for fiscal year 2022 on May 10, 2023 and subsequently submitted them to the Supervisory Board for review and approval at its meeting on May 12, 2023. With reference to Section 264 (3) of the German Commercial Code, the subsidiary Evotec International GmbH does not prepare a management report (Section 289 of the German Commercial Code).

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
Summary of significant accounting policies	Dec. 31, 2022
Summary of significant accounting policies
Summary of significant accounting policies	(2) Summary of significant accounting policies The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and its interpretations as issued by the International Accounting Standards Board (IASB), as adopted by the European Union (EU) and additionally as issued by the IASB. The accounting policies below have been applied consistently to all periods presented in the consolidated financial statements and have been applied consistently by all entities except as explained in the Notes “Recent accounting pronouncements, not yet adopted” as well as “Changes in accounting policies” which address changes in accounting policies. - Use of estimates The preparation of the accompanying consolidated financial statements requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities as of the balance sheet date of the financial year as well as income and expenses during the reporting period. Main estimates and assumptions affect the following subjects: – Acquisitions: Assets and liabilities acquired in a business combination are initially accounted for at fair value on the acquisition date. Fair values are determined using a discounted cash flow model which relies on input parameters derived from observable market data. These parameters involve management judgment whenever no comparable market data is available. Significant input parameters used in determining the fair values are the estimated useful life of the assets identified, the long-term business plan as the basis for determining the expected cash flow from these assets and the discount rate applied. – Revenues: Where we have certain fixed-price arrangements with customers, the stage of completion of performance obligations is reviewed by reference to input-based methods, such as hours delivered or full cost incurred (e.g., labor, materials, and other costs) under a contract in relation to expected total hours or total costs needed to fulfil the performance obligation. Revisions made to the estimated stage of completion can result in an adjustment to revenues in the current or future financial periods (see Note 24) and – Impairment testing and fair values: Management has identified the discount rate as well as the growth rate in the terminal value as key assumptions that have the potential to vary and thereby cause the recoverable amount to be lower than the carrying amount. Fair values for long-term investments at the time of acquisition correspond to the acquisition cost. Changes in fair value may occur due to adjusted scientific or financial plans or new financing rounds. (see Note 10, 11, 12, 13, 14 and 15). Other estimates and assumptions were exercised in the following areas: – Earn-out Provisions: Management estimates are made on discounted expected future cash flows. These cash flows are based on the contracts underlying the conditional consideration and the relevant project or business planning. The discount rate considers the risk underlying cash flows (usually weighted average cost of capital of the acquired entity). Additional non-observable input factors include, for example, marketing success probabilities. (see Note 18 and 30), – Measurement of the Share-based payment plans: Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including risk-free interest rates and volatility measures. (see Note 22), – Valuation of deferred tax assets: Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the tax losses can be charged. Management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the expected business performance of the tax subject and respective business plans (see Note 20). – Exercising significant influence on an investee: To determine whether an investor with minority voting rights has significant influence over an investee requires judgement, regarding participation rights in significant financial and operating decisions of these entities (see Note 35d). Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are made prospectively in the period in which the estimates are revised. - Principles of consolidation In the consolidated financial statements of Evotec SE, all domestic and foreign companies which are under its control are included. Evotec controls an entity if it is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are included in the consolidated financial statements from the date on which control is obtained until the date Evotec´s control ceases. If Evotec loses control over a subsidiary, all assets, and liabilities of that subsidiary together with any related non-controlling interests and other equity components are derecognized. Any resulting gain or loss is recognized in the income statement. Any retained interest in the former subsidiary is measured at fair value at the time of loss of control. All intercompany receivables, liabilities and all intercompany revenue, income, expenses and all intragroup profits or losses are eliminated in the consolidation. The financial statements of all to be consolidated subsidiaries are prepared using the same reporting date as the consolidated financial statements (31 December). - Transactions in foreign currency The Group’s consolidated financial statements are presented in euros, which is also the parent company’s functional currency. For each to be consolidated entity the respective functional currency will be determined. ● Subsidiaries The assets and liabilities of foreign subsidiaries with functional currencies other than the Euro are translated into Euro using the respective exchange rates at the end of the reporting period, while the income statements of such subsidiaries are translated using monthly average exchange rates during the period. Gains or losses resulting from translating foreign functional currency financial statements are recognized directly in other comprehensive income and realized on disposal of the subsidiary. ● Associated companies and joint ventures The currency translation of the proportionate equity of joint ventures and associated companies is performed at the respective closing rate of inclusion. The share of the results of associated companies and joint ventures is translated at the average exchange rate and recognized as share of the result of associates accounted for using the equity method, in the statement of comprehensive income. ● Transactions and balances Transactions in foreign currencies are translated in the respective functional currency using the transaction foreign exchange rate. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated into the respective functional currency using the exchange rates at the end of the period. - Financial instruments Recognition of financial instruments Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the financial instrument. Regular way purchase and sales of financial instruments are generally recognized on the settlement date. Derivatives are recognized on the day of trading. Derecognition of financial instruments Financial assets are derecognized if either the payment rights arising from the instrument have expired or substantially all risks and rewards attributable to the instrument have been transferred. Financial liabilities are derecognized if the obligations have expired or have been discharged or cancelled. Measurement of financial assets The initial recognition is measured at fair value. The subsequent measurement depends on the classification of the categories as defined in IFRS 9. Classification is based on two criteria: the Group’s business model for managing assets and whether the instruments’ contractual cash flows represent solely payments of principal and interest on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model. For the financial assets the following applies: Debt instruments are held by Evotec with the intention to collect contractual cash flows (interest and principal) and to sell these debt instruments. Consequently, they are measured at fair value through OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit or loss. Equity instruments are measured at fair value through profit and loss. At Evotec this primarily relates to the long-term investments. All other non-derivative financial assets are measured at amortized cost and therefore according to the effective interest method. Non-derivative financial liabilities For subsequent measurement, non-derivative financial liabilities are measured at amortized cost. Impairment of financial assets Impairment is recognized for all financial assets not held at fair value through profit or loss and contract assets to be recognized in accordance with IFRS 15 using the expected credit loss (ECL) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that Evotec expects to receive. For trade receivables and contract assets, Evotec applies a simplified approach in calculating ECLs. Therefore, Evotec does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. See Notes (5) and (6) for details. Offsetting financial instruments Financials assets and liabilities are only offset, and the net amount presented in the consolidated statement of financial position when, and only when, Evotec has the legal right to offset the amounts and either to settle on a net basis or to realize the asset and settle the liability simultaneously. Derivative financial instruments and hedge accounting Evotec uses foreign currency derivative financial instruments as well as interest swaps to hedge its exposure to foreign exchange risks and interest rate fluctuations. Derivative financial instruments are measured at fair value through P&L. For these economic hedge relationships Evotec does not apply hedge accounting under IFRS 9. Derivatives embedded for financial liabilities in host contracts are accounted for separately if the economic characteristics and risk of the host contract and the embedded derivative are not closely related. In accordance with its treasury policy, the Company does not hold or issue derivative financial instruments for trading purposes. Basis for determining fair values of financial instruments. The following summarizes the significant methods and assumptions used in estimating the fair values of financial instruments. The fair value is determined primarily based on publicly determinable bid prices at the reporting date. For unlisted equity instruments or financial instruments without an active market, fair value is estimated using valuation techniques. Unless otherwise reported, the fair values of financial instruments equal the carrying amounts. - Cash and cash equivalents The Company considers all highly liquid short-term investments with original maturities at the date of acquisition of three months or less to be cash equivalents. - Contract assets A contract asset is the right to a consideration in exchange for goods or services transferred to the customer. If Evotec fulfils its contractual obligations by transferring goods or services to a customer before the customer pays the consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional. - Trade receivables A trade receivable is recognized if an amount of consideration that is unconditional is due from the customer. Appropriate allowances are made for identifiable risks. - Inventories In accordance with IAS 2, inventories are valued at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. Costs consist of purchased component costs and manufacturing costs, which are comprised of direct material and labor costs and systematic allocated costs. Costs are removed from inventories to costs of revenue based on specific identification. - Property, plant, and equipment Property, plant, and equipment is measured at cost less accumulated depreciation and impairment losses. Property, plant, and equipment acquisitions, including leasehold improvements, are recorded at cost. Depreciation of property, plant and equipment is generally calculated using the straight-line method over the estimated useful lives of the assets. Depreciation of leasehold improvements is calculated using the straight-line method over the shorter of the related lease term or the estimated useful life. The useful lives are as follows: Buildings and leasehold improvements 3-30 years Plant, machinery, and equipment 4-15 years Furniture and fixtures 3-15 years The depreciation period is reviewed at each balance sheet date. Differences from previous estimates are accounted for as a change in an accounting estimate in accordance with IAS 8. The costs included in property, plant and equipment related to assets under construction are not depreciated until the assets are placed into service by the Company. Upon sale or retirement, the costs and the related accumulated depreciation are removed from the respective accounts and any gain or loss is included in other operating income and expenses. Maintenance and repairs of property, plant and equipment are expensed as incurred. - Leases Evotec as a lessee Evotec recognizes and measures all leases (excluding short-term leases and leases of low-value assets) using the Right-of-Use model. The Company recognizes liabilities to make lease payments and Right-of-Use assets representing the right to use the underlying assets. i) Right-of-Use assets Evotec recognizes Right-of-Use assets at the commencement date (i.e., the point in time the underlying leased asset is available for use). Right-of-Use assets are measured at cost less any accumulated depreciation and any accumulated impairment losses. The cost of Right-of-Use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-Use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets as follows: Right-of Use assets relating to buildings >1-20 years Right-of Use assets relating to plant and machinery 2-7 years Right-of Use assets relating to motor vehicles 3-4 years If legal ownership of the leased asset transfers to Evotec at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the leased asset. ii) Lease liabilities On the provision date of the lease, Evotec recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or an interest rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, Evotec uses an incremental borrowing rate at the lease commencement date when the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification to the lease, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. iii) Short-term leases and leases of low-value assets Evotec applies the short-term lease recognition exemption to all its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). Evotec also applies the lease of low-value assets recognition exemption to all leases that are considered to be low-value. Lease payments on short-term leases and leases of low-value assets are recognized as expense. - Associates and joint ventures Associates and joint ventures are entities in which Evotec has significant influence over the financial and operating policies. This significant influence is usually exercised through a direct or indirect share of voting power of 20% to 50%. Significant influence can also exist through a direct or indirect share of voting power of less than 20%, indicators are: ● Representation on the board of directors and/or on the supervisory board, ● (Significant) participation in operating policies, including participation in decisions about dividends of the investee, ● Interchange of managerial personnel, ● Material transactions between the entity and its investee, ● Provision of essential technical information. In case one or more of the above-mentioned indicators apply, Evotec verifies if significant influence exists. Associates and joint ventures are accounted for in the consolidated financial statements using the at-equity method and initially measured at cost. After acquisition, Evotec’s share in the associates and joint ventures profit, or loss is included in the consolidated statement of comprehensive income. Unrealized gains and losses from transactions between Evotec and its associates or joint ventures are recognized only to the extent of unrelated investors` interests in the associates and joint ventures. - Intangible assets, excluding goodwill Intangible assets, excluding goodwill, consist of separately identified intangible assets such as developed technologies, customer related intangibles and patents, which were acquired in business combinations, purchased licenses and patents. Intangible assets with definite useful lives are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the assets. The useful lives are as follows: Trademarks 2-10 years Developed technologies 6-18 years Patents and licenses Up to 15 years Developed technologies acquired in business combinations are amortized as soon as the intangible assets start to generate sustainable benefits and tested for impairment at least annually. Intangible assets excluding goodwill with finite useful lives are tested for impairment whenever there is an indication that the asset may be impaired. If the recoverable amount of the asset is less than the carrying amount, an impairment loss is recognized. If the reason for a previously recognized impairment loss no longer exists, the impairment loss is reversed and the carrying amount of the asset is increased to its amortized cost. Impairment losses are recognized in the income statement as other operating expenses and reversals of impairment losses as other operating income. The amortization period is reviewed at each balance sheet date. - Goodwill Goodwill recognized in a business combination according to the acquisition method is recognized as an asset. If the net assets acquired exceed the fair value of the consideration transferred, the income from bargain purchase is recognized in the consolidated income statement following a reassessment. - Impairment of non-financial non-current assets and goodwill The Company reviews non-financial non-current assets (property, plant and equipment and intangible assets including goodwill) for impairment, in the respect to the recoverable amount in accordance with IAS 36. An impairment review is performed at least annually for intangible assets with indefinite useful lives, intangible assets not yet available for use and goodwill, or whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. In line with the Company’s policy concerning the impairment of intangible assets with indefinite useful lives and goodwill, the Company carried out an impairment test in the fourth quarter of 2022 and 2021 based on 30 September balance sheet information, see Note (13) and (14). An impairment loss is recognized if the carrying amount of an asset (or a group of assets when considering a cash-generating unit) exceeds its recoverable amount, which is the higher of its fair value less costs to sell or value in use. The value in use for an asset or cash-generating unit, which is used by Evotec for the impairment testing of non-financial non-current assets and goodwill, is calculated by estimating the net present value of future cash flows arising from that asset or cash-generating unit. The discount rate used to calculate the value in use is determined to reflect the risks inherent for each asset or cash-generating unit. The evaluation of the further use is based on a mid-range or where applicable long-range forecast. Management judgment is necessary to estimate discounted future cash flows. Any impairment loss is reported as a separate component of other operating expenses in the consolidated income statement. An impairment of property, plant and equipment and intangible assets excluding goodwill is again reversed if there has been a change in the estimates used to determine the recoverable amount leading to an increase in value for a previously impaired asset or group of assets as one cash-generating unit. It is reversed only to the extent that the assets or the group of assets carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been previously recognized. Impairments of goodwill are not reversed. - Provisions Provisions are recognized when the Company has a present obligation because of a past event which will result in a probable outflow that can be reliably estimated. The amount recognized represents the best estimate of the settlement amount of the present obligation as of the balance sheet date. Non-current provisions are discounted applying a risk adjusted market interest rate. A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from such a contract are lower than the unavoidable expenses of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected expenses of terminating the contract and the expected net expense of continuing with the contract. Before a provision is established, Evotec recognizes any impairment expense on the assets associated with that contract. - Pension and similar obligations The Company’s net obligation for defined benefit and other postretirement benefit plans have been calculated using the projected unit credit method. The calculation is based on actuarial expertise considering the relevant biometric factors. Actuarial gains and losses are recognized in other comprehensive income.Service and interest costs for pensions and other postretirement obligations are recognized as an expense in the operating result. The Company’s obligations for contributions to defined contribution plans are recognized as expense in the consolidated income statement. - Contract liabilities A contract liability is the obligation of Evotec to transfer goods or services to a customer for which Evotec has received a consideration (or an amount of consideration is due). If a customer pays the consideration before Evotec transfers goods or services to the customer, a contract liability is recognized when the payment is made, or the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when Evotec fulfils its contractual obligation. Evotec contracts do not include financing components as all up-front consideration received are prepayments on service obligations. - Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of ordinary shares are recognized net of tax as a deduction from equity. The Company applies the regulations of IAS 32 in accounting for treasury shares. When ordinary shares recognized as equity would be reacquired, the amount of the consideration paid for those treasury shares is recognized as a deduction from equity. If treasury shares are subsequently sold or granted, the proceeds will be recognized net of tax as an increase in equity. - Stock options and Share Performance Awards The Company applies the regulations of IFRS 2 with regard to accounting for options granted under its stock option plans and under its Share Performance Plan. All plans are settled in shares and therefore are recorded through equity. Compensation cost from the issuance of employee and Management Board stock options are measured using the fair value method at the grant date and charged straight-line to expense over the service period. This is also the case for the grant of Share Performance Awards to employees and to members of the Management Board. In case the estimates regarding the achievement of the key performance indicators change, the fair value of Share Performance Awards is adjusted as long as if it is not a share price-based indicator. - Revenues from contracts with customers Revenue is recognized when the control over separable services or research services is transferred to the customer, provided that a contract with enforceable rights and obligations exists and that collectability of consideration is probable. The Company assesses collectability based on a number of factors, including past transaction history with the customer and the customer’s creditworthiness. The Company has entered into contracts which can have multiple-elements and thoroughly determined whether the different revenue-generating elements are sufficiently separable and whether there exists sufficient evidence of their fair values to separately account for some or all of the individual elements of the contracts. Only if an element is considered to meet these criteria it does represent a separate unit of accounting. When allocating the transaction price to individual performance components, Evotec uses FTE-rates as indicator of the fair value of these components. Evotec’s revenues include service fees, FTE-based research payments revenue for delivered goods and deliverable kind of services, recharges, technology access fees as well as milestone fees, licenses, and royalties. Service fees, FTE-based research payments as well as deliverable services Revenues generated from service contracts or FTE-based research contracts, or deliverable kind of services are recognized as the services are rendered. Evotec applies an input-based method to measure the progress of completion of its performance obligations. In rare cases and only for specific contracts, output-based methods are applied whenever the contracts warrant such measurement. Payments for those services are generally paid in full or in parts in advance and recorded as contract liabilities. Contract assets are recognized in case Evotec’s progress of completion of its performance obligations exceeds the amount of the payments received. Those contracts may also contain variable compensation, which Evotec only includes in the transaction price when it becomes highly probable that such payments will be received. This is rarely the case upon contract inception or in early stages of contracts, owing to the nature of the services. Technology access fees Revenue from technology access fees is recognized pro rata over the related forecasted service period. Payments for technology access fees are generally paid in full or in parts in advance and recorded as contract liabilities until earned. Milestone fees Revenue contingent upon the achievement of certain milestones is recognized in the period the milestone is successfully achieved or all the performance obligation fulfilled. This occurs when the Company’s contract partner agrees that the requirements stipulated in the agreement have been met. Under IFRS 15, earlier recognition carries an increased risk of revenue corrections required and hence Evotec refrains from an earlier recognition. Licenses Revenue from the sale of licenses is recognized at the date of the sale. Revenue from out-licensing in combination with a collaboration is realized pro rata over the collaboration period. Payments from the sale of licenses are received on the day of the sale or thereafter. Royalties Revenue from royalties, which are dependent on other company’s respective product sales, is recognized in the period in which the royalty report or the payment is received. Payments are received either on the same day as the royalty report or thereafter. Royalties are typically contract components with a variable consideration which will as mentioned above only be realized as revenues when it is highly probable that the consideration will be received. Main estimates and assumptions > Identifying performance obligations, allocating the transaction price, and determining the stage of completion of contracts with service fees, FTE-based research payments as well as deliverable kind of services. Evotec performs research and development (R&D) services for a variety of customers under different contractual arrangements. When performance obligations are individually capable of being distinct and distinct in the context of the contract, Evotec allocates the transaction price to distinct performance obligations based on relative stand-alone selling prices of the obligations. Primarily, contracts for research and development (R&D) services often contain a large amount number of individual services, trigger upfront payments to cover the entire transaction price and are concluded for the overall purpose of identifying new research results partially or fully. The Group has determined that services under such contracts are integrated and qualify as one performance obligation. As far as other distinct services are included in those type of contracts, Evotec allocates the transaction price on the basis of relative stand-alone selling prices of the obligations. Such fixed-price arrangements are recognized over time as the respective performance obligation is fulfilled. Evotec applies an input-based method to measure the progress of completion of its performance obligations such as hours delivered or full cost incurred (e.g., labor, materials, and other costs) under a contract in relation to expected total hours or total costs needed to fulfil the performance obligations. For each contract, Evotec selects the input-based method that most faithfully depicts the transfer of services stated in the contract. In rare cases and only for specific contracts, output-based methods are applied whenever the contract warrants such measurement. > Determining the method to estimate variable compensation and assessing the constraint. Customer contracts often contain success-based variable compensation for research services and other contingent payments. The contingency often relates to few and specific research services, which is why Evotec determines the most likely amount payable under the contract. In addition, Evotec assesses whether a constraint exists in reference

Segment information

Segment information	12 Months Ended
Segment information	Dec. 31, 2022
Segment information
Segment information	(3) Segment information EVT Execute and EVT Innovate were identified by the Management Board as operating segments. EVT Execute includes mainly fee-for-service and FTE-rate arrangements where our customers own the intellectual property, whereas EVT Innovate comprises of internal R&D activities as well as services and partnerships that originate from these R&D activities where we typically own or co-own intellectual property with our strategic partners. The responsibility for EVT Execute was allocated to the COO, Dr. Craig Johnstone, while the responsibility for EVT Innovate was allocated to the Chief Scientific Officer (CSO), Dr. Cord Dohrmann. Management does not allocate assets and liabilities to segments. The assessment of the individual operating segments is based on revenues and adjusted EBITDA. Intersegment revenues are valued on an arms-length principle. Adjusted EBITDA is calculated excluding non-operating income (expenses) and excluding the adjustments shown in the reconciliation below. Expenses and income below operating profit are not included in the segment result. Management had previously excluded recharges from the segments; however, in 2021, management changed its presentation of segment information to include recharges in the segments and the amounts of segment revenues and costs of revenues below were restated accordingly. As a result, revenues from recharges, previously shown in the column “Transition” and not allocated to the segments, are allocated to the segments EVT Execute and EVT Innovate in 2020. The segment information for the financial year 2022 is as follows: EVT EVT Intersegment Evotec in k€ Execute 1) Innovate eliminations Group Revenues 735,635 204,730 (188,917) 751,448 Operating income (loss) 32,523 (11,673) — 20,850 1) The segment information for the financial year 2021 is as follows: EVT EVT Intersegment Evotec in k€ Execute 1) Innovate eliminations Group Revenues 610,168 146,982 (139,116) 618,034 Operating income (loss) 63,109 (22,113) — 40,996 1) The segment information for the financial year 2020 is as follows: EVT EVT Intersegment Evotec in k€ Execute 1) Innovate eliminations Group Revenues 509,870 106,830 (115,776) 500,924 Operating income (loss) 77,362 (28,806) — 48,556 1) Non-current assets categorized by the location of the companies as of 31 December can be analyzed as follows: Non-current Assets 2022 2021 k€ k€ United States 231,439 209,508 United Kingdom 211,115 196,543 Italy 227,113 188,858 France 205,749 129,178 Germany 160,970 105,283 Switzerland — 14,089 Austria 3,914 2,697 Canada 1,906 1,913 1,042,206 848,069

Acquisitions

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2022
Acquisitions
Acquisitions	(4) Acquisitions Effective 1 July 2022, Evotec acquired 100% of the shares in Rigenerand Srl. in Medolla, Italy. The acquired company operates a certified facility integrating state-of-the-art cGMP manufacturing with R&D, QC and development laboratories. The entity will continue operation under the name Evotec (Modena) Srl. with this acquisition, Evotec is able to expand its cell therapy platform EVOcells with its own high-quality cGMP manufacturing facility. The purchase price for the shares was k€ 23,000 in cash, increased by an unlimited earn-out as contingent consideration. The contingent consideration is based on a share of net revenues for a cell-based gene therapy product acquired as part of the acquisition (see below). At the time of acquisition, the earn-out was determined based on the discounted expected future cash flows, weighted by the probability that the respective payments will have to be made, in the amount of k€ 14. As of 31 December 2022, the earn-out provision amounts to k€ 14. The underlying developed technology (cell-based gene therapy product) was recognized at a fair value of k€ 120 on the basis of a risk-adjusted discounted cash flow model, adjusting the previous capitalization at cost. Two further developed technologies were adjusted to a fair value of k€ 0, taking into account the expected future economic potential. The fair value of the other assets and liabilities was determined on the basis of the net carrying amounts at the acquisition date. The preliminary purchase price allocation resulted in goodwill of k€ 19,622, which is allocated to the Execute segment and the cash-generating unit Aptuit Execute. The main drivers of the goodwill recognized is the ability to have highly qualified employees in combination with a cGMP-certified cell therapy production facility available in a short period of time to meet the needs of internal and external customers. Evotec’s income statement for the fiscal year 2022 includes a profit of k€ 159 and revenues of k€ 1,715 from the acquisition of Rigenerand. On a pro forma base, Evotec would have recognized revenues of k€ 1,781 and a loss of k€ 889. The transaction costs incurred of k€ 773 were recognized as selling, general and administrative expenses in the income statement in 2022. The preliminary purchase price allocation as of 1 July 2022 results in the fair values of Evotec (Modena) Srl. at the acquisition date as shown in the following table: in k€ as of 1 July 2022 Cash and cash equivalents 263 Trade accounts receivables 244 Inventories 29 Property, plant, and equipment 3,809 Intangible assets 727 Deferred tax asset 344 Other assets 374 Trade accounts payable (382) Current liabilities (564) Non-current liabilities (1,009) Other liabilities (370) Other accrued liabilities (73) Net assets acquired 3,392 Goodwill 19,622 Cost of acquisition 23,014 Contingent consideration (14) Cash and cash equivalents acquired (263) Cash outflow on acquisition 22,737 Evotec acquired 100% of the shares in Central Glass Germany GmbH, Halle (Westphalia), Germany, effective as of 1 November 2022. The acquired company has a team of highly skilled chemistry experts and a fully operational EU-cGMP certified manufacturing facility. Central Glass Germany GmbH was renamed to Evotec Drug Substance (Germany) GmbH (“Evotec DS”) and continues to operate under this name. The strategic transaction strengthens Evotec’s clinical and commercial manufacturing capacity and capabilities for small molecule therapeutics. The purchase price for the shares in Central Glass Germany GmbH was € 1 in cash. A performance-based component was not included. In the course of the acquisition Evotec also acquired receivables from an inter-company loan between the seller and Central Glass Germany GmbH. As part of the preliminary purchase price allocation, an order backlog with a negative fair value of k€ (2,200) was identified based on the Multi-Period Excess Earnings Method (MEEM). In addition, a negative fair value adjustment of inventories in the amount of k€ (981) was recognised. For the other assets and liabilities, the fair value was determined on the basis of the net book values at the time of acquisition. The transaction generated a bargain purchase price that was recorded in other operating income. The bargain purchase price of k€ 4,909 was determined taking the intrinsic added value on the Group’s operation compared to the seller’s present obligations if it had to discontinue the current operations. Evotec’s net result for the financial year 2022 includes a loss after tax of k€ 559 and revenues from customer contracts of k€ 2,097 from the acquisition of Central Glass Germany. On a pro forma base, Evotec would have recognised revenues from contracts with customers of k€ 5,396 and a loss of k€ (5,261). Transaction costs of k€ 943 were recognised in the income statement as selling, general and administrative expenses in 2022. The acquisition was allocated to the Aptuit Execute segment.The purchase price allocation results in the acquisition values of Evotec DS at the date of acquisition shown in the table below: in k€ as of 1 November 2022 Cash and cash equivalents 16,099 Trade accounts receivables 1,210 Inventories 2,903 Prepaid expenses 77 Property, plant, and equipment 6,213 Intangible assets 23 Deferred tax asset 725 Trade accounts payable (43) Current provisions (609) Contract liabilities (705) Current tax payables (76) Other payables (7) Non-current provisions (553) Non-current lease liabilities (3,940) Order intake (2,200) Acquired net assets 19,117 Bargain Purchase (4,909) Consideration transferred 14,208 Cash and cash equivalents 16,099 Purchase price for shareholder loan (14,208) Cash outflow on acquisition 1,891 Both acquisitions are still within the initial measurement period as defined within IFRS 3.

Cash, cash equivalents and inve

Cash, cash equivalents and investments	12 Months Ended
Cash, cash equivalents and investments	Dec. 31, 2022
Cash, cash equivalents and investments
Cash, cash equivalents and investments	(5) Cash, cash equivalents and investments Included in investments are corporate bonds, which are reported at fair value. The corporate bonds and similar instruments are classified as measured at fair value through OCI. As of 31 December 2022, unrealized gains in the amount of k€ 12,064 (31 December 2021: gains of k€ 1,448) were recognized in other comprehensive income relating to those assets. While managing liquidity, Evotec is investing in deposits with maturities beyond three months which are also included in investments. These deposits are measured at amortized costs. Based on the expected credit loss, an allowance of k€ 225 has been recognized as of 31 December 2022 (31 December 2021: k€ 239). As of 31 December 2022, k€ 14,458 of the cash balances with credit institutions were restricted (31 December 2021 k€ 7,736).

Trade accounts receivables

Trade accounts receivables	12 Months Ended
Trade accounts receivables	Dec. 31, 2022
Trade accounts receivable
Trade accounts receivables	(6) Trade accounts receivables The Company has assessed the non-payment risk of all trade accounts receivables. The resulting valuation allowance as of 31 December 2022 amounts to k€ 3,223 (31. December 2021:k€ 2,100) and includes a risk provision for specific default risks of trade receivables in the amount of k€ 2,312 (31. December 2021: k€ 1,584) as well as for expected credit risks according to IFRS 9 in the amount of k€ 911 (31 December 2021: k€ 516). The maturities of trade receivables as at 31 December, taking into account risk provisions, are as follows: 31 Dec 31 Dec 2022 2021 k€ k€ Not past due 136,372 95,556 Risk provision not past due — — Past due 1-30 days 24,425 31,222 Risk provision 1-30 days (67) (30) Past due 31-120 days 6,301 5,164 Risk provision 31-120 days (323) (89) More than 120 days 4,778 2,236 Risk provision more than 120 days (2,833) (1,981) Total trade accounts receivables 168,653 132,078 The risk provision for expected credit risks in accordance with IFRS 9 of k€ 911 (31 December 2021: k€ 516) has been determined with estimates. Expected failure rates between 0.078% and 16.758% (31 December 2021: 0.024% and 21.8%) and is included in the allowance.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2022
Inventories
Inventories	(7) Inventories Inventories consist of the following: 31 Dec 31 Dec 2022 2021 k€ k€ Raw materials 27,917 25,043 Work-in-progress 1,908 750 Total inventories 29,825 25,793 The increase in raw materials is mainly due to the acquisition of Evotec DS. Raw materials are mainly consumables, cell culture media and disposables. Allowances on inventories exist at the balance sheet date in the amount of k€ 1,679 (31 December 2021: k€ 595).

Contract assets

Contract assets	12 Months Ended
Contract assets	Dec. 31, 2022
Contract assets.
Contract assets	(8) Contract assets Contract assets consist of assets resulting from customer contracts. As of 31 December 2022, no material risk provision was recorded.

Prepaid expenses and other curr

Prepaid expenses and other current assets	12 Months Ended
Prepaid expenses and other current assets	Dec. 31, 2022
Prepaid expenses and other current assets
Prepaid expenses and other current assets	(9) Prepaid expenses and other current assets Prepaid expenses as of 31 December 2022 mainly relate to prepayments for insurance premiums. The other current assets mainly comprise VAT-related receivables of k€ 19,035 (31 December 2021: k€ 14,943) and positive fair values of forward exchange contracts in the amount of k€ 8,215. 31 Dec 31 Dec 2022 2021 k€ k€ Prepaid expenses 16,948 19,210 Other 40,178 20,685 Total prepaid expenses and other current assets 57,126 39,895

Long-term Investments accounted

Long-term Investments accounted for using the equity method	12 Months Ended
Long-term Investments accounted for using the equity method	Dec. 31, 2022
Long-term Investments accounted for using the equity method
Long-term Investments accounted for using the equity method	(10) Long-term Investments accounted for using the equity method Individually immaterial shares in companies accounted for using the equity method are presented in aggregate, provided that at the balance sheet date the equity book value did not exceed k€ 10,000 or Evotec’s share of earnings in the result were less than k€ 2,000 in the company’s profit or loss. As at the balance sheet date, five investments were classified as significant and eight investments were classified as insignificant. The additions to the significant investments in 2022 are entirely related to financing rounds (capital contributions). The additions to insignificant investments in 2022 amount to k€ 3,754 and include the acquisition of Tucana Biosciences Inc.for k€ 2,504. The following table summarizes the development of the long-term investments during year 2022: Breakpoint Dark Blue Topas Autobahn Therapeutic Curexsys Therapeutics Therapeutics Insignificant in k€ Labs LLC GmbH GmbH Ltd GmbH Investments Total Balance at 1 January 2022 — 2,774 4,212 405 1,497 4,180 13,068 Additions 3,634 — 2,564 7,167 1,821 3,754 18,940 Pro rata net result (2,263) (2,774) (2,809) (3,550) (2,913) (1,656) (15,965) Loss against other current assets — — — — — — — Impairment — — — — — — — Discontinued use of equity method — — — — — — — Net book value 31 December 2022 1,371 — 3,967 4,022 405 6,278 16,043 The following table summarizes the development of the long-term investment during the year 2021: Breakpoint Exscientia NephThera Therapeutics Insignificant in k€ plc 1 GmbH 2) GmbH investments Total Balance at 1 January 2021 21,040 486 1,918 16,266 39,710 Additions — — 3,667 7,244 10,911 Pro rata net result (1,577) (486) (2,811) (11,696) (16,570) Loss against other current assets — — — 977 977 Impairment — — — (2,497) (2,497) Discontinued use of equity method (19,463) 1) — — — (19,463) Net book value 31 December 2021 — — 2,774 10,294 13,068 1) In the first half of 2021, Evotec did not participate in two financing rounds of Exscientia plc (before: Exscientia Ltd.), resulting in Evotec’s shareholding decreasing from 20.32% to 14.84% . In the third quarter of 2021, Exscientia plc was listed for the first time on the NASDAQ and the shareholding further decreased through dilution to 11.70% as of 31 December 2021 through dilution. Consequently, Exscientia plc is no longer accounted for using the equity method but at fair value in accordance with IFRS 9. 2) NephThera GmbH is a joint venture. Further financial information on the significant investments accounted for using the equity method is presented below: Breakpoint Dark Blue Topas Autobahn Therapeutics Curexsys Therapeutics Therapeutics Labs LLC GmbH GmbH Ltd GmbH 2022 k€ k€ k€ k€ k€ Current assets 4,029 7,204 3,409 14,244 6,795 Non-current assets 6 2 484 32 — Current liabilities 672 1,068 302 1,065 843 Non-current liabilities — 143 85 8,208 — Revenues from 1 Jan to 31 Dec — — 15 — — Net result from 1 Jan to 31 Dec (6,144) (11,789) (6,940) 1,025 (9,340) Breakpoint NephThera Therapeutics GmbH GmbH 2021 k€ k€ Current assets 8,013 18,501 Non-current assets 10 2 Current liabilities 525 719 Non-current liabilities — — Revenues from 1 Jan to 31 Dec — — Net result from 1 Jan to 31 Dec (5,769) (8,283)

Other long-term investments

Other long-term investments	12 Months Ended
Other long-term investments	Dec. 31, 2022
Other long-term investments
Other long-term investments	(11) Other long-term investments The development of investments measured at fair value in accordance with IFRS 9 is shown below: 2022 2021 k€ k€ Balance at 1 January 268,793 19,289 Additions 46,137 6,647 Additions due to discontinue use of equity method — 19,463 Adjustments at fair value, affecting net income (172,159) 223,394 Adjustments at fair value, affecting OCI (11,729) — Net book value 31 December 131,042 268,793 Exscientia was previously accounted for using the equity method (please refer to Note 10 for information). Investments are continuously tested for fair value adjustments. Fair value adjustments of k€ 174,729 mainly relate to two financing rounds of Exscientia in which Evotec did not participate as well was the first-time listing of Exscientia.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
Property, plant and equipment	Dec. 31, 2022
Property, plant and equipment.
Property, plant and equipment.	(12) Property, plant, and equipment The development of property, plant, and equipment in 2022 and 2021 is shown in the following tables. The table below also includes the right of use assets (see note 13 Leases) with a net book value of k€ 168,327 as of 31 December 2022 (31. December 2021 k€ 145,038). 2022 k€ Plant, Buildings and machinery leasehold and Furniture Assets under improvements equipment and fixtures construction Total Acquisition and manufacturing costs Amount beginning of the year 378,467 227,611 39,658 40,350 686,086 Foreign currency translation 3,234 839 (62) 883 4,894 Additions 61,673 59,611 11,663 95,618 228,565 Business combination 6,534 3,309 107 94 10,044 Disposals 3,573 3,101 1,243 862 8,779 Reclass 16,727 1,667 1,308 (19,702) — Amount end of the year 463,062 289,936 51,431 116,381 920,810 Depreciation, amortisation, and write-downs Amount beginning of the year 63,379 113,901 24,209 — 201,489 Foreign currency translation (196) (355) (168) — (719) Additions 33,126 30,490 9,061 — 72,677 Disposals 44 1,563 1,231 — 2,838 Reclass 2,194 (2,166) (28) — — Amount end of the year 98,459 140,307 31,843 — 270,609 Net book value Amount beginning of the year 315,088 113,710 15,449 40,350 484,597 Amount end of the year 364,603 149,629 19,588 116,381 650,201 2021 k€ Plant, Buildings and machinery Assets leasehold and Furniture under improvements equipment and fixtures construction Total Acquisition and manufacturing costs Amount beginning of the year 215,055 168,224 27,445 71,155 481,879 Foreign currency translation 9,099 4,576 718 3,362 17,755 Additions 83,535 36,082 7,546 63,653 190,816 Business combination — — — — — Disposals 3,022 443 860 39 4,364 Reclass 73,800 19,172 4,809 (97,781) — Amount end of the year 378,467 227,611 39,658 40,350 686,086 Depreciation, amortisation, and write-downs Amount beginning of the year 40,472 87,048 17,062 — 144,582 Foreign currency translation 1,919 2,628 620 — 5,167 Additions 23,463 24,826 7,307 — 55,596 Disposals 2,552 424 880 — 3,856 Reclass 77 (177) 100 — — Amount end of the year 63,379 113,901 24,209 — 201,489 Net book value Amount beginning of the year 174,583 81,176 10,383 71,155 337,297 Amount end of the year 315,088 113,710 15,449 40,350 484,597 The increase in the net book value of property, plant, and equipment of k€ 165,604 is mainly attributed to new buildings technical equipment, and construction in progress. This is due to the continued construction of the J.POD factory in Toulouse, France (increase of k€ 55,705).

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2022
Leases
Leases	(13) Leases Set out below are the carrying amounts of right-of use assets recognized and the movements during the period: 2022 k€ Right of use Right of Plant, use machinery Furniture Right of use and and Buildings equipment Fixtures Total Acquisition and manufacturing costs Amount beginning of the year 177,602 8,077 997 186,676 Foreign currency translation (919) (17) — (936) Additions 38,393 306 338 39,037 Business combination 3,940 — 22 3,962 Disposals — — — — Reclass 3,718 (3,678) (40) — Amount end of the year 222,734 4,688 1,317 228,739 Depreciation, amortisation, and write-downs Amount beginning of the year 35,722 5,384 532 41,638 Foreign currency translation 8 109 — 117 Additions 17,855 575 229 18,659 Disposals — — — — Reclass 2,194 (2,166) (28) — Amount end of the year 55,779 3,902 733 60,414 Net book value Amount beginning of the year 141,880 2,693 465 145,038 Amount end of the year 166,955 786 584 168,325 2021 k€ Right of use Right of Plant, use machinery Furniture Right of use and and Buildings equipment Fixtures Total Acquisition and manufacturing costs Amount beginning of the year 158,454 8,382 529 167,365 Foreign currency translation 7,442 30 — 7,472 Additions 14,077 — 215 14,292 Business combination — — — — Disposals 2,453 — — 2,453 Reclass 82 (335) 253 — Amount end of the year 177,602 8,077 997 186,676 Depreciation, amortisation, and write-downs Amount beginning of the year 21,169 3,939 147 25,255 Foreign currency translation 2,573 120 24 2,717 Additions 14,160 1,462 207 15,829 Disposals 2,163 — — 2,163 Reclass (17) (137) 154 — Amount end of the year 35,722 5,384 532 41,638 Net book value Amount beginning of the year 137,285 4,443 382 142,110 Amount end of the year 141,880 2,693 465 145,038 Set out below are the carrying amounts of lease liabilities and the movements during the period: 2022 2021 k€ k€ Amount beginning of the year 150,437 145,554 Foreign currency translation (923) 6,691 Additions 38,784 14,292 Business combination 3,962 — Disposals (232) (58) Accretion of interest 3,841 3,728 Payments (19,046) (19,770) Amount end of the year 176,823 150,437 The lease liabilities are due as follows: 31 Dec 22 31 Dec 21 k€ k€ Current portion of lease obligations 14,825 14,473 Long-term lease obligations 161,998 135,964 176,823 150,437 The following amounts are recognised in profit and loss: 2022 2021 2020 k€ k€ k€ Depreciation expense of right-of-use assets 18,659 15,829 16,035 Interest expense on lease liability 3,841 3,728 3,125 Expense relating to short-term leases 476 839 807 Expense relating to leases of low-value assets 50 56 33 Variable lease payments — — — Total amount recognised in profit and loss 23,026 20,452 20,000 The Group’s cash outflows for leases amounted to k€19,046 in 2022 (2021: k€20,665; 2020: k€ 21,014). Future cash outflows for leases that have not yet begun are set out in the explanation “(31) Commitments and contingencies”.

Intangible assets, excluding go

Intangible assets, excluding goodwill	12 Months Ended
Intangible assets, excluding goodwill	Dec. 31, 2022
Intangible assets, excluding goodwill
Intangible assets, excluding goodwill	(14) Intangible assets, excluding goodwill The development of intangible assets in 2022 and 2021 is shown in the following tables. 2022 k€ Patents and Developed Customer Favorable licenses technology related Trademarks Contract Total Acquisition and manufacturing costs Amount beginning of the year 11,211 99,784 69,089 6,539 — 186,623 Foreign currency translation — 34 — — — 34 Additions — 917 — — — 917 Business combination 1,672 — — — — 1,672 Disposals — — — — — — Reclass — — — — — — Amount end of the year 12,883 100,735 69,089 6,539 — 189,246 Depreciation, amortization and write-downs Amount beginning of the year 10,182 92,983 47,391 5,216 — 155,772 Foreign currency translation — (438) 45 — — (393) Additions 1,223 1,559 6,969 297 — 10,048 Disposals — — — — — — Reclass (56) 56 — — — — Impairment — — — — — — Amount end of the year 11,349 94,160 54,405 5,513 — 165,427 Net book value Amount beginning of the year 1,029 6,801 21,698 1,323 — 30,851 Amount end of the year 1,534 6,575 14,684 1,026 — 23,819 2021 k€ Patents and Developed Customer Favorable licenses technology related Trademarks Contract Total Acquisition and manufacturing costs Amount beginning of the year 10,772 98,845 67,647 6,539 62,033 245,836 Foreign currency translation — 939 1,442 — — 2,381 Additions 439 — — — — 439 Business combination — — — — — — Disposals — — — — 62,033 62,033 Reclass — — — — — — Amount end of the year 11,211 99,784 69,089 6,539 — 186,623 Depreciation, amortization and write-downs Amount beginning of the year 10,095 90,272 37,786 4,574 5,073 147,800 Foreign currency translation — 348 691 — — 1,039 Additions 87 1,680 8,914 642 689 12,012 Disposals — — — — 5,762 5,762 Reclass — — — — — — Impairment — 683 — — — 683 Amount end of the year 10,182 92,983 47,391 5,216 — 155,772 Net book value Amount beginning of the year 677 8,573 29,861 1,965 56,960 98,036 Amount end of the year 1,029 6,801 21,698 1,323 — 30,851 Intangible assets excluding goodwill decreased by k€ 7,032 from k€ 30,851 at 31 December 2021 to k€ 23,819 at 31 December 2022. This decrease is mainly due to amortization of the Evotec customer base of k€ 6,969, of which k€ 5,557 relates to the Aptuit customer base. In the financial year 2021 a developed technology in the amount of k€ 683 was impaired.

Goodwill

Goodwill	12 Months Ended
Goodwill	Dec. 31, 2022
Goodwill
Goodwill	(15) Goodwill The Company has tested the cash-generating units for impairment on the annual designated test date in the fourth quarter 2022 based on the net book values as of 30 September 2022. The impairment tests are performed by determining the recoverable amount based on discounted cash flows. The recoverable amount is based either on value in use or fair value less costs to sell in 2022 and 2021. With respect to the development of goodwill please refer to the following detailed schedules. OAI/Evotec OAI/Evotec Evotec International International Aptuit (US) Just Execute Innovate Execute Execute Execute Total k€ k€ k€ k€ k€ k€ 1 January 2022 84,480 9,204 128,845 4,197 30,843 257,569 Business combination — — 19,622 — — 19,622 Disposal — — — — — — Reclass — — — — — — Foreign currency translation (2,257) (40) (2,243) 260 1,908 (2,372) 31 December 2022 82,223 9,164 146,224 4,457 32,751 274,819 The goodwill addition in financial year 2022 to the Aptuit Execute cash-generating unit was a result of the acquisition of Evotec (Modena) Srl, see (Note 4). Foreign currency translation resulted in a decrease of k€ 2,372. OAI/Evotec OAI/Evotec Evotec International International Aptuit (US) Just Execute Innovate Execute Execute Execute Total k€ k€ k€ k€ k€ k€ 1 January 2021 79,816 9,154 126,059 3,874 28,467 247,370 Business combination — — — — — — Disposal — — — — — — Reclass — — — — — — Foreign currency translation 4,664 50 2,786 323 2,376 10,199 31 December 2021 84,480 9,204 128,845 4,197 30,843 257,569 For the cash generating units OAI/Evotec International Execute, OAI/Evotec International Innovate and Evotec (US) Execute, the impairment tests are based on value in use calculations. For the cash generating units Aptuit Execute and Just Execute the fair value less costs to sell method was applied. With the exception of the Just Execute cash-generating unit, the estimated future cash flows are based on a strategic plan of up to five years, extrapolated over a simplified transition period to a total forecast period of ten years and then extrapolated using a perpetual rate. As the J.POD is a new technology and the corresponding estimated cash flows are subject to a higher degree of uncertainty during the expected high growth in the start-up phase, the estimated future cash flows for the Just Execute cash-generating unit are based on an extended detailed planning period of ten years, after which the cash flows are extrapolated using a perpetual annuity. Management has identified the cash flow schedule, the terminal value growth rate, and the discount rate as key assumptions to which the recoverable amount is most sensitive. Management has determined the values for the key assumptions as follows: – The cash flow plan is based on past experience and management’s expectations for the future, taking into account specific expectations regarding customer growth and product performance, volume increases, changes in product mix and specific investments. – The terminal value growth rate is based on the current estimates of long-term inflation in the regions relevant to Evotec’s operations. – The discount rates of the cash-generating units correspond to their weighted average cost of capital before tax, based on capital market data of a peer group. The following tables show the relevant pre-tax discount rate as well as the growth rates used to determine the terminal value in the respective discounted cash flows. Cash-generating units 2022 OAI/Evotec OAI/Evotec Evotec International International (US) Aptuit Just Execute Innovate Execute Execute Execute Denominated in GBP/EUR GBP/EUR USD GBP/EUR USD Pre-tax discount rate 10.15 % 11.93 % 9.32 % 13.12 % 11.71 % Growth rate for terminal value 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % Cash-generating units 2021 OAI/Evotec OAI/Evotec Evotec International International (US) Aptuit Just Execute Innovate Execute Execute Execute Denominated in GBP/EUR GBP/EUR USD GBP/EUR USD Pre-tax discount rate 8.19 % 11.51 % 7.87 % 9.83 % 9.22 % Growth rate for terminal value 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % A sensitivity analysis was performed for all cash-generating units with regard to reasonable changes in the key assumptions used for 2022. The analysis was based on a 10% decrease in future cash flows, a 10% increase in the discount rate or a 1% decrease in the terminal sustainable growth rate. Management concluded that in the event of these changes in key assumptions, no impairment would recorded In 2022 and 2021, the Company did not recognise any impairment losses as a result of the annual impairment tests.

Non-current tax receivables

Non-current tax receivables	12 Months Ended
Non-current tax receivables	Dec. 31, 2022
Non-current tax receivables
Non-current tax receivables	(16) Non-current tax receivables Non-current tax receivables as of 31 December 2022 and 2021 relate mainly to tax refunds from tax development programs in the context of qualifying R&D expenses in France (crédit d’impôt recherche).

Loan liabilities

Loan liabilities	12 Months Ended
Loan liabilities	Dec. 31, 2022
Loan liabilities
Loan liabilities	(17) Loan liabilities Throughout the years 2022 and 2021, Evotec met all covenants under the various loan agreements shown below. All loans are unsecured. 31 December 31 December 2022 2022 2021 2021 Nominal interest Maturity Fair Carrying Fair Carrying Country of lender Currency rate until Value amount Value amount k€ k€ k€ k€ Germany EUR fixed interest rate of 0.9% to 3.8% 2024-2029 198,281 214,671 254,911 249,530 Germany EUR 1.60% 2024-2027 71,846 75,000 78,596 75,000 Germany EUR 1.20% 2029 6,358 6,722 8,014 7,797 Germany EUR 1.40% 2031 19,099 20,367 21,332 20,367 Italy EUR fixed interest rate of 1.3% to 3.05% 2026-2027 1,218 1,257 — — France EUR 0.55% 2025 10,038 10,742 8,559 8,650 306,840 328,759 371,412 361,344 Current loan liabilities as of 31 December 2022 consist of interest liabilities of k€ 1,092 (31 December 2021: k€ 1,136). As of 31 December 2022, Evotec maintained unutilized lines of credit totaling k€ 245,509 (31 December 2021: k€ 99,601). On 29 December 2022, Evotec signed a facility agreement of k€ 150,000 with the European Investment Bank (EIB). As of 31 December 2022, Evotec has not drawn any amount from this facility agreement.

Provisions

Provisions	12 Months Ended
Provisions	Dec. 31, 2022
Provisions.
Provisions	(18) Provisions The current provisions consist of the following: 31 Dec 31 Dec 2022 2021 k€ k€ Other personnel expenses 47,490 33,983 Pensions 1,730 1,478 Other provisions 5,190 3,799 Total current provisions 54,410 39,260 The non-current provisions consist of the following: 31 Dec 31 Dec 2022 2021 k€ k€ Pensions 12,531 12,950 Other personnel expenses 1,209 2,029 Other provisions 2,687 3,042 Total non-current provisions 16,427 18,021 The following table summarizes the development of total provisions recorded during 2022: Business Foreign 31 Dec 1. Jan. 22 combination Consumption Release exchange Additions 2022 k€ k€ k€ k€ k€ k€ k€ Other personnel expenses 36,012 419 23,105 3,374 (2,525) 41,272 48,699 Pensions 14,428 553 1,629 1,404 (12) 2,325 14,261 Other provisions 6,841 287 1,103 3,182 (63) 5,097 7,877 Total 57,281 1,259 25,837 7,960 (2,600) 48,694 70,837 The following table summarizes the development of total provisions recorded during 2021: Business Foreign 31 Dec 1. Jan. 21 combination Consumption Release exchange Additions 2021 k€ k€ k€ k€ k€ k€ k€ Other personnel expenses 37,005 — 33,018 3,644 636 35,033 36,012 Pensions 14,441 — 463 813 — 1,263 14,428 Other provisions 11,133 — 4,760 7,021 655 6,834 6,841 Total 62,579 — 38,241 11,478 1,291 43,130 57,281 The provision for personnel expenses mainly consists of bonus accruals (31 December 2022: k€ 26,704; 31 December 2021: k€ 22,396) and accrued vacation (31 December 2022: k€ 16,637; 31 December 2021: k€ 13,904). The provision for pensions relates mainly to pensions in France (see Note 31). The other provisions mainly consist of provisions to address the risk of a potential divergent interpretation of selected contracts by the tax authorities (31 December 2022: k€ 2,139; 31 December 2021: k€ 2,139). Additionally, earn-out provisions (31 December 2022: k€ 306; 31 December 2021: k€ 1,103) were recorded, audit fees (31 December 2022: k€ 2,111; 31 December 2021: k€ 878) and maintenance fees (31 December 2022: k€ 1,483; 31 December 2021: €k 1,598) were recorded.

Contract liabilities

Contract liabilities	12 Months Ended
Contract liabilities	Dec. 31, 2022
Contract liabilities.
Contract liabilities	(19) Contract liabilities As of December 2022 and December 2021, contract liabilities mainly originate from the upfront payments relating to the customer contracts with BMS in the amount of k€ 235,652 (31 December 2021: k€ 94,988) of which k€ 42,506 (31 December 2021: k€ 62,568) is classified as current contract liabilities.

Income taxes

Income taxes	12 Months Ended
Income taxes	Dec. 31, 2022
Income taxes
Income taxes	(20) Income taxes The financial year ending 31 December 2020 has been adjusted for the effects of the IFRIC agenda decision of April 2021 regarding the benefits to be considered depending on the length of service. The adjustment of the previous year’s values led to an overall decrease in deferred tax assets of k€ 558. See note 2 “Changes in accounting policies”. a) Amounts recognised in consolidated income statement Income tax benefit and expense for the years 2022, 2021 and 2020 comprise the following. 2022 2021 2020 k€ k€ k€ Current taxes: - Current tax expense (14,132) (12,309) (12,804) - Adjustment for prior years 156 (4,095) 739 Total current taxes (13,976) (16,404) (12,065) Deferred taxes: - Tax loss carry forwards (10,862) (5,140) (10,319) - Temporary differences 3,140 74 2,822 Total deferred taxes (7,722) (5,066) (7,497) Total income tax expense) (21,698) (21,470) (19,562) b) Reconciliation of effective tax rate The difference between the actual income tax expense and the result of the net income and the applicable Group tax rate in the reporting year and the previous year is made up as follows: 2022 2021 2020 k€ k€ k€ Income before taxes (153,956) 236,980 25,840 Expected German income tax rate 32.28 % 32.28 % 32.28 % Expected income tax benefit (expense) 49,697 (76,497) (8,341) Non-deductible expenses (59,543) (511) (2,533) Taxable income not recognized in income before tax — — (7,796) R&D tax credits 13,454 6,742 5,983 Tax free income 3,184 71,917 5,485 Permanent differences from GILTI (3,724) (444) (1,401) Tax effects from investments accounted for using the equity method (5,152) (9,300) (2,884) Deviation tax rates to expected tax rate 448 1,815 690 Change in tax rates 636 521 124 Change in recognition of deferred tax assets (19,167) (10,247) (9,317) Non-periodic taxes Current Taxes 156 (4,095) 739 Deferred Taxes (1,348) (570) 203 Other (339) (801) (514) Effective income tax income (expense) (21,698) (21,470) (19,562) Effective income tax rate (14.09 %) 9.06 % 75.70 % The group tax rate includes corporate income tax plus solidarity surcharge of 15.825% and trade tax, which ranges from 10.850% - 16.625% depending on the municipality. The initial public offering of Exscientia plc in the United States resulted in 2021 in a significant increase of the investment which impacts income and is tax free. Taxable income not recognised in income before tax in 2020 was generated from revealing hidden reserves from in-kind contributions of assets. Deferred income tax assets and liabilities calculated with the anticipated tax rates of each entity as of 31 December 2021 and 2020 relate to the following: 01 Jan 2022 Recognized in 31 Dec 2022 Recognized other Foreign Deferred Deferred In comprehensive currency tax tax Net balance profit or loss Income translation Acquisition Net assets liabilities k€ k€ k€ k€ k€ k€ k€ Property, plant, and equipment (4,855) (5,140) — 508 30 (9,457) 1,563 (11,020) Intangible assets (22,348) 2,536 — (130) 296 (19,646) 965 (20,611) Right of use assets (21,979) (6,860) — — — (28,839) — (28,839) Financial assets (3,985) 2,539 — — — (1,446) 453 (1,899) Provisions and deferred income 3,965 5,640 (357) 2 — 9,250 12,759 (3,509) Lease obligations 19,927 5,351 — — — 25,278 25,278 — Other 4,949 (727) — 22 — 4,244 5,778 (1,534) Tax credits 1,034 (199) (633) * 71 — 273 273 — Loss carryforward 22,963 (10,862) — 45 — 12,146 12,146 — Total (329) (7,722) (990) 518 326 (8,197) 59,215 (67,412) Set off of tax — — — — — — (48,888) 48,888 Net (329) (7,722) (990) 518 326 (8,197) 10,327 (18,524) * Recorded in Equity without any impact on other comprehensive income 01 Jan 2021 Recognized in 31 Dec 2021 Recognized other Foreign Deferred Deferred in comprehensive currency tax tax Net balance profit or loss Income translation Net assets liabilities k€ k€ k€ k€ k€ k€ k€ Property, plant, and equipment (2,840) (1,969) — (46) (4,855) 1,528 (6,383) Intangible assets (25,314) 3,296 — (330) (22,348) 468 (22,816) Right of use assets (23,535) 1,556 — — (21,979) — (21,979) Financial assets (316) (3,669) — — (3,985) 401 (4,386) Provisions and deferred income 4,801 (768) 7 (75) 3,965 6,516 (2,551) Lease obligations 23,274 (3,347) — — 19,927 20,297 (370) Other (1,309) 6,245 — 13 4,949 5,254 (305) Tax credits 1,521 (1,270) 708 * 75 1,034 1,034 — Loss carryforward 27,711 (5,140) — 392 22,963 22,963 — Total 3,993 (5,066) 715 29 (329) 58,461 (58,790) Set off of tax — — — — — (41,102) 41,102 Net 3,993 (5,066) 715 29 (329) 17,359 (17,688) * c) Unrecognised deferred tax liabilities Concerning undistributed foreign subsidiaries earnings, temporary differences in the amount of k€ 20,576 were not recognized according to IAS 12.39 (31 December 2021: k€ 12,009) as Evotec controls the timing of such reversal and it is not planned to distribute the foreign subsidiaries earnings. d) Unrecognised deferred tax assets The Company’s deferred tax assets are recorded to the extent it is probable that such tax benefits would be realised in future years. As of 31 December 2021, no additional deferred tax assets on tax loss carryforwards exceeding the recognised deferred tax liabilities, were recognised for two German, one French, one United Kingdom entity, the United States entities as well as the Swiss, Austrian and Indian entity. In the following schedule, tax loss carryforwards, interest carryforwards and tax credits for which no deferred tax assets were recorded are shown. Tax loss carryforwards on different types of income taxes were aggregated into one total amount. 2022 2021 2020 k€ k€ k€ Tax loss carryforwards (not expiring) 474,989 307,682 272,796 Time-limited tax losses - expiring until 2027 (2021: 2026)(2020: 2025) 13,297 21,409 19,259 - expiring from 2028 to 2032 (2021: 2027-2031) (2020: 2026-2030) 45,696 38,207 45,409 - expiring after 2032 (2021: 2031)(2020: 2030) 57,662 73,811 43,945 Interest carryforward — — — Tax credits 1,313 1,286 1,119 Total 592,957 442,395 382,528 The table above does not include U.S. tax losses which are subject to s382 restrictions. In addition to unrecognized deferred tax assets from tax loss carryforwards, a net asset position for temporary differences amounting to k€ 11,354 (31 December 2021: k€ 6,346; 31 December 2020: k€ 2,707) was not recognised as there was no sufficient taxable income foreseen.

Other current financial liabili

Other current financial liabilities	12 Months Ended
Other current financial liabilities	Dec. 31, 2022
Other current financial liabilities
Other current financial liabilities	(21) Other current financial liabilities Other current financial liabilities of k€ 7,087 relate to the negative fair value of forward exchange contracts (December 31, 2021: k€ 8,565 derivatives and k€ 3,550 other liabilities).

Stock-based compensation

Stock-based compensation	12 Months Ended
Stock-based compensation	Dec. 31, 2022
Stock-based compensation
Stock-based compensation	(22) Stock-based compensation a) Share Performance Awards In order to continue to incentivise executives in the form of variable compensation components with long-term incentives, in June 2022, June 2020 and June 2017, the Annual General Meeting approved the respective conditional capital required for the so-called Restricted Share Plan 2020 (“RSP 2020”) as well as the so-called Share Performance Plan 2022 (“SPP 2022”) and Share Performance Plan 2017 (“SPP 2017”). Under these plans, Restricted Share Awards (“RSA”) for up to 1,200,000 shares (RSP 2020) and Share Performance Awards (“SPA”) for up to 6,000,000 shares (SPP 2022) and 6,000,000 shares (SPP 2017) of Evotec SE ordinary bearer shares without par value (no-par value shares) may be issued to members of the Management Board and other executives upon maturity. Each RSA grants one subscription right to Evotec SE shares, while each SPA grants up to two subscription rights to Evotec SE shares, each of which in turn entitles the holder to subscribe for one Evotec SE share. SPAs from SPP 2022 and SPP 2017 will be automatically exercised within ten RSAs under RSP 2020 may only be exercised if and to the extent that the performance target is achieved within each of the four consecutive calendar years. This performance target relates to the Company’s adjusted EBITDA. The performance target for each individual tranche of RSAs is set by the Supervisory Board annually at the time of issue. The Restricted Share Plan 2020 is subject to some restrictions with regard to issuance periods and allocation of awards to members of the Executive Board or selected executives. The RSP 2020 is no longer part of the new 2022 compensation system for the Executive Board and no more restricted share awards have been issued for the Executive Board since its effective date on June 22, 2022. The grant value of the Restricted Share Plan 2020 for the Executive Board has been reallocated to the short-term and long-term (“Share Performance Plan 2022”) compensation components. SPAs from SPP 2022 and SPP 2017 can only be exercised if and to the extent that two defined equally weighted performance targets (“Key Performance Indicators”) are achieved within each of the four consecutive calendar years. These performance indicators consist of Evotec’s share price (relevant here is the XETRA price) and the relative total shareholder return, which is derived by comparison with the return of the TecDax index. The performance targets for each individual tranche of the SPAs are set by the Supervisory Board annually at the time of issue. The Share Performance Plan 2022 and the Share Performance Plan 2017 are subject to certain restrictions with regard to issuance periods and allocation of awards to members of the Executive Board or selected executives. A summary of the status of the Share Performance Plans as of 31 December 2022 and 2021 and the changes during the year then ended is presented as follows: 31 December 2022 2022 2021 2021 2020 2020 Share Weighted Share Weighted Share Weighted Performance Average Performance Average Performance Average Awards Exercise Awards Exercise Awards Exercise (SPAs) price (SPAs) price (SPAs) price € per share € per share € per share Outstanding at beginning of the year 1,325,450 1.00 1,570,113 1.00 2,149,562 1.00 SPAs granted 468,706 1.00 608,710 1.00 325,612 1.00 SPAs exercised (209,043) 1.00 (701,278) 1.00 (865,687) 1.00 SPAs forfeited (80,475) 1.00 (152,095) 1.00 (39,374) 1.00 Outstanding at end of the year 1,504,638 1.00 1,325,450 1.00 1,570,113 1.00 Thereof exercisable — 1.00 — 1.00 432,450 1.00 Evotec’s average weighted share price at the exercise day of SPAs in financial year 2022 was € 34.27 (31 December 2021: € 37.97; 31 December 2020: € 24.26). In the financial year 2022, 139,229 Awards (31 December 2021: 160,048 Awards; 31 December 2020: 77,214 Awards) from the total granted 468,706 SPAs (31 December 2021: 608,710 SPA’s; 31 December 2020: 325,612 SPA’s) were given to the members of the Management Board. The SPAs exercised in 2022 correspond to 344,458 shares (31 December 2021: 1,195,954 shares; 31 December 2020: 1,501,254 shares). The fair value of the grant of Share Performance Awards was estimated on the date of grant using a Monte-Carlo-Simulation model with the following assumptions: 27 October 27 May 28 January 2022 2022 2022 Risk-free interest rate in % 2.03 0.57 (0.46) Volatility of Evotec share in % 51.00 45.00 37.00 Volatility of TecDAX index in % — — 17.00 Fluctuation in % 5.00 0.0 – 5.0 0.0 – 5.0 Exercise price in Euro 1.00 1.00 1.00 Share price at grant date in Euro 19.47 25.26 34.90 Market value of TecDAX index at grant date in Euro — — 3,411.87 Fair value according to IFRS 2 at grant date per SPA of the Management Board in Euro — 22.87 31.30 Fair value according to IFRS 2 at grant date per SPA of executives in Euro 18.57 24.29 33.66 22 October 28 May 1 February 2021 2021 2021 Risk-free interest rate in % (0.43) (0.57) (0.78) Volatility of Evotec share in % 35.00 40.00 42.00 Volatility of TecDAX index in % — — 29.00 Fluctuation in % 5.00 0.0 – 5.0 0.0 – 5.0 Exercise price in Euro 1.00 1.00 1.00 Share price at grant date in Euro 44.98 35.49 32.25 Market value of TecDAX index at grant date in Euro — — 3,375.67 Fair value according to IFRS 2 at grant date per SPA of the Management Board in Euro — 33.50 31.34 Fair value according to IFRS 2 at grant date per SPA of executives in Euro 43.96 34.47 36.65 29 October 15 January 2020 2020 Risk-free interest rate in % (0.85) (0.55) Volatility of Evotec share in % 40.0 37.0 Volatility of TecDAX index in % — 18.0 Fluctuation in % 5.00 0.0 – 5.0 Exercise price in Euro 1.00 1.00 Share price at grant date in Euro 22.92 23.39 Market value of TecDAX index at grant date in Euro — 3,099.05 Fair value according to IFRS 2 at grant date per SPA of the Management Board in Euro — 22.69 Fair value according to IFRS 2 at grant date per SPA of executives in Euro 21.89 25.28 The performance measurement period for all grants started on 01 January of the corresponding year. The expected dividend yield is zero. The expected life is 4 years for the vesting periods starting in January, and 5 years for the vesting periods starting in May and October. The base for the expected volatility is the historic volatilities of the year before the grant date. b) Share option plans In the beginning of 2020, there remained a few stock options from the past. A summary of the status of the stock option plans as of 31 December 2020 and the changes during the year then ended is presented as follows: 2020 Weighted 2020 average Options exercise price € per share Outstanding at beginning of the year 32,594 2.79 Options exercised (32,594) 2.79 Options expired — — Options forfeited — — Outstanding at end of the year — — Thereof exercisable — — As of 31 December 2020, no more stock options were outstanding. Evotec’s average share price at the exercise day of share options amounted to € 25.17 in the financial year 2020. The Company recognized current service costs for all Share Performance Awards and Restricted Share Awards totaling to k€ 9,919 in 2022, to k€ 7,805 in 2021 and to k€ 5,285 in 2020, which were recognized as operating expenses in the consolidated income statement. Thereof, k€ 2,791 are related to Share Performance Awards of the Management Board in 2022 (31 December 2021: k€2,002; 31 December 2020: k€ 1,902). In 2022, 2021 and 2020, no current service costs related to stock options were recognized. The expenses relating to accelerated vesting as well as the adjustment of current service costs due to changes in assumptions in the financial year 2022 are included in the amount above.

Stockholders' equity

Stockholders' equity	12 Months Ended
Stockholders' equity	Dec. 31, 2022
Stockholders' equity
Stockholders' equity	(23) Stockholders’ equity The share capital is made up of: 2022 2021 2020 Shares in Shares in Shares in thousands thousands thousands Issued as of 01 January 176,608 163,915 150,903 Capital increase (cash contribution) — 11,497 11,478 Exercise of share purchase rights 345 1,196 1,534 Issued as of 31 December 176,953 176,608 163,915 As of 31 December 2022, 176,952,653 shares of Evotec SE with a nominal values of € 1.00 per share have been issued and are outstanding Evotec SE’s conditional capital as at 31 December 2022 consists of 12,773,576 shares available for the Share Performance Plans and the Stock Option Plans and 29,959,289 shares available for the issuance of non-par value bearer shares to holders or creditors of convertible bonds and/or bonds with warrants, profit participation rights, and/or income bonds or a combination of these instruments. Evotec SE may grant these on the basis of the resolution of the General Meeting held on 22 June 2022. The remaining conditional capital of Evotec as of 31 December 2022 thus amounts to 42,732,865 shares. Pursuant to Section 5 of the Company’s Articles of Association, the Management Board is authorised, with the approval of the Supervisory Board, to increase the Company’s share capital by up to € 35,321,639 by issuing new shares against cash or non-cash contributions on one or more occasions until 21 June 2025. All shares to be issued on this basis shall be subject to the statutory subscription rights of Evotec shareholders. However, the Management Board may, with the approval of the Supervisory Board, exclude the shareholders’ subscription rights for a portion of the shares on one or more occasions under certain well-defined conditions. As of 31 December 2022, Evotec holds 249,915 shares (31 December 2021: 249,915), representing 0.1% (31 December 2021: 0.1%) of Evotec’s total share capital.

Revenues

Revenues	12 Months Ended
Revenues	Dec. 31, 2022
Revenues
Revenues	(24) Revenues The following schedule analyses the revenues Evotec recognized in the financial year 2022: in k€ EVT Execute EVT Innovate Evotec Group Revenues Service fees and FTE-based research payments 498,719 185,268 683,987 Material recharges 38,668 5,768 44,436 Compound access fees 1,464 1,109 2,573 Milestone fees 6,054 12,012 18,066 Licenses 1,813 573 2,386 Total 546,718 204,730 751,448 Timing of revenue recognition At a point in time 44,722 17,780 62,502 Over a period of time 501,996 186,950 688,946 Total 546,718 204,730 751,448 Revenues by region United States 283,755 134,550 418,305 Germany 32,765 26,130 58,895 France 22,546 9,728 32,274 United Kingdom 105,557 9,699 115,256 Rest of the world 102,095 24,623 126,718 Total 546,718 204,730 751,448 The following schedule shows the revenue in the financial year 2021: in k€ EVT Execute EVT Innovate Evotec Group Revenues Service fees and FTE-based research payments 431,184 99,570 530,754 Material recharges 34,104 1,887 35,991 Compound access fees 1,532 43 1,575 Milestone fees 4,232 45,237 49,469 Licenses — 245 245 Total 471,052 146,982 618,034 Timing of revenue recognition At a point in time 38,336 47,124 85,460 Over a period 432,716 99,858 532,574 Total 471,052 146,982 618,034 Revenues by region United States 236,009 101,593 337,602 Germany 24,279 22,573 46,852 France 16,876 13,715 30,591 United Kingdom 98,735 5,905 104,640 Rest of the world 95,153 3,196 98,349 Total 471,052 146,982 618,034 The following schedule shows the revenue in the financial year 2020: in k€ EVT Execute EVT Innovate Evotec Group Revenues Service fees and FTE-based research payments 366,946 93,648 460,594 Material recharges 20,728 1,107 21,835 Compound access fees 1,361 — 1,361 Milestone fees 5,059 12,033 17,092 Licenses — 42 42 Total 394,094 106,830 500,924 Timing of revenue recognition At a certain time 25,787 13,140 38,927 Over a period 368,307 93,690 461,997 Total 394,094 106,830 500,924 Revenues by region United States 189,488 58,360 247,848 Germany 19,529 24,792 44,321 France 21,499 15,561 37,060 United Kingdom 89,258 4,729 93,987 Rest of the world 74,320 3,388 77,708 Total 394,094 106,830 500,924 The revenues are allocated to regions according to the head office of the external customers. The transaction price allocated to the remaining performance obligation (unsatisfied or partially unsatisfied) are as follows: 31 Dec 31 Dec 31 Dec 2022 2021 2020 k€ k€ k€ Within one year 405,710 225,061 377,216 After one year 158,068 67,619 69,328 In the year under review no material revenues were recognized for which the performance obligation was fully or partially fulfilled in prior periods. In the financial year 2022 and 2021, BMS, Evotec’s largest customer, contributed more than 10% of the Group revenues in the EVT Execute and EVT Innovate segments with k€ 138,737 (2021: k€ 98,616, 2020: k€ 62,561). Included in the revenues for EVT Execute are revenues from contribution in the year 2022 in the amount of k€ 10,551 (2021: k€ 8,565, 2020: k€ 4,648).

Research and Development

Research and Development	12 Months Ended
Research and Development	Dec. 31, 2022
Research and Development
Research and Development	(25) Research and Development In 2022, research expenses mainly related to Innovate proprietary R&D projects of k€ 62,100 (31 December 2021: k€ 64,064; 31 December 2020: k€ 55,992) and research activities of Execute reporting segment of k€ 2,345 (31 December 2021: k€ 2,528; 31 December 2020: k€ 3,636). The overheads consist mainly of patent costs and personnel overheads, amounting to k€ 12,198 (31 December 2021: k€ 8,136; 31 December 2020: k€ 9,341). The increase in R&D costs compared to the 2021 and 2020 financial year is mainly due to platform R&D initiatives. Research and Development costs include amortisation of intangible assets and depreciation of property, plant, and equipment of k€ 471 (31 December 2021: k€ 1,042; 31 December 2020: k€ 789).

Selling, general and administra

Selling, general and administrative expenses	12 Months Ended
Selling, general and administrative expenses	Dec. 31, 2022
Selling, general and administrative expenses
Selling, general and administrative expenses	(26) Selling, general and administrative expenses Included in selling, general and administrative expenses in 2022 are expenses for sales and marketing in the amount of k€ 13,491 (2021: k€ 9,422, 2020: k€ 9,503). Other administrative expenses in 2022 amount to k€ 142,699 (2021: k€ 96,023, 2020: k€ 67,356). The increase in administrative costs from 2021 (and 2020) to 2022 is due to higher expenses for the implementation of SOX regulations, increased personnel cost as a result of company growth, and the introduction of a new ERP which includes associated consulting services. Included in selling, general and administrative expenses are amortisation for intangible assets and depreciation for property, plant and equipment of k€ 38,025 (2021: k€ 24,957, 2020: k€ 19,840).

Other operating income

Other operating income	12 Months Ended
Other operating income	Dec. 31, 2022
Other operating income.
Other operating income	(27) Other operating income In 2022 and 2021, and 2020, other operating income mainly relates to refunds from Sanofi relating to the development of portfolios in Lyon and Toulouse (2020 only) amounting to k€ 34,174 (2021: k€ 35,762, 2020: k€ 43,398). Further included are refunds from French CIR (crédit d’impôt recherche) of k€ 25,068 (2021: k€ 22,691, 2020: k€ 19,308) and Italy of k€ 7,342 (2021: k€ 2,784, 2020: k€ 124) as well as similar refunds in United Kingdom from the “R&D Expenditure Credit”(RDEC) in the amount of k€ 7,250 (2021: k€ 6,502, 2020: k€ 4,337). Additionally, 2022 was the first year Evotec received R&D tax refunds from the German government of k€ 3,280 (2021: k€ 0, 2020: k€ 0). These tax refunds from tax development programmes are akin to a government grant and as a result shown as other operating income.

Financial instruments

Financial instruments	12 Months Ended
Financial instruments	Dec. 31, 2022
Financial instruments
Financial instruments	(28) Financial instruments -Financial risk management Evotec is exposed to the following risks arising from financial instruments: – currency risks – interest rate risks – liquidity risks (see Note 29) – capital management risk (see Note 29) – credit risks (see Note 29) – market risks (see Note 29) The Management Board has overall responsibility for the establishment and oversight of the Company’s risk management framework. The Management Board has installed a Group Risk Manager. The Group Risk Manager is responsible for developing and monitoring the overall risk exposure of the Group and to ensure compliance within the Group’s risk management policies. The Group Risk Manager reports regularly to the Management Board on its activities. The Audit Committee of the Supervisory Board oversees how management monitors compliance with the Company’s risk management policies and procedures. Currency risks The Company is exposed to currency risks, if Evotec companies enter into revenues, purchases and borrowings that are denominated in a currency other than the functional currency of the respective Evotec company. The functional currencies of all Evotec companies consist mainly of Euro, U.S. Dollar, and Pound Sterling. The Evotec companies are particularly exposed to currency fluctuations between U.S. Dollar, Pound Sterling, and the Euro in the course of their ordinary business activities. The following table shows the average currency rates as well as the currency rates on 31 December 2022 and 2021 each against the Euro: Average rate 2022 2021 31 December 01 January - 01 January - 31 December 31 December 2022 2021 € € € € USD 0.9496 0.8455 0.9376 0.8829 GBP 1.1727 1.1633 1.1275 1.1901 A strengthening (weakening) of the Euro, the United States Dollar, and the British Pound among themselves and against other currencies, as shown below as of 31 December, would lead to an increase (reduction) in equity and earnings with the amounts mentioned below. This analysis relates to financial instruments held for sale on condition that all other variables remain constant and ignore the impact of purchases and sales. Variance 2022 Variance 2021 Variance 2020 Profit and Profit and Profit and Equity Loss Equity Loss Equity Loss k€ k€ k€ k€ k€ k€ USD (10% strengthening) 31,007 31,007 42,053 42,053 11,321 11,321 USD (10% weakening) (31,007) (31,007) (42,053) (42,053) (11,321) (11,321) GBP (10% strengthening) 3,967 3,967 6,643 6,643 5,702 5,702 GBP (10% weakening) (3,967) (3,967) (6,643) (6,643) (5,702) (5,702) EUR (10% strengthening) 34,974 34,974 48,699 48,699 17,032 17,032 EUR (10% weakening) (34,974) (34,974) (48,699) (48,699) (17,032) (17,032) The Company manages the foreign exchange exposure via natural hedges and selective hedging instruments such as forward currency contracts. The hedging instruments used do not expose the Company to any material additional risk. The objective of these transactions is to reduce the risk of exchange rate fluctuations of the Company’s foreign currency denominated cash flows. Evotec does not enter derivative transactions for trading or speculative purposes. Foreign currency contracts are carried at fair value. Gains and losses from the fair value accounting related to foreign currency derivatives are included in non-operating income and expense and amounted to a net gain of k€ 9,424 in the financial year 2021 (2021: net loss k€ 12,410 2020: net loss of k€ 20). This net gain results mainly from the USD devaluation in autumn 2022. Derived regularly from the summarised quantitative data about the Company’s currency risks, based on the report to the Management Board, the expected future USD cash flows which should be hedged with USD/GBP forward contracts and USD/EUR forward contracts are determined. As of 31 December 2022, cash flows of kUSD 394,039 (31 December 2021: kUSD 344,830, 31 December 2020: kUSD 70,500), thereof kUSD 349,639 against Euro (31 December 2021: kUSD 300,430, 31 December 2020: kUSD 45,000), and kUSD 44,400 (31 December 2021: kUSD 44,400, 31 December 2020: kUSD 25,500) and cash outflows of k€ 8,400 against GBP were hedged. The fair value of cash and cash equivalents, investments, trade accounts receivable and trade accounts payable approximate their carrying values in the consolidated financial statements due to their short-term nature. Financial assets are accounted for at the settlement date. Interest rate risks Due to securities and other cash investments as well as loans, the Company is exposed to interest rate risks in Germany, United Kingdom, and United States. Financial instruments with fixed interest rates are not subject to interest rate risk and therefore are not included in the sensitivity analysis. Financial instruments with variable market interest rates as of 31 December 2022 and 2021 are included in the sensitivity analysis for the period of their existence. If the interest rate had been 100 basis points higher (lower) on 31 December 2022, the effect on income before taxes would have been k€ 3,014 (+1% point) higher and k€ 1,714 (-1% point) lower (31 December 2021: net income k€ 2,570 and k€ 827 higher (lower) respectively, 31 December 2020: net income k€ 415 higher ( lower The fair value of debt varies from the carrying amount if there is a difference between the underlying interest rate to the market interest rate. The fair value is then determined using an appropriate market interest rate. The fair values of the loans and current investments with variable market interest rates as of 31 December 2022 and 2021 would vary by the following amounts: 31 Dec 31 Dec 2022 2021 k€ k€ Variable interest rate +1% point 3,014 2,570 Variable interest rate (1)% point (1,714) (827) The Company is exposed to interest rate risk due to floating rate loans, which is considered immaterial. Evotec regularly uses interest rate swaps to economically hedge the interest rate risks from its borrowings. In June 2019, two interest rate swaps with a notional of k€ 48,250 were agreed to swap portions of the variable interest-bearing tranches of the promissory note against a fixed rate of 0.17% and 0.24%, respectively. In addition, two additional interest rate swaps with a notional of k€ 22,500 each were concluded in 2021 and redeemed in 2022; this resulted in a loss in 2022 of k€ 4,683. Other price risks The Company is not exposed to any price risks associated to their financial instruments.

Risks

Risks	12 Months Ended
Risks	Dec. 31, 2022
Risks
Risks	(29) Risks Liquidity risks Revenue fluctuations, external events and changes in the business environment might negatively impact Evotec’s short- to mid-term profitability and cash reserves. To actively address any related risk, Evotec’s management has defined minimum liquidity levels and prepared a scenario planning to safeguard its cash position. Evotec believes that existing liquidity reserves are sufficient to cope with the cumulative impact of all identified risks. Evotec currently has sufficient liquidity reserves, due to a public placement in the United States in 2021. However, the option of increasing capital is always considered. This additional financing might be required if new opportunities arise in terms of M&A or in-licensing. The Company does not intend to engage in projects unless adequate funding is allocated or secured. Evotec has successfully increased liquidity through market positioning and growth. Given the current business environment with economic and political uncertainties, Evotec assesses the associated liquidity risks still to be low (previous year: low). The general risk of losing a significant amount of cash in cash investments should continuously be mitigated by spreading the investments across several different banks in high-credit quality instruments in full compliance with the Company’s approved investment policy. Evotec monitors its banks and investments on an ongoing basis. Therefore, Evotec assesses the current default risks to be low, remaining unchanged in comparison to the previous year. Currency exchange movements also impact Evotec’s reported liquidity primarily through the translation of liquid assets held in U.S. Dollars or Pound Sterling into Euros. A portion of the funds is held in currencies other than Euro to meet local operating needs. This risk has increased due to extensive political uncertainty and a potentially strong market reaction in the forthcoming months, but was already subject to increasing volatility in previous years. The contractual maturities of financial liabilities, including estimated interest payments as of 31 December 2022 are included in the following tables: 31 Dec 2022 Carrying Contractual Due in Due in More than amount cash flow 1 year 2 - 5 years 5 years k€ k€ k€ k€ k€ Non-derivative financial liabilities Loans (329,851) (345,522) (7,266) (272,749) (65,507) Lease obligations (176,823) (186,894) (19,422) (78,152) (89,320) Contingent consideration (306) (372) (76) (291) (5) Trade accounts payable (97,277) (97,277) (97,277) — — Other financial liabilities (977) (977) (977) — — Total non-derivative financial liabilities (605,234) (631,042) (125,018) (351,192) (154,832) Derivative financial liabilities Interest rate swaps/FX forwards (7,358) (7,358) (6,965) (393) — Total derivative financial liabilities (7,358) (7,358) (6,965) (393) — 31 Dec 2021 Carrying Contractual Due in Due in More than amount cash flow 1 year 2 - 5 years 5 years k€ k€ k€ k€ k€ Non-derivative financial liabilities Loans (362,480) (382,867) (40,467) (253,391) (89,009) Lease obligations (150,437) (175,040) (17,343) (69,396) (88,301) Contingent consideration (1,103) (1,156) (1,156) — — Trade accounts payable (72,598) (72,598) (72,598) — — Other financial liabilities (4,017) (4,017) (4,017) — — Total non-derivative financial liabilities (590,635) (635,678) (135,581) (322,787) (177,310) Derivative financial liabilities Interest rate swaps/FX forwards (9,344) (9,344) (7,423) (1,660) (261) Total derivative financial liabilities (9,344) (9,344) (7,423) (1,660) (261) Capital management risk. Evotec actively manages its funds to primarily ensure liquidity and principal preservation while seeking to maximise returns. Evotec’s cash and short-term investments are located at several different banks. Financial investments are made in liquid, highly diversified investment instruments having at minimum a Standard & Poor’s rating (or equivalent) of at least BBB-. The following table shows the total assets, equity as well as equity ratio and net cash (cash and cash equivalents minus current and non-current loan liabilities and current and non-current finance lease obligations): 31 Dec 31 Dec 2022 2021 k€ k€ Total assets 2,257,247 2,235,161 Equity attributable to the shareholders of Evotec SE 1,187,184 1,377,685 Equity ratio (in )% 52.6 % 61.6 % Net cash (91,518) 186,409 Evotec remains well financed with an equity ratio relating to equity attributable to Evotec’s shareholders of 52.6 % as of 31 December 2022 (31 December 2021: 61.6%) and currently has no necessity to raise capital to maintain its operations in the near to mid-term. However, the option to increase capital must always be considered if new opportunities arise in terms of M&A or in-licensing which require additional financing. Furthermore, the acquisition of anchor investors can be of strategic importance for the company. No minimum capital requirements are stipulated in Evotec’s statutes. The Company has obligations to issue shares out of the conditional capital relating to the exercise of stock options based on miscellaneous stock option plans as well as Share Performance Awards on the basis of Share Performance Plans (see Note 21). Credit risks Credit risk is the risk of financial loss to the Company if a customer fails or partly fails to meet any of its contractual obligations and arises primarily from the receivables from customers, contract assets and investment securities. The maximum exposure to credit risk for trade receivables at the reporting date by geographic region was: 31 Dec 31 Dec 2022 2021 k€ k€ United States 92,034 78,543 France 24,429 17,098 United Kingdom 20,451 12,391 Germany 7,767 6,283 Rest of Europe 13,622 10,363 Rest of the world 10,350 7,400 168,653 132,078 The maximum exposure to credit risk for contract assets on 31 December 2022 equals the net book value in the amount of k€ 30,516 (31 December 2021: k€ 18,614). The Company has exposure to credit risk primarily with respect to its trade accounts receivables. The Company performs ongoing credit evaluations of its customers’ financial condition and maintains an appropriate specific allowance for uncollectible accounts receivable based upon the expected collectability of all accounts receivable. The Company’s accounts receivables are generally unsecured and are not backed by collateral from its customers. As of 31 December 2022, one customer accounted for 22% of trade receivables (31 December 2021: 23%). Concentrations of credit risk with respect to trade accounts receivables are generally limited by several geographically diverse customers and the Company’s monitoring procedures. Market risks The market environment and competitive landscape for licensing and licensed projects or individual drug candidates, in general or for individual treatments might change while engaging in individual projects. Revenues generated under the collaboration agreements are allocated to either the EVT Execute or the EVT Innovate segment depending on the type of contract with Evotec’s customers, the intellectual property right and the project stage. This partnership model, which Evotec believes to be unique, allows the risks of drug discovery to be balanced and spread. Reconciliation of cash flows from financing activities to the changes in financial liabilities Lease Loan liabilities obligations Loan notes k€ k€ k€ As of 1 Jan 2022 362,480 150,437 3 Proceeds from issuance of loans — — — Repayment (34,067) (19,046) — Cashflow from financing activities (34,067) (19,046) — Disposal of finance lease obligation — (232) — Foreign currency translation — (1,120) — Changes in fair value — — — Interest increase 1,438 4,068 — Issue of finance lease obligation — 42,716 — As of 31 Dec 2022 329,851 176,823 3 Lease Loan liabilities obligations Loan notes k€ k€ k€ As of 1 Jan 2021 346,411 145,554 3 Proceeds from issuance of loans 30,791 — — Repayment (16,018) (19,770) — Cashflow from financing activities 14,773 (19,770) — Disposal of finance lease obligation — (58) — Foreign currency translation — 6,691 — Changes in fair value 160 — — Interest increase 1,136 3,728 — Issue of finance lease obligation — 14,292 — As of 31 Dec 2021 362,480 150,437 3

Fair values

Fair values	12 Months Ended
Fair values	Dec. 31, 2022
Fair values
Fair values	(30) Fair values Cash and cash equivalents, trade accounts receivable, contract assets, other current and non-current financial assets, current loan liabilities, current portion of lease obligations, long term lease obligations, trade accounts payable, current contract liabilities, non-current contract liabilities, and other current and non-current financial liabilities are classified as amortized cost and approximate their carrying amounts. Non- current loan liabilities are classified as amortized cost (31 December 2022: T€ 328,295 and 31 December 2021 T€ 326,344) for which the fair value was on 31 December 2022 T€ 306,574 and at 31 December 2021 T€ 336,412 based on level 3 in the fair value hierarchy. The fair values of financial assets and liabilities other than classified at amortized cost, together with the carrying amounts shown in the balance sheet, are as follows: 31 Dec 2022 31 Dec 2021 Classification Carrying Fair Carrying Fair in k€ according to IFRS 9 amount Value amount value Investments Fair value through other comprehensive income 311,899 311,899 158,908 158,908 Long-term investments Fair value through profit and loss 122,477 122,477 268,793 268,793 Assets from derivative financial instruments Fair value through profit and loss 8,215 8,215 0 0 Liabilities from derivative financial instruments Fair value through profit and loss (7,358) (7,358) (9,344) (9,344) Contingent consideration Fair value through profit and loss (306) (306) (1,103) (1,103) 434,927 434,927 417,254 417,254 Unrecognised (gain)/loss — — In determining the fair values on level 2 and 3 the following valuation techniques are used: Financial instruments measured at fair value. The fair value of derivative financial instruments is determined using market-related methods. The valuation model is based on quoted values of similar instruments, the characteristics of which are broadly in line with the instruments to be evaluated. The fair values for contingent consideration are determined using discounted cash flow models. The capital flows used are basically based on the contracts underlying the conditional consideration and the relevant project or business planning. The discount rate considers the risk structure underlying capital flows (usually weighted average cost of capital of the acquired entity). Additional non-observable input factors include, for example, marketing success probabilities. At the time of acquisition of investments, the fair value corresponds to the acquisition costs. Changes in fair value may occur due to scientific or financial plan discrepancies or new financing rounds. These deviations are determined by means of discounted cash flow valuation models . Financial instruments not measured at fair value. For cash and cash equivalents, trade accounts receivables, contract assets, trade accounts payable, contract liabilities, loan liabilities, lease obligations and other current financial assets and liabilities, fair value is determined without the use of significant unobservable inputs, respectively the net book values represent an appropriate approximation of the fair value. Assets and liabilities that are not measured at fair value but whose fair value is expressed. The present value for long-term credit liabilities was calculated using a simplified model using unobservable input factors (discount rate 3.06%) and thus corresponds to the level 3 investigation hierarchy. Hierarchy levels The following table allocates financial assets and financial liabilities to the three levels of the fair value hierarchy as defined in IFRS 13: 31 Dec 2022 in k€ Level 1 Level 2 Level 3 Total Assets at fair value through other comprehensive income 311,899 — — 311,899 Assets at fair value through profit and loss 70,133 8,215 52,344 130,692 Liabilities at fair value through other comprehensive income — — — — Liabilities at fair value through profit and loss — (7,358) (306) (7,664) 31 Dec 2021 in k€ Level 1 Level 2 Level 3 Total Assets at fair value through other comprehensive income 158,908 — — 158,908 Assets at fair value through profit and loss 244,866 — 23,927 268,793 Liabilities at fair value through other comprehensive income — — — — Liabilities at fair value through profit and loss — (9,344) (1,103) (10,447) The levels of the fair value hierarchy and its application to Evotec’s financial assets and financial liabilities are described below: Level 1: Level 2: Level 3: The following tables show the movement of fair values at level 3 for the financial years 2022 and 2021, respectively: Other Contingent in k€ Note investments consideration Balance at 1 Jan 2022 23,927 (1,103) Exchange rate differences — — Addition (11);(18) 25,846 (14) Additions due to discontinuation of the use of equity method — — Consumption — — Reclassification to Liabilities — — Net income/expense effected (11) 2,571 811 Balance on 31 Dec 2022 52,344 (306) Other Contingent in k€ Note investments consideration Balance at 1 Jan 2021 19,289 (6,381) Exchange rate differences — (268) Addition (11);(18) 6,647 — Additions due to discontinuation of the use of equity method — — Consumption — 445 Reclassification to Liabilities — 3,571 Net income/expense effected (11) (2,009) 1,530 Balance on 31 Dec 2021 23,927 (1,103) The effects recognised in the income statement above from the adjustment of the fair values at level 3 were included in the consolidated income statement “Other operating income” and “interest expense”. For the fair value of the level 3 hierarchy, possible alternative assumptions of significant unobservable inputs would have ceteris paribus the following effects as of 31 December 2022 and 2021: 2022 2021 Net result Net result in k€ Increase Decrease Increase Decrease Contingent consideration Discount rate (movement of 1.5 %-points) (7) 7 (11) 11 Commercialization success rate (movement of 10 %-points) — — 109 (109) Long-term investments Discount rate (movement of 1.5 %-points) (8,478) 12,539 (4,118) 6,279 In the financial years 2022 and 2021, no reclasses were made among the individual levels.

Pension plan

Pension plan	12 Months Ended
Pension plan	Dec. 31, 2022
Pension plan
Pension plan	(31) Pension plan Defined contribution pension plans Evotec operates a defined contribution Group Personal Pension Plan (GPPP) in the United Kingdom and makes contributions to employees’ own schemes. The pension charge for the year represents contributions payable by the Company to the fund (and to employees’ own pension schemes) and amounted to k€ 3,346 in 2022 (2021: k€ 4,519). Contributions amounting to k€ 379 (2021: k€ 152) were payable to the fund at the year-end 2022 and are included in provisions. The Company’s contribution rate is employee-specific and is determined by the level of an employee’s contribution and the relevant legislation. Further, Evotec operates defined contribution 401K plans in the United States with the contribution to these plans amounting to k€ 575 during 2022 (2021: k€ 646). Defined benefit pension plans Evotec operates a defined benefit pension plan for employees in France. The calculation of the provision for this pension obligation is based on the projected unit credit method according to IAS 19. In 2022 and 2021, the obligation is based on the following assumptions: 31 Dec 31 Dec 2022 2021 Actuarial interest rate 3.35 % 0.80 % Salary increases 3.00 % 1.90 % Employee turnover 0% - 2.51 % 0% - 1.10 % Retirement age 62 years 62 years Duration 8.7 years 9.2 years For the measurement of the mortality rate, the mortality tables of France according to l’INSEE 2016-2018 were used. The mortality rate is not subject to material sensitivity as the payment is processed at the beginning of the retirement. The sensitivity of the actuarial interest rate and the resulting change of the relating pension provision is shown in the following table. This change would be recognized as actuarial gain or loss in other comprehensive income in equity. For the other assumptions, no material change is expected, as they are based on historical values, which will not change much over a year. 31 Dec 31 Dec in k€ 2022 2021 Actuarial interest rate +0.50 %-points (550) (626) Actuarial interest rate -0.50 %-points 592 676 In Germany, Evotec maintains defined benefit pension plans for a former member of the Management Board of Evotec SE and for the newly acquired Evotec DS. The pension provisions are calculated using the projected unit credit method in accordance with IAS 19. Actuarial reports have been prepared for both companies. For Evotec SE, the calculations are based on assumed pension increases of 2.00% (2021: 1.50%) and a discount rate of 3.51% (2021: 1.06%). For Evotec DS, the projected annual pension increase is 2.00 % and the underlying actuarial interest rate is 3.70 %. The discount rates reflect market conditions. The provisions for both companies amounted to T€ 722 as of 31 December 2022 (31 December 2021: T€ 189 only Evotec SE).The pension provisions developed as follows: 31 Dec 31 Dec in k€ 2022 2021 Pension provision at beginning of the year 14,428 14,441 Addition at acquisition date 553 — Benefit payments from the employer (692) (468) Included in other comprehensive income: Actuarial gains/losses from: Changes in financial assumptions (1,899) (551) Experience adjustments 469 (116) Impact of changes in demographic assumptions 10 3 Included in net income: Current service costs 1,282 1,021 Interest cost 110 98 Pension provision at year-end 14,261 14,428 The pension provisions are mainly unfunded and relate to French Group companies in the amount of k€ 13,539. The expected payments of undiscounted benefits for the financial year 2023 amount to k€ 1,751. Expenses for the statutory retirement obligations are explained in Note (34).

Commitments and contingencies

Commitments and contingencies	12 Months Ended
Commitments and contingencies	Dec. 31, 2022
Commitments and contingencies
Commitments and contingencies	(32) Commitments and contingencies (a) Lease obligations The future minimum lease payments under non-cancellable lease agreements but not yet commenced, are as follows: 31 Dec 31 Dec 2022 2021 k€ k€ Less than one year 1,561 801 Between one and five years 16,373 10,595 More than five years 44,979 46,474 Total 62,913 57,870 In addition, the Company maintains leases which were not recognised in accordance with the exemptions in IFRS 16. These amounts are not material and therefore not presented here. (b) Other commitments and contingencies The future minimum payments associated with miscellaneous long-term commitments total approximately k€ 22,111 and k€ 9,459 on 31 December 2022 and 2021, respectively. The significant portion thereof related to long-term commitments in connection with facility expenses. As of 31 December 2022, the Company has entered into purchase commitments in the amount of k€ 152,289 (31 December 2021: k€ 66,154). The Company has licensed or acquired certain third-party intellectual property for use in its business. Under these agreements, the Company is required to pay milestones, dependent on development progress and/or royalties and milestones dependent on present and future net income or on sublicensing fees received from third parties. The Company also agreed with several third parties on acquiring access to their technology and know-how for use in Evotec’s business activities or within collaborations. Under those agreements, the Company could be required to pay a share of the revenue relating to those technologies and know-how to the respective third parties. The Company is not aware of any material actual or threatened litigation as of 31 December 2022.

Related party transactions

Related party transactions	12 Months Ended
Related party transactions	Dec. 31, 2022
Related party transactions
Related party transactions	(33) Related party transactions Related persons and entities within the meaning of IAS 24 represent for the Group shareholders who (jointly) have a dominant or significant influence, as well as subsidiaries, associates and joint ventures, key management personnel as well as members of the Supervisory Board. Evotec has not entered into any material transactions with any key management personnel or member of the Supervisory Board. The remuneration paid to key personnel is presented in note 34 b) “Management Board”; the remuneration paid to the members of the Supervisory Board is shown in note 34 c) “Supervisory Board”. In addition to the business relationships with the subsidiaries eliminated in the consolidated financial statements by means of full consolidation, mainly business transactions with associated companies and joint ventures exist. The terms and conditions of all transactions were made on terms and conditions that prevail in an arm´s length transaction. The balances from the transactions with related parties are unsecured and are fulfilled by payment or service. In the period under review, the Group has recorded expenses for allowances on outstanding balances in the amount of k€ 1,477 (2021: k€ 8,969). Revenues from Cost of Contracts/ revenue/ Trade accounts Other financial Interest income Interest expense receivables assets Other liabilities 1. Jan-31. Dec 2022 1. Jan-31. Dec 2022 31. Dec 2022 31. Dec 2022 31. Dec 2022 Transactions with k EUR k EUR k EUR k EUR k EUR associated companies and joint ventures 36,677 — 3,146 925 — other related party companies — — — — — Revenues from Cost of Contracts/ revenue/ Trade Interest income Interest expense accounts Other financial 1. Jan- 1. Jan- Receivables assets Other liabilities 31. Dec 2021 31. Dec 2021 31. Dec 2021 31. Dec 2021 31. Dec 2021 Transactions with k EUR k EUR k EUR k EUR k EUR associated companies and joint ventures 28,868 146 2,643 153 — other related party companies — — — — — Revenues from Cost of Contracts/ revenue/ Trade Interest income Interest expense accounts Other financial 1. Jan- 1. Jan- receivables assets Other liabilities 31. Dec 2020 31. Dec 2020 31. Dec 2020 31. Dec 2020 31. Dec 2020 Transactions with k EUR k EUR k EUR k EUR k EUR associated companies and joint ventures 35,450 497 2,984 6,435 5,635 other related party companies 32,961 — 6,492 — — Other liabilities to associates result from capital transactions.

Personnel expenses and cost of

Personnel expenses and cost of material	12 Months Ended
Personnel expenses and cost of material	Dec. 31, 2022
Personnel expenses and cost of material
Personnel expenses and cost of material	(34) Personnel expenses and cost of material The personnel expenses of the Company in 2022 amounted to k€ 388,050 of which k€ 284,452 relate to personnel expenses outside Germany, in the United Kingdom, Italy, Switzerland, France and United States (2021: k€ 319,353 and k€ 240,947 respectively, 2020: k€ 250,082 and k€ 187,677, respectively). Thereof expenses for the statutory retirement insurance amounted to k€ 15,106 of which k€ 9,066 relate to expenses outside Germany in the United Kingdom, Italy, Switzerland, France, and United States (2021: k€ 12,407 and k€7,566 respectively, 2020: k€ 10,065 and k€ 6,292 respectively.) Cost of materials in 2022 amounted to k€ 120,568 thereof k€ 90,901 were cost of materials outside Germany in the United Kingdom, Italy, Switzerland, France, and United States (2021: k€ 107,837 and k€ 83,275 respectively, 2020: k€ 92,827 and k€ 73,064, respectively.)

Other disclosures

Other disclosures	12 Months Ended
Other disclosures	Dec. 31, 2022
Other disclosures
Other disclosures	(35) Other disclosures (a) Consolidated subsidiaries and equity investees Information below shows Evotec’s direct and indirect voting rights in their subsidiaries and other investments. Evotec’s direct and indirect voting rights in dormant companies are not included. 2022 Company’s voting rights % Subsidiaries Aptuit Global LLC, Princeton, United States 100.00 Aptuit (Verona) SRL, Verona, Italy 100.00 Aptuit (Oxford) Ltd., Abingdon, United Kingdom 100.00 Aptuit (Potters Bar) Ltd., Abingdon, United Kingdom 100.00 Cyprotex Discovery Ltd., Manchester, United Kingdom 100.00 Cyprotex Ltd., Manchester, United Kingdom 100.00 Cyprotex US, LLC., Framingham, United States 100.00 Evotec (France) SAS, Toulouse, France 100.00 Evotec ID (Lyon) SAS, Marcy l’Étoile, France 100.00 Evotec (Hamburg) GmbH, Hamburg, Germany 100.00 Evotec GT GmbH, Orth an der Donau, Austria 100.00 Evotec (India) Private Limited, Thane, India* 100.00 Evotec International GmbH, Hamburg, Germany 100.00 Evotec (München) GmbH, Martinsried, Germany 100.00 Evotec (UK) Ltd., Abingdon, United Kingdom 100.00 Evotec (US), Inc., Princeton, United States 100.00 Just-Evotec Biologics, Inc., Seattle, United States 100.00 Just-Evotec Biologics EU SAS, Toulouse, France 100.00 Evotec Drug Substance (Germany), Halle, Germany 100.00 Evotec (Modena) Srl., Medolla, Italy 100.00 2022 Company’s voting rights % Associates and joint ventures Ananke Therapeutics Inc., Boston, United States 20.09 Autobahn Labs, Palo Alto, United States 35.94 Breakpoint Therapeutics GmbH, Hamburg, Germany 34.12 Celmatix Inc., New York, United States 39.09 Curexsys GmbH, Göttingen, Germany 43.44 Dark Blue Therapeutics Ltd., Oxford, United Kingdom 39.11 Eternygen GmbH, Berlin, Germany 24.97 NephThera GmbH, Hamburg, Germany 50.00 Pancella Inc, Toronto, Canada 12.65 Quantro Therapeutics GmbH, Wien, Austria 38.79 Topas Therapeutics GmbH, Hamburg, Germany 22.14 Tucana Biosciences Inc., Boston, United States 26.92 Other Investments Aeovian Pharmaceuticals Inc., San Francisco, United States 3.79 ArgoBio SAS, Paris, France 10.02 Aurobac Therapeutics SAS, Lyon, France 12.50 Blacksmith Medicines Inc., San Diego, United States 18.00 Cajal Neuroscience Inc., Seattle, United States 1.67 Carma Fund I, Munich, Germany 10.00 Carrick Therapeutics Ltd., Dublin, Ireland 3.48 Centauri Therapeutics Ltd., Sandwich (Kent), United Kingdom 13.17 Curie Bio LLC, Boston, United States 0.11 Curie Bio Seed Fund I L.P., Boston, United States 2.82 Exscientia plc (formely Exscientia Ltd.), Oxford, United Kingdom 11.42 Extend Srl, Rome, Italy 10.00 Fibrocor LLP, Toronto, Canada 16.26 Fibrocor Therapeutics Inc., Toronto, Canada 8.98 IMIDomics Inc., San Francisco, United States 11.77 Immunitas, Therapeutics, Inc., Waltham, United States 6.17 Leon Nanodrugs GmbH, München, Germany 13.24 Mission BioCapital V LP, Cambridge, United States 3.64 OxVax Ltd., Oxford, United Kingdom 12.22 Sernova Corp., Ontario, Canada 5.16 Tubulis GmbH, Munich, Germany 6.90 * in voluntary liquidation The subsidiaries listed in this table are included in the consolidated financial statements. In the second half of the year, Evotec completed the acquisition of Rigenerand Srl. The Medolla, Italy-based cell technology company, a leader in the field of cGMP manufacturing of cell therapies, now operates as Evotec (Modena) Srl. Also in the second half of the year, Evotec SE completed the acquisition of Central Glass Germany. Operating as Evotec Drug Substance (Germany) GmbH, the acquisition strengthens Evotec’s clinical and commercial drug manufacturing capabilities, particularly for rare diseases and precision therapeutics. Associates and joint ventures are accounted for using the equity method. Through the Pancella Inc. shareholders’ agreement, Evotec participates in all significant financial and operational decisions. The Group has therefore determined that it has significant influence over this company, even though it holds less than 20% of the voting rights. The Group’s investments in subisidiaries, associates, and joint ventures are not hedged as these currency positions are considered to be long term. (b) Management Board The Management Board of Evotec consists of the following members: Dr. Werner Lanthaler, Business Executive, (CEO, Chairman of the Board), Dr. Cord Dohrmann, Biologist, (CSO, Head of Research), Dr. Craig Johnstone, Chemist, (COO), Enno Spillner, Business Executive, (CFO, left 31 March 2023), Laetitia Rouxel, Business Executive, (CFO, started 1 April 2023) and Dr Matthias Evers, Neurobiologist, (CBO, started 1 May 2022). The fixed salary component consists of a fixed basic remuneration and fringe benefits such as pension allowances, travel allowances, contributions to certain insurance policies as well as the non-cash benefit for the private use of a company car or an allowance for a private vehicle. The variable remuneration component is based on a bonus program. The bonus is determined on the basis of the achievement of certain targets set by the Remuneration and Nomination Committee of the Supervisory Board and subsequently approved by the Supervisory Board for each financial year. Furthermore, the Executive Board receives Share Performance Awards as a component with a long-term incentive effect. With the new remuneration system coming into effect in 2022, the Restricted Share Plan 2020 is no longer part of the multi-year remuneration component. The variable remuneration for the 2022 financial year is based on the achievement of nine company-related goals (strategic goals). For the 2022 financial year, 50% of these company-related targets relate to defined strategic and ESG company targets and 50% to defined financial company targets.The payment of the variable remuneration in 2022 for the financial year 2021 was based on the achievement of eight company-related targets (strategic targets). In the 2021 financial year, 40% of these company-related targets related to defined corporate targets and 60% to defined corporate financial targets. In addition to their fixed and variable remuneration, the members of the Executive Board also receive long-term multi-year remuneration in the form of participation in the company’s various multi-year remuneration programs. These are two different share-based programs, the payment of which is subject to a vesting period of four years. With the entry into force of the new remuneration scheme in 2022, the aforementioned link to corporate success and sustainable corporate growth has been continued, however, the Restricted Share Plan 2020 is no longer part of the multi-year remuneration component. These Share Performance Awards vest four years after issuance according to the degree of achievement of defined key performance indicators measured over this period (31 December 2021: four years). Further information on the SPA can be found in Note (22). The remuneration granted to the members of the Management Board for the financial years 2022 and 2021 are shown below: 2022 2022 2022 2022 2022 Fixed Variable Share Performance Fair value of remuneration remuneration and Restricted SPAs and Total (short-term) (short-term) Share Awards RSAs granted remuneration k€ k€ in pcs k€ k€ Dr. Werner Lanthaler 741 578 27,040 1,200 2,519 Dr. Cord Dohrmann 469 335 13,520 600 1,404 Dr. Craig Johnstone 442 270 48,500 1,400 2,112 Enno Spillner 387 216 10,816 480 1,083 Dr. Matthias Evers 304 180 39,353 900 1,384 Total 2,343 1,579 139,229 4,580 8,502 2021 2021 2021 2021 2021 Fixed Variable Share Performance Fair value of remuneration remuneration and Restricted SPAs and Total (short-term) (short-term) Share Awards RSAs granted remuneration k€ k€ in pcs k€ k€ Dr. Werner Lanthaler 711 590 100,769 3,313 4,614 Dr. Cord Dohrmann 451 275 40,956 1,348 2,074 Dr. Craig Johnstone 382 234 9,439 296 912 Enno Spillner 384 220 8,884 278 882 Total 1,928 1,319 160,048 5,235 8,482 The individual contracts of the Executive Board members contain a customary clause in the event of a takeover of the company by a third party. This clause allows the Executive Board members to terminate their existing contracts under extraordinary circumstances in the event of a takeover. A takeover within the meaning of this clause has taken place as soon as more than 30% of the shares are taken over by a third party. Should Executive Board members exercise this right of termination, they are entitled to the following severance payments: Dr Werner Lanthaler shall receive a severance payment in the amount of two years’ basic salary, Dr Craig Johnstone, as well as Dr Cord Dohrmann in the amount of 18 months’ basic salary plus the agreed bonus. In no Evotec Maintains a directors and officers liability insurance (“D&O Insurance”) for the members of the Management Board. This insurance covers the personal liability risk in the event that claims are made against members of the Management Board for pecuniary loss in the course of their duties. The insurance includes a deductivle for the Executive Board members that comply with the requirements of the German Stock Corporation Act. (c) Supervisory Board The Supervisory Board of Evotec consists of the following members: Prof. Dr. Iris Löw-Friedrich, Member of the Management Board (Chief Medical Officer) at UCB S.A.; Chairperson of the Supervisory Voard and of the Remuneration and Nomination Committee Roland Sackers, CFO and Managing Director of QIAGEN N.V.; Vice Chairman of the Supervisory Board and Chairperson of the Audit and Compliance Committee Dr Camilla Macapili, Head of Life Sciences, Mubadala Investment Company (MIC Head of Life Sciences), Member of the Supervisory Board since June 2022 Dr. Mario Polywka, non-independent consultant; Former Member of the Management board Evotec SE. Dr. Elaine Sullivan, independent consultant, CEO of KELTIC Pharma Therapeutics Ltd until September 2022, Member of the Supervisory Board Kasim Kutay, Chairman of the Board of Directors of Novo Holdings A/S, Member of the Supervisory board until June 2022 Dr. Constanze Ulmer-Eilfort, Partner of the law firm Peters, Schönberger & Partner (PSP Munich); Member of the Supervisory Board and Chair of the ESG Committee The remuneration accrued for the members of the Supervisory Board in the financial year was as follows: 2022 2021 Remuneration Remuneration k€ k€ Prof. Dr. Iris Löw-Friedrich 150.0 113.6 Roland Sackers 95.0 90.5 Dr. Mario Polywka 60.0 55.5 Dr. Elaine Sullivan 65.3 60.0 Kasim Kutay 28.4 60.0 Dr. Constanze Ulmer-Eilfort 73.2 32.7 Prof. Dr. Wolfgang Plischke — 68.2 Camilla Macapili Languille 31.6 — Total 503.5 480.5 In the 2022 and 2021 financial years, the remuneration per the Supervisory Board member amounted to k€ 50 per annum. In the 2022 financial year, the Chairperson received k€ 125 (31 December 2021: k€ 125) and his deputy k€ 60 (31 December 2021: k€ 60). The members of the Supervisory Board committees receive k€ 10 (2021: k€ 10) per committee, the chairperson of a committee receives k€ 25 (31 December 2021: k€ 25). No remuneration in the form of shares was paid to the Supervisory Board in the financial years 2022 and 2021. The members of the Supervisory Board and their other supervisory board offices and offices in comparable domestic and foreign supervisory bodies of commercial enterprises within the meaning of § 125 para. 1 sentence 5 AktG are listed below: Prof. Dr. Iris Löw-Friedrich Member of the Supervisory Board: Fresenius SE & Co. KGaA. Bad Homburg/DE TransCelerate BioPharma Inc. King of Prussia/United States Member of the Board of Directors: PhRMA Foundation, Washington DC/uSA Roland Sackers Member of the Board of Directors: BIO Deutschland e.V. Berlin/DE Dr Mario Polywka Non-Executive Board Director: Forge Therapeutics, Blacksmith Medicines Inc. San Diego/United States Exscentia Plc Orb it Discovery Limited C4X Discovery Holdings PLC. Dr Elaine Sullivan Member of the Supervisory Board: Active Biotech AB, Lund/SE hVIVO PLC (formerly Open Orphan PLC) IP Group PLC Nykode Therapeutics ASA Kasim Kutay Member of the Supervisory Board: Novo Nordisk A/S. Hellerup/DK Novo Nordisk A/S, Hellerup DK Balcão Novozymes A/S. Bagsværd/DK Dr. Constanze Ulmer-Eilfort Chairperson of the Advisory Board: S4DX GmbH Member of the Advisory Committee: Proxygen GmbH Camilla Macapili Languille Member of the Board of Directors: PCI Pharma Services (KPCI Holdings Limited) Norstella (Caerus PikCo S.A.R.L.) Envirotainer A/S

Subsequent events

Subsequent events	12 Months Ended
Subsequent events	Dec. 31, 2022
Subsequent events
Subsequent events	(36) Subsequent events The Supervisory Board of Evotec SE has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board with effect from 1 April 2023. On April 6th 2023, the Group suffered from a criminal cyber attack that targeted many of Evotec’s operations which caused disruptions to many of its IT systems in several countries and temporarily stopped or reduced the Research and Production activities. The Group has been working relentlessly and prompt actions were taken to contain the incident, mitigate its impact and to return the operations to normal as soon as possible. Operations quickly recovered within days however it is possible that there may be a significant impact on the Group’s 2023 financial performance. The Group is currently assessing the estimated impacts this criminal action may have on the Group’s operations. The financial impacts are expected to be partially mitigated by the Group’s business interruption insurance, however due to the early stage of discussions with insurers the expected amount of reimbursement cannot be determined at this time. As a result of the cyber attack, a delay in external reporting occurred, which has led to a likely temporary exclusion from the indices of the Frankfurt Stock Exchange. Evotec expects to rejoin the relevant indices after the next regular review of admission requirements by Deutsche Börse.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
Summary of significant accounting policies (Policies)	Dec. 31, 2022
Summary of significant accounting policies
Use of estimates	- Use of estimates The preparation of the accompanying consolidated financial statements requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities as of the balance sheet date of the financial year as well as income and expenses during the reporting period. Main estimates and assumptions affect the following subjects: – Acquisitions: Assets and liabilities acquired in a business combination are initially accounted for at fair value on the acquisition date. Fair values are determined using a discounted cash flow model which relies on input parameters derived from observable market data. These parameters involve management judgment whenever no comparable market data is available. Significant input parameters used in determining the fair values are the estimated useful life of the assets identified, the long-term business plan as the basis for determining the expected cash flow from these assets and the discount rate applied. – Revenues: Where we have certain fixed-price arrangements with customers, the stage of completion of performance obligations is reviewed by reference to input-based methods, such as hours delivered or full cost incurred (e.g., labor, materials, and other costs) under a contract in relation to expected total hours or total costs needed to fulfil the performance obligation. Revisions made to the estimated stage of completion can result in an adjustment to revenues in the current or future financial periods (see Note 24) and – Impairment testing and fair values: Management has identified the discount rate as well as the growth rate in the terminal value as key assumptions that have the potential to vary and thereby cause the recoverable amount to be lower than the carrying amount. Fair values for long-term investments at the time of acquisition correspond to the acquisition cost. Changes in fair value may occur due to adjusted scientific or financial plans or new financing rounds. (see Note 10, 11, 12, 13, 14 and 15). Other estimates and assumptions were exercised in the following areas: – Earn-out Provisions: Management estimates are made on discounted expected future cash flows. These cash flows are based on the contracts underlying the conditional consideration and the relevant project or business planning. The discount rate considers the risk underlying cash flows (usually weighted average cost of capital of the acquired entity). Additional non-observable input factors include, for example, marketing success probabilities. (see Note 18 and 30), – Measurement of the Share-based payment plans: Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including risk-free interest rates and volatility measures. (see Note 22), – Valuation of deferred tax assets: Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the tax losses can be charged. Management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the expected business performance of the tax subject and respective business plans (see Note 20). – Exercising significant influence on an investee: To determine whether an investor with minority voting rights has significant influence over an investee requires judgement, regarding participation rights in significant financial and operating decisions of these entities (see Note 35d). Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are made prospectively in the period in which the estimates are revised.
Principles of consolidation	- Principles of consolidation In the consolidated financial statements of Evotec SE, all domestic and foreign companies which are under its control are included. Evotec controls an entity if it is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are included in the consolidated financial statements from the date on which control is obtained until the date Evotec´s control ceases. If Evotec loses control over a subsidiary, all assets, and liabilities of that subsidiary together with any related non-controlling interests and other equity components are derecognized. Any resulting gain or loss is recognized in the income statement. Any retained interest in the former subsidiary is measured at fair value at the time of loss of control. All intercompany receivables, liabilities and all intercompany revenue, income, expenses and all intragroup profits or losses are eliminated in the consolidation. The financial statements of all to be consolidated subsidiaries are prepared using the same reporting date as the consolidated financial statements (31 December).
Transactions in foreign currency	- Transactions in foreign currency The Group’s consolidated financial statements are presented in euros, which is also the parent company’s functional currency. For each to be consolidated entity the respective functional currency will be determined. ● Subsidiaries The assets and liabilities of foreign subsidiaries with functional currencies other than the Euro are translated into Euro using the respective exchange rates at the end of the reporting period, while the income statements of such subsidiaries are translated using monthly average exchange rates during the period. Gains or losses resulting from translating foreign functional currency financial statements are recognized directly in other comprehensive income and realized on disposal of the subsidiary. ● Associated companies and joint ventures The currency translation of the proportionate equity of joint ventures and associated companies is performed at the respective closing rate of inclusion. The share of the results of associated companies and joint ventures is translated at the average exchange rate and recognized as share of the result of associates accounted for using the equity method, in the statement of comprehensive income. ● Transactions and balances Transactions in foreign currencies are translated in the respective functional currency using the transaction foreign exchange rate. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated into the respective functional currency using the exchange rates at the end of the period.
Financial instruments	- Financial instruments Recognition of financial instruments Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the financial instrument. Regular way purchase and sales of financial instruments are generally recognized on the settlement date. Derivatives are recognized on the day of trading. Derecognition of financial instruments Financial assets are derecognized if either the payment rights arising from the instrument have expired or substantially all risks and rewards attributable to the instrument have been transferred. Financial liabilities are derecognized if the obligations have expired or have been discharged or cancelled. Measurement of financial assets The initial recognition is measured at fair value. The subsequent measurement depends on the classification of the categories as defined in IFRS 9. Classification is based on two criteria: the Group’s business model for managing assets and whether the instruments’ contractual cash flows represent solely payments of principal and interest on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model. For the financial assets the following applies: Debt instruments are held by Evotec with the intention to collect contractual cash flows (interest and principal) and to sell these debt instruments. Consequently, they are measured at fair value through OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit or loss. Equity instruments are measured at fair value through profit and loss. At Evotec this primarily relates to the long-term investments. All other non-derivative financial assets are measured at amortized cost and therefore according to the effective interest method. Non-derivative financial liabilities For subsequent measurement, non-derivative financial liabilities are measured at amortized cost. Impairment of financial assets Impairment is recognized for all financial assets not held at fair value through profit or loss and contract assets to be recognized in accordance with IFRS 15 using the expected credit loss (ECL) model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that Evotec expects to receive. For trade receivables and contract assets, Evotec applies a simplified approach in calculating ECLs. Therefore, Evotec does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. See Notes (5) and (6) for details. Offsetting financial instruments Financials assets and liabilities are only offset, and the net amount presented in the consolidated statement of financial position when, and only when, Evotec has the legal right to offset the amounts and either to settle on a net basis or to realize the asset and settle the liability simultaneously. Derivative financial instruments and hedge accounting Evotec uses foreign currency derivative financial instruments as well as interest swaps to hedge its exposure to foreign exchange risks and interest rate fluctuations. Derivative financial instruments are measured at fair value through P&L. For these economic hedge relationships Evotec does not apply hedge accounting under IFRS 9. Derivatives embedded for financial liabilities in host contracts are accounted for separately if the economic characteristics and risk of the host contract and the embedded derivative are not closely related. In accordance with its treasury policy, the Company does not hold or issue derivative financial instruments for trading purposes. Basis for determining fair values of financial instruments. The following summarizes the significant methods and assumptions used in estimating the fair values of financial instruments. The fair value is determined primarily based on publicly determinable bid prices at the reporting date. For unlisted equity instruments or financial instruments without an active market, fair value is estimated using valuation techniques. Unless otherwise reported, the fair values of financial instruments equal the carrying amounts.
Cash and cash equivalents	- Cash and cash equivalents The Company considers all highly liquid short-term investments with original maturities at the date of acquisition of three months or less to be cash equivalents.
Contract assets	- Contract assets A contract asset is the right to a consideration in exchange for goods or services transferred to the customer. If Evotec fulfils its contractual obligations by transferring goods or services to a customer before the customer pays the consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.
Trade receivables	- Trade receivables A trade receivable is recognized if an amount of consideration that is unconditional is due from the customer. Appropriate allowances are made for identifiable risks.
Inventories	- Inventories In accordance with IAS 2, inventories are valued at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. Costs consist of purchased component costs and manufacturing costs, which are comprised of direct material and labor costs and systematic allocated costs. Costs are removed from inventories to costs of revenue based on specific identification.
Property, plant and equipment	- Property, plant, and equipment Property, plant, and equipment is measured at cost less accumulated depreciation and impairment losses. Property, plant, and equipment acquisitions, including leasehold improvements, are recorded at cost. Depreciation of property, plant and equipment is generally calculated using the straight-line method over the estimated useful lives of the assets. Depreciation of leasehold improvements is calculated using the straight-line method over the shorter of the related lease term or the estimated useful life. The useful lives are as follows: Buildings and leasehold improvements 3-30 years Plant, machinery, and equipment 4-15 years Furniture and fixtures 3-15 years The depreciation period is reviewed at each balance sheet date. Differences from previous estimates are accounted for as a change in an accounting estimate in accordance with IAS 8. The costs included in property, plant and equipment related to assets under construction are not depreciated until the assets are placed into service by the Company. Upon sale or retirement, the costs and the related accumulated depreciation are removed from the respective accounts and any gain or loss is included in other operating income and expenses. Maintenance and repairs of property, plant and equipment are expensed as incurred.
Leases	- Leases Evotec as a lessee Evotec recognizes and measures all leases (excluding short-term leases and leases of low-value assets) using the Right-of-Use model. The Company recognizes liabilities to make lease payments and Right-of-Use assets representing the right to use the underlying assets. i) Right-of-Use assets Evotec recognizes Right-of-Use assets at the commencement date (i.e., the point in time the underlying leased asset is available for use). Right-of-Use assets are measured at cost less any accumulated depreciation and any accumulated impairment losses. The cost of Right-of-Use assets include the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-Use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets as follows: Right-of Use assets relating to buildings >1-20 years Right-of Use assets relating to plant and machinery 2-7 years Right-of Use assets relating to motor vehicles 3-4 years If legal ownership of the leased asset transfers to Evotec at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the leased asset. ii) Lease liabilities On the provision date of the lease, Evotec recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or an interest rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognized as expenses in the period in which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, Evotec uses an incremental borrowing rate at the lease commencement date when the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification to the lease, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. iii) Short-term leases and leases of low-value assets
Associates and joint ventures	- Associates and joint ventures Associates and joint ventures are entities in which Evotec has significant influence over the financial and operating policies. This significant influence is usually exercised through a direct or indirect share of voting power of 20% to 50%. Significant influence can also exist through a direct or indirect share of voting power of less than 20%, indicators are: ● Representation on the board of directors and/or on the supervisory board, ● (Significant) participation in operating policies, including participation in decisions about dividends of the investee, ● Interchange of managerial personnel, ● Material transactions between the entity and its investee, ● Provision of essential technical information. In case one or more of the above-mentioned indicators apply, Evotec verifies if significant influence exists. Associates and joint ventures are accounted for in the consolidated financial statements using the at-equity method and initially measured at cost. After acquisition, Evotec’s share in the associates and joint ventures profit, or loss is included in the consolidated statement of comprehensive income. Unrealized gains and losses from transactions between Evotec and its associates or joint ventures are recognized only to the extent of unrelated investors` interests in the associates and joint ventures.
Intangible assets, excluding goodwill	- Intangible assets, excluding goodwill Intangible assets, excluding goodwill, consist of separately identified intangible assets such as developed technologies, customer related intangibles and patents, which were acquired in business combinations, purchased licenses and patents. Intangible assets with definite useful lives are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the assets. The useful lives are as follows: Trademarks 2-10 years Developed technologies 6-18 years Patents and licenses Up to 15 years Developed technologies acquired in business combinations are amortized as soon as the intangible assets start to generate sustainable benefits and tested for impairment at least annually. Intangible assets excluding goodwill with finite useful lives are tested for impairment whenever there is an indication that the asset may be impaired. If the recoverable amount of the asset is less than the carrying amount, an impairment loss is recognized. If the reason for a previously recognized impairment loss no longer exists, the impairment loss is reversed and the carrying amount of the asset is increased to its amortized cost. Impairment losses are recognized in the income statement as other operating expenses and reversals of impairment losses as other operating income. The amortization period is reviewed at each balance sheet date.
Goodwill	- Goodwill Goodwill recognized in a business combination according to the acquisition method is recognized as an asset. If the net assets acquired exceed the fair value of the consideration transferred, the income from bargain purchase is recognized in the consolidated income statement following a reassessment.
Impairment of non-financial non-current assets and goodwill	- Impairment of non-financial non-current assets and goodwill The Company reviews non-financial non-current assets (property, plant and equipment and intangible assets including goodwill) for impairment, in the respect to the recoverable amount in accordance with IAS 36. An impairment review is performed at least annually for intangible assets with indefinite useful lives, intangible assets not yet available for use and goodwill, or whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. In line with the Company’s policy concerning the impairment of intangible assets with indefinite useful lives and goodwill, the Company carried out an impairment test in the fourth quarter of 2022 and 2021 based on 30 September balance sheet information, see Note (13) and (14). An impairment loss is recognized if the carrying amount of an asset (or a group of assets when considering a cash-generating unit) exceeds its recoverable amount, which is the higher of its fair value less costs to sell or value in use. The value in use for an asset or cash-generating unit, which is used by Evotec for the impairment testing of non-financial non-current assets and goodwill, is calculated by estimating the net present value of future cash flows arising from that asset or cash-generating unit. The discount rate used to calculate the value in use is determined to reflect the risks inherent for each asset or cash-generating unit. The evaluation of the further use is based on a mid-range or where applicable long-range forecast. Management judgment is necessary to estimate discounted future cash flows. Any impairment loss is reported as a separate component of other operating expenses in the consolidated income statement. An impairment of property, plant and equipment and intangible assets excluding goodwill is again reversed if there has been a change in the estimates used to determine the recoverable amount leading to an increase in value for a previously impaired asset or group of assets as one cash-generating unit. It is reversed only to the extent that the assets or the group of assets carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been previously recognized. Impairments of goodwill are not reversed.
Provisions	- Provisions Provisions are recognized when the Company has a present obligation because of a past event which will result in a probable outflow that can be reliably estimated. The amount recognized represents the best estimate of the settlement amount of the present obligation as of the balance sheet date. Non-current provisions are discounted applying a risk adjusted market interest rate. A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from such a contract are lower than the unavoidable expenses of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected expenses of terminating the contract and the expected net expense of continuing with the contract. Before a provision is established, Evotec recognizes any impairment expense on the assets associated with that contract.
Pension and similar obligations	- Pension and similar obligations The Company’s net obligation for defined benefit and other postretirement benefit plans have been calculated using the projected unit credit method. The calculation is based on actuarial expertise considering the relevant biometric factors. Actuarial gains and losses are recognized in other comprehensive income.Service and interest costs for pensions and other postretirement obligations are recognized as an expense in the operating result. The Company’s obligations for contributions to defined contribution plans are recognized as expense in the consolidated income statement.
Contract liabilities	- Contract liabilities A contract liability is the obligation of Evotec to transfer goods or services to a customer for which Evotec has received a consideration (or an amount of consideration is due). If a customer pays the consideration before Evotec transfers goods or services to the customer, a contract liability is recognized when the payment is made, or the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when Evotec fulfils its contractual obligation. Evotec contracts do not include financing components as all up-front consideration received are prepayments on service obligations.
Share capital	- Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of ordinary shares are recognized net of tax as a deduction from equity. The Company applies the regulations of IAS 32 in accounting for treasury shares. When ordinary shares recognized as equity would be reacquired, the amount of the consideration paid for those treasury shares is recognized as a deduction from equity. If treasury shares are subsequently sold or granted, the proceeds will be recognized net of tax as an increase in equity.
Stock options and Share Performance Awards	- Stock options and Share Performance Awards The Company applies the regulations of IFRS 2 with regard to accounting for options granted under its stock option plans and under its Share Performance Plan. All plans are settled in shares and therefore are recorded through equity. Compensation cost from the issuance of employee and Management Board stock options are measured using the fair value method at the grant date and charged straight-line to expense over the service period. This is also the case for the grant of Share Performance Awards to employees and to members of the Management Board. In case the estimates regarding the achievement of the key performance indicators change, the fair value of Share Performance Awards is adjusted as long as if it is not a share price-based indicator.
Revenues	- Revenues from contracts with customers Revenue is recognized when the control over separable services or research services is transferred to the customer, provided that a contract with enforceable rights and obligations exists and that collectability of consideration is probable. The Company assesses collectability based on a number of factors, including past transaction history with the customer and the customer’s creditworthiness. The Company has entered into contracts which can have multiple-elements and thoroughly determined whether the different revenue-generating elements are sufficiently separable and whether there exists sufficient evidence of their fair values to separately account for some or all of the individual elements of the contracts. Only if an element is considered to meet these criteria it does represent a separate unit of accounting. When allocating the transaction price to individual performance components, Evotec uses FTE-rates as indicator of the fair value of these components. Evotec’s revenues include service fees, FTE-based research payments revenue for delivered goods and deliverable kind of services, recharges, technology access fees as well as milestone fees, licenses, and royalties. Service fees, FTE-based research payments as well as deliverable services Revenues generated from service contracts or FTE-based research contracts, or deliverable kind of services are recognized as the services are rendered. Evotec applies an input-based method to measure the progress of completion of its performance obligations. In rare cases and only for specific contracts, output-based methods are applied whenever the contracts warrant such measurement. Payments for those services are generally paid in full or in parts in advance and recorded as contract liabilities. Contract assets are recognized in case Evotec’s progress of completion of its performance obligations exceeds the amount of the payments received. Those contracts may also contain variable compensation, which Evotec only includes in the transaction price when it becomes highly probable that such payments will be received. This is rarely the case upon contract inception or in early stages of contracts, owing to the nature of the services. Technology access fees Revenue from technology access fees is recognized pro rata over the related forecasted service period. Payments for technology access fees are generally paid in full or in parts in advance and recorded as contract liabilities until earned. Milestone fees Revenue contingent upon the achievement of certain milestones is recognized in the period the milestone is successfully achieved or all the performance obligation fulfilled. This occurs when the Company’s contract partner agrees that the requirements stipulated in the agreement have been met. Under IFRS 15, earlier recognition carries an increased risk of revenue corrections required and hence Evotec refrains from an earlier recognition. Licenses Revenue from the sale of licenses is recognized at the date of the sale. Revenue from out-licensing in combination with a collaboration is realized pro rata over the collaboration period. Payments from the sale of licenses are received on the day of the sale or thereafter. Royalties Revenue from royalties, which are dependent on other company’s respective product sales, is recognized in the period in which the royalty report or the payment is received. Payments are received either on the same day as the royalty report or thereafter. Royalties are typically contract components with a variable consideration which will as mentioned above only be realized as revenues when it is highly probable that the consideration will be received. Main estimates and assumptions > Identifying performance obligations, allocating the transaction price, and determining the stage of completion of contracts with service fees, FTE-based research payments as well as deliverable kind of services. Evotec performs research and development (R&D) services for a variety of customers under different contractual arrangements. When performance obligations are individually capable of being distinct and distinct in the context of the contract, Evotec allocates the transaction price to distinct performance obligations based on relative stand-alone selling prices of the obligations. Primarily, contracts for research and development (R&D) services often contain a large amount number of individual services, trigger upfront payments to cover the entire transaction price and are concluded for the overall purpose of identifying new research results partially or fully. The Group has determined that services under such contracts are integrated and qualify as one performance obligation. As far as other distinct services are included in those type of contracts, Evotec allocates the transaction price on the basis of relative stand-alone selling prices of the obligations. Such fixed-price arrangements are recognized over time as the respective performance obligation is fulfilled. Evotec applies an input-based method to measure the progress of completion of its performance obligations such as hours delivered or full cost incurred (e.g., labor, materials, and other costs) under a contract in relation to expected total hours or total costs needed to fulfil the performance obligations. For each contract, Evotec selects the input-based method that most faithfully depicts the transfer of services stated in the contract. In rare cases and only for specific contracts, output-based methods are applied whenever the contract warrants such measurement. > Determining the method to estimate variable compensation and assessing the constraint. Customer contracts often contain success-based variable compensation for research services and other contingent payments. The contingency often relates to few and specific research services, which is why Evotec determines the most likely amount payable under the contract. In addition, Evotec assesses whether a constraint exists in reference to revenue recognition for such variable compensations. Based on Evotec’s historical experience and due to the inherent risk of research, success-based variable compensations are regularly not included in the transaction price upon contract inception but are only included when the contingent events occur or become highly probable. -Revenue recognition from contributions Evotec receives private contributions for which the existence of an adequate exchange transaction for research projects serving the public good is refuted. A realization of revenue from contracts with customers is not possible. A private contribution exists for which a contribution revenue item is recognized. The effect on profit or loss is immediate or occurs over the period in which the subsidized service is provided. A liability item must be recognized for a contribution that has already been received, but this is not a contractual obligation, but rather other liability. The reversal of the liability item is gross, i.e., as contribution revenue separately from the revenues.
Government grants	- Government grants Government grants are recognized when all the condition associated to those grants have been substantially complied with. When the grant relates to an expense item, it is recognized as a reduction of the related expense. When the grant relates to an asset, it is recognized as income in equal amounts over the expected useful life of the related asset. Under the terms of the grants, governmental agencies generally have the right to audit qualifying expenses submitted by the Company.
Research and development (R&D)	- Research and development (R&D) Research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are expensed as incurred. Due to the high uncertainty associated with development activities in the pharmaceutical sector the precondition for the capitalization of development expenses is generally not fulfilled. Evotec did not capitalize any pharmaceutical development costst costs in 2022 and 2021 respectively. R&D projects that are acquired in a business combination are capitalized at fair value when those R&D projects are expected to generate probable future economic benefits to the Company. R&D costs acquired in a business combination are not regularly amortized until they are sustainably generating benefits. The development expenses for internally generated software are capitalized when the recognition criteria are met. The development expenses for internally generated software are capitalized when the following recognition criteria are met. The software will generate future economic benefits, and its cost can be determined reliably, and the following can be demonstrated: – technical feasibility, – intention to use, – ability to use or sell, – how it will generate probable future economic benefits, – the availability of adequate technical – financial – and other resources, – ability to measure the attributable expenditure reliable.
Other operating income	- Other operating income Evotec receives tax credits from tax development programs in the context of qualifying R&D expenses in different jurisdictions. Such tax refunds regularly result in amounts which can be offset against taxable income, to provide a partial or full relief from tax or other payments to fiscal authorities. Evotec determined that under its significant tax development programmes, the feature of the credit is provided in a way which allows either offsetting against taxable income or instead, when insufficient taxable profits are available, direct reimbursement and payment in cash. In addition, the tax development programmes are provided for specific activities, often limited to specific R&D expenses. As such, Evotec accounts for such tax development programmes as other operating income and does not account for such income as tax income or offsets tax credits from income tax expense. In certain cases, Evotec recharges costs to third parties. The income from those recharges is recognized in other operating income when it is a direct reimbursement of costs. There is no underlying direct exchange of services for this income and therefore a recognition as revenues is not suitable. The relating expenses are recognized in other operating expenses as well as in R&D expenses.
Interest income and expense	- Interest income and expense Interest is recorded as expense or income in the period to which it relates. All interest income and expense including the unwind of the discount on contingent considerations are recognized in the income statement using the effective interest rate method. Evotec considers assets with a construction term over 12 months as qualifying assets. To determine the amount of borrowing eligible for capitalization when funds are borrowed for general purposes, the Group computes a weighted average cost of borrowing, which is then applied to qualifying assets as a capitalization rate.
Income taxes	- Income taxes Income taxes comprise the current taxes on income in the individual countries as well as the deferred taxes. For uncertain tax positions tax assets or liabilities are recorded. Current income tax Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group generates taxable income. The tax rates for domestic companies are 27%-32% and for foreign companies 19%-31% (2021: 27%-32% and 19%-28%, respectively and 2020: 27%-32% and 19%-31%, respectively). Deferred tax Deferred tax is recognized using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred taxes are recognized for all taxable temporary differences, except: ● temporary differences arising on the initial recognition of goodwill, ● temporary differences on the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss, ● temporary differences relating to investments in subsidiaries, associates, and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. Deferred tax assets are recognized for all deductible temporary differences, unused tax loss carry forwards and unused tax credits to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the unused tax loss carryforwards and tax credits can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Future tax rate changes are considered if, in the scope of a legislative procedure, substantial prerequisites for its future applicability are met. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the income taxes relate to the same taxable entity and the same taxation authority. Tax exposure In determining the amount of current and deferred taxes Evotec considers the impact of uncertain tax positions and whether additional taxes and interest maybe due. This assessment relies on estimates and assumptions and may involve a series of judgement about future events. New information may become available that forces the Company to change its judgement regarding the adequacy of existing tax liabilities. Such changes to tax liabilities will impact tax expenses in the period in which such determination is made.
Net income per share	- Net income per share The undiluted results per share is calculated by dividing the net income (loss) by the weighted average number of ordinary shares outstanding for the period, excluding common stock equivalents. The weighted average number of ordinary shares are calculated as follows: 2022 2021 2020 Shares in Shares in Shares in thousands thousands thousands Issued ordinary shares 1 January 176,608 163,915 150,903 Treasury shares 1 January (250) (250) (250) Effect of weighted average share capital increase 316 1,953 2,508 Effect of weighted average share options exercised — 788 591 Weighted average number of ordinary shares 31 December 176,674 166,406 153,752 Diluted net income per share is computed by dividing the surplus attributable to shareholders of Evotec SE, by the weighted-average number of ordinary shares and share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, stock options and Share Performance Awards are common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. In 2022, the number of potentially dilutive shares to be issued from stock options and Share Performance Awards amounted to 463,415 (2021: 722,286; 2020: 1,172,673). For calculating the diluted net result per share, the resulting dilutive shares are included from the beginning of the period.
First time adoption of new accounting standards in the financial year 2022	First time adoption of new accounting standards in the financial year 2022 Standards/Interpretation Mandatory application Expected Effect Annual Improvement cycle 2018-2020: - IFRS 1 - IFRS 9 - IAS 41 IFRS 1: Subsidiary as a first-time adopter IFRS 9: Clarification with regard to fees in the 10 per cent test for derecognition of financial liabilities. IAS41: Taxation in fair value measurements 1.01.2022 No effects Amendments to IFRS 3: Reference to the Conceptual Framework Replacement a reference to the Framework for the Preparation and Presentation of Financial Statements, without significantly changing its requirements. 1.01.2022 No effects Amendments to IAS 16: Proceeds before Intended Use Change in accounting of proceeds before intended use. 1.01.2022 No effects Amendments to IAS 37: Onerous Contracts – Cost of Fulfilling a Contract Specification which costs an entity needs to include when assessing whether a contract is onerous or loss making. 1.01.2022 No effects Other changes for first time adoption in fiscal year 2023 did also not have a significant impact on the Evotec Group.
Recent accounting pronouncements, not yet adopted	- Recent accounting pronouncements, not yet adopted The following standards and interpretations published by the IASB are not yet mandatory because the date of their first mandatory application has not yet been reached: Standards/Interpretation Mandatory application Endorsement by European Commission Expected Effect Amendments to IAS 1: Disclosure of Accounting Policies An entity is required to disclose its “material” accounting policy information instead of its “significant” accounting policies 1.01.2023 Yes No material effects Amendments to IAS 1: Classification of Liabilities as Current or Non-current Clarification that classification of liabilities as current or non-current should be based on rights that are in existence at end of reporting period 1.01.2024 No No effects Amendments to IAS 1: Non-current Liabilities with Covenants Requirement to disclose information about long term debt with covenants that enable investors to understand the risk of early repayment 1.01.2024 No Effects are still being analyzed Amendments to IAS 8: Definition of Accounting Estimates Clarification of distinction between changes in accounting policies and changes in accounting estimates 1.01.2023 Yes No material effects Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction Amendments narrowed scope of the recognition exemption in IAS 12.15 and IAS 12.24 so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences 1.01.2023 Yes Effects are still being analyzed Amendments to IFRS 16: Lease Liability in a Sale and Leaseback Clarification on how a seller-lessee subsequently measures sale and leaseback transactions that satisfy the requirements in IFRS 15 to be accounted for as a sale 1.01.2024 No Effects are still being analyzed IFRS 17: Insurance Contracts New accounting standard for insurance contracts covering recognition, measurement, presentation and disclosure 1.01.2023 Yes No effects Amendments to IFRS 17: Initial Application of IFRS 17 and IFRS 9 – Comparative Information Adds a transition option for a “classification overlay” to address possible accounting mismatches 1.01.2023 Yes No effects
Changes in accounting policies	- Changes in accounting policies In its April 2021 Update, the IFRS IC published an agenda decision clarifying how to calculate the obligation relating to certain defined benefit plans under which the retirement benefit is (i) contingent on the employee being employed by the entity at the time of retirement; (ii) capped at a specified number of years of service; and (iii) linked to the employee’s length of service at the date of retirement. In that decision, the IFRS IC took the view that the obligation should be recognized only over the years of service preceding the date of retirement in respect of which the employee generates entitlement to the benefit. Applying that decision has resulted in a change in accounting policy, the effects of which have been reflected retrospectively in 2020 in accordance with IAS 8 (Accounting Policies, Changes in Accounting Estimates and Errors). Consequently, the 2020 financial statements were adjusted, with the impact of first-time application reflected as from 1 January 2019, the beginning of the earliest comparative financial period presented. The opposite entry to the adjustment as of that date was recognized in equity. The service cost (including past service cost), interest cost and actuarial gains and losses were adjusted, as have the related deferred taxes.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	12 Months Ended
Summary of significant accounting policies (Tables)	Dec. 31, 2022
Summary of significant accounting policies
Schedule of useful lives of property, plant and equipment	Buildings and leasehold improvements 3-30 years Plant, machinery, and equipment 4-15 years Furniture and fixtures 3-15 years
Schedule of useful lives of right-of-use assets	Right-of Use assets relating to buildings >1-20 years Right-of Use assets relating to plant and machinery 2-7 years Right-of Use assets relating to motor vehicles 3-4 years
Schedule of useful lives of intangible assets	Trademarks 2-10 years Developed technologies 6-18 years Patents and licenses Up to 15 years
Schedule of weighted average number of ordinary shares	2022 2021 2020 Shares in Shares in Shares in thousands thousands thousands Issued ordinary shares 1 January 176,608 163,915 150,903 Treasury shares 1 January (250) (250) (250) Effect of weighted average share capital increase 316 1,953 2,508 Effect of weighted average share options exercised — 788 591 Weighted average number of ordinary shares 31 December 176,674 166,406 153,752
Schedule of impact changes in accounting policies

Segment information (Tables)

Segment information (Tables)	12 Months Ended
Segment information (Tables)	Dec. 31, 2022
Segment information
Summary of segment information	The segment information for the financial year 2022 is as follows: EVT EVT Intersegment Evotec in k€ Execute 1) Innovate eliminations Group Revenues 735,635 204,730 (188,917) 751,448 Operating income (loss) 32,523 (11,673) — 20,850 1) The segment information for the financial year 2021 is as follows: EVT EVT Intersegment Evotec in k€ Execute 1) Innovate eliminations Group Revenues 610,168 146,982 (139,116) 618,034 Operating income (loss) 63,109 (22,113) — 40,996 1) The segment information for the financial year 2020 is as follows: EVT EVT Intersegment Evotec in k€ Execute 1) Innovate eliminations Group Revenues 509,870 106,830 (115,776) 500,924 Operating income (loss) 77,362 (28,806) — 48,556 1)
Summary of non-current assets categorized by the location	2022 2021 k€ k€ United States 231,439 209,508 United Kingdom 211,115 196,543 Italy 227,113 188,858 France 205,749 129,178 Germany 160,970 105,283 Switzerland — 14,089 Austria 3,914 2,697 Canada 1,906 1,913 1,042,206 848,069

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
Acquisitions (Tables)	Dec. 31, 2022
Evotec (Modena) Srl., Medolla, Italy
Acquisitions
Schedule of fair values at the date of acquisition	in k€ as of 1 July 2022 Cash and cash equivalents 263 Trade accounts receivables 244 Inventories 29 Property, plant, and equipment 3,809 Intangible assets 727 Deferred tax asset 344 Other assets 374 Trade accounts payable (382) Current liabilities (564) Non-current liabilities (1,009) Other liabilities (370) Other accrued liabilities (73) Net assets acquired 3,392 Goodwill 19,622 Cost of acquisition 23,014 Contingent consideration (14) Cash and cash equivalents acquired (263) Cash outflow on acquisition 22,737
Evotec Drug Substance (Germany), Halle, Germany
Acquisitions
Schedule of fair values at the date of acquisition	in k€ as of 1 November 2022 Cash and cash equivalents 16,099 Trade accounts receivables 1,210 Inventories 2,903 Prepaid expenses 77 Property, plant, and equipment 6,213 Intangible assets 23 Deferred tax asset 725 Trade accounts payable (43) Current provisions (609) Contract liabilities (705) Current tax payables (76) Other payables (7) Non-current provisions (553) Non-current lease liabilities (3,940) Order intake (2,200) Acquired net assets 19,117 Bargain Purchase (4,909) Consideration transferred 14,208 Cash and cash equivalents 16,099 Purchase price for shareholder loan (14,208) Cash outflow on acquisition 1,891

Trade accounts receivables (Tab

Trade accounts receivables (Tables)	12 Months Ended
Trade accounts receivables (Tables)	Dec. 31, 2022
Trade accounts receivable
Schedule of aging of trade accounts receivable	31 Dec 31 Dec 2022 2021 k€ k€ Not past due 136,372 95,556 Risk provision not past due — — Past due 1-30 days 24,425 31,222 Risk provision 1-30 days (67) (30) Past due 31-120 days 6,301 5,164 Risk provision 31-120 days (323) (89) More than 120 days 4,778 2,236 Risk provision more than 120 days (2,833) (1,981) Total trade accounts receivables 168,653 132,078

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2022
Inventories
Schedule of inventories	31 Dec 31 Dec 2022 2021 k€ k€ Raw materials 27,917 25,043 Work-in-progress 1,908 750 Total inventories 29,825 25,793

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	12 Months Ended
Prepaid expenses and other current assets (Tables)	Dec. 31, 2022
Prepaid expenses and other current assets
Schedule of prepaid expenses and other current assets	31 Dec 31 Dec 2022 2021 k€ k€ Prepaid expenses 16,948 19,210 Other 40,178 20,685 Total prepaid expenses and other current assets 57,126 39,895

Long-term Investments account_2

Long-term Investments accounted for using the equity method (Tables)	12 Months Ended
	Dec. 31, 2022
Long-term Investments accounted for using the equity method
Summary of development of the entity's equity method investment	The following table summarizes the development of the long-term investments during year 2022: Breakpoint Dark Blue Topas Autobahn Therapeutic Curexsys Therapeutics Therapeutics Insignificant in k€ Labs LLC GmbH GmbH Ltd GmbH Investments Total Balance at 1 January 2022 — 2,774 4,212 405 1,497 4,180 13,068 Additions 3,634 — 2,564 7,167 1,821 3,754 18,940 Pro rata net result (2,263) (2,774) (2,809) (3,550) (2,913) (1,656) (15,965) Loss against other current assets — — — — — — — Impairment — — — — — — — Discontinued use of equity method — — — — — — — Net book value 31 December 2022 1,371 — 3,967 4,022 405 6,278 16,043 The following table summarizes the development of the long-term investment during the year 2021: Breakpoint Exscientia NephThera Therapeutics Insignificant in k€ plc 1 GmbH 2) GmbH investments Total Balance at 1 January 2021 21,040 486 1,918 16,266 39,710 Additions — — 3,667 7,244 10,911 Pro rata net result (1,577) (486) (2,811) (11,696) (16,570) Loss against other current assets — — — 977 977 Impairment — — — (2,497) (2,497) Discontinued use of equity method (19,463) 1) — — — (19,463) Net book value 31 December 2021 — — 2,774 10,294 13,068 1) In the first half of 2021, Evotec did not participate in two financing rounds of Exscientia plc (before: Exscientia Ltd.), resulting in Evotec’s shareholding decreasing from 20.32% to 14.84% . In the third quarter of 2021, Exscientia plc was listed for the first time on the NASDAQ and the shareholding further decreased through dilution to 11.70% as of 31 December 2021 through dilution. Consequently, Exscientia plc is no longer accounted for using the equity method but at fair value in accordance with IFRS 9. 2) NephThera GmbH is a joint venture.
Schedule of financial information of significant investments	Further financial information on the significant investments accounted for using the equity method is presented below: Breakpoint Dark Blue Topas Autobahn Therapeutics Curexsys Therapeutics Therapeutics Labs LLC GmbH GmbH Ltd GmbH 2022 k€ k€ k€ k€ k€ Current assets 4,029 7,204 3,409 14,244 6,795 Non-current assets 6 2 484 32 — Current liabilities 672 1,068 302 1,065 843 Non-current liabilities — 143 85 8,208 — Revenues from 1 Jan to 31 Dec — — 15 — — Net result from 1 Jan to 31 Dec (6,144) (11,789) (6,940) 1,025 (9,340) Breakpoint NephThera Therapeutics GmbH GmbH 2021 k€ k€ Current assets 8,013 18,501 Non-current assets 10 2 Current liabilities 525 719 Non-current liabilities — — Revenues from 1 Jan to 31 Dec — — Net result from 1 Jan to 31 Dec (5,769) (8,283)

Other long-term investments (Ta

Other long-term investments (Tables)	12 Months Ended
Other long-term investments (Tables)	Dec. 31, 2022
Other long-term investments
Schedule of other long term investments	The development of investments measured at fair value in accordance with IFRS 9 is shown below: 2022 2021 k€ k€ Balance at 1 January 268,793 19,289 Additions 46,137 6,647 Additions due to discontinue use of equity method — 19,463 Adjustments at fair value, affecting net income (172,159) 223,394 Adjustments at fair value, affecting OCI (11,729) — Net book value 31 December 131,042 268,793

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
Property, plant and equipment (Tables)	Dec. 31, 2022
Property, plant and equipment.
Schedule of development of property, plant and equipment	The development of property, plant, and equipment in 2022 and 2021 is shown in the following tables. The table below also includes the right of use assets (see note 13 Leases) with a net book value of k€ 168,327 as of 31 December 2022 (31. December 2021 k€ 145,038). 2022 k€ Plant, Buildings and machinery leasehold and Furniture Assets under improvements equipment and fixtures construction Total Acquisition and manufacturing costs Amount beginning of the year 378,467 227,611 39,658 40,350 686,086 Foreign currency translation 3,234 839 (62) 883 4,894 Additions 61,673 59,611 11,663 95,618 228,565 Business combination 6,534 3,309 107 94 10,044 Disposals 3,573 3,101 1,243 862 8,779 Reclass 16,727 1,667 1,308 (19,702) — Amount end of the year 463,062 289,936 51,431 116,381 920,810 Depreciation, amortisation, and write-downs Amount beginning of the year 63,379 113,901 24,209 — 201,489 Foreign currency translation (196) (355) (168) — (719) Additions 33,126 30,490 9,061 — 72,677 Disposals 44 1,563 1,231 — 2,838 Reclass 2,194 (2,166) (28) — — Amount end of the year 98,459 140,307 31,843 — 270,609 Net book value Amount beginning of the year 315,088 113,710 15,449 40,350 484,597 Amount end of the year 364,603 149,629 19,588 116,381 650,201 2021 k€ Plant, Buildings and machinery Assets leasehold and Furniture under improvements equipment and fixtures construction Total Acquisition and manufacturing costs Amount beginning of the year 215,055 168,224 27,445 71,155 481,879 Foreign currency translation 9,099 4,576 718 3,362 17,755 Additions 83,535 36,082 7,546 63,653 190,816 Business combination — — — — — Disposals 3,022 443 860 39 4,364 Reclass 73,800 19,172 4,809 (97,781) — Amount end of the year 378,467 227,611 39,658 40,350 686,086 Depreciation, amortisation, and write-downs Amount beginning of the year 40,472 87,048 17,062 — 144,582 Foreign currency translation 1,919 2,628 620 — 5,167 Additions 23,463 24,826 7,307 — 55,596 Disposals 2,552 424 880 — 3,856 Reclass 77 (177) 100 — — Amount end of the year 63,379 113,901 24,209 — 201,489 Net book value Amount beginning of the year 174,583 81,176 10,383 71,155 337,297 Amount end of the year 315,088 113,710 15,449 40,350 484,597

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2022
Leases
Schedule of carrying amounts of right-of use assets recognized and the movements during the period	2022 k€ Right of use Right of Plant, use machinery Furniture Right of use and and Buildings equipment Fixtures Total Acquisition and manufacturing costs Amount beginning of the year 177,602 8,077 997 186,676 Foreign currency translation (919) (17) — (936) Additions 38,393 306 338 39,037 Business combination 3,940 — 22 3,962 Disposals — — — — Reclass 3,718 (3,678) (40) — Amount end of the year 222,734 4,688 1,317 228,739 Depreciation, amortisation, and write-downs Amount beginning of the year 35,722 5,384 532 41,638 Foreign currency translation 8 109 — 117 Additions 17,855 575 229 18,659 Disposals — — — — Reclass 2,194 (2,166) (28) — Amount end of the year 55,779 3,902 733 60,414 Net book value Amount beginning of the year 141,880 2,693 465 145,038 Amount end of the year 166,955 786 584 168,325 2021 k€ Right of use Right of Plant, use machinery Furniture Right of use and and Buildings equipment Fixtures Total Acquisition and manufacturing costs Amount beginning of the year 158,454 8,382 529 167,365 Foreign currency translation 7,442 30 — 7,472 Additions 14,077 — 215 14,292 Business combination — — — — Disposals 2,453 — — 2,453 Reclass 82 (335) 253 — Amount end of the year 177,602 8,077 997 186,676 Depreciation, amortisation, and write-downs Amount beginning of the year 21,169 3,939 147 25,255 Foreign currency translation 2,573 120 24 2,717 Additions 14,160 1,462 207 15,829 Disposals 2,163 — — 2,163 Reclass (17) (137) 154 — Amount end of the year 35,722 5,384 532 41,638 Net book value Amount beginning of the year 137,285 4,443 382 142,110 Amount end of the year 141,880 2,693 465 145,038
Schedule of carrying amounts of lease liabilities and the movements	2022 2021 k€ k€ Amount beginning of the year 150,437 145,554 Foreign currency translation (923) 6,691 Additions 38,784 14,292 Business combination 3,962 — Disposals (232) (58) Accretion of interest 3,841 3,728 Payments (19,046) (19,770) Amount end of the year 176,823 150,437
Schedule of lease liabilities	31 Dec 22 31 Dec 21 k€ k€ Current portion of lease obligations 14,825 14,473 Long-term lease obligations 161,998 135,964 176,823 150,437
Schedule of amounts are recognised in profit and loss	2022 2021 2020 k€ k€ k€ Depreciation expense of right-of-use assets 18,659 15,829 16,035 Interest expense on lease liability 3,841 3,728 3,125 Expense relating to short-term leases 476 839 807 Expense relating to leases of low-value assets 50 56 33 Variable lease payments — — — Total amount recognised in profit and loss 23,026 20,452 20,000

Intangible assets, excluding _2

Intangible assets, excluding goodwill (Tables)	12 Months Ended
Intangible assets, excluding goodwill (Tables)	Dec. 31, 2022
Intangible assets, excluding goodwill
Schedule of development of intangible assets	The development of intangible assets in 2022 and 2021 is shown in the following tables. 2022 k€ Patents and Developed Customer Favorable licenses technology related Trademarks Contract Total Acquisition and manufacturing costs Amount beginning of the year 11,211 99,784 69,089 6,539 — 186,623 Foreign currency translation — 34 — — — 34 Additions — 917 — — — 917 Business combination 1,672 — — — — 1,672 Disposals — — — — — — Reclass — — — — — — Amount end of the year 12,883 100,735 69,089 6,539 — 189,246 Depreciation, amortization and write-downs Amount beginning of the year 10,182 92,983 47,391 5,216 — 155,772 Foreign currency translation — (438) 45 — — (393) Additions 1,223 1,559 6,969 297 — 10,048 Disposals — — — — — — Reclass (56) 56 — — — — Impairment — — — — — — Amount end of the year 11,349 94,160 54,405 5,513 — 165,427 Net book value Amount beginning of the year 1,029 6,801 21,698 1,323 — 30,851 Amount end of the year 1,534 6,575 14,684 1,026 — 23,819 2021 k€ Patents and Developed Customer Favorable licenses technology related Trademarks Contract Total Acquisition and manufacturing costs Amount beginning of the year 10,772 98,845 67,647 6,539 62,033 245,836 Foreign currency translation — 939 1,442 — — 2,381 Additions 439 — — — — 439 Business combination — — — — — — Disposals — — — — 62,033 62,033 Reclass — — — — — — Amount end of the year 11,211 99,784 69,089 6,539 — 186,623 Depreciation, amortization and write-downs Amount beginning of the year 10,095 90,272 37,786 4,574 5,073 147,800 Foreign currency translation — 348 691 — — 1,039 Additions 87 1,680 8,914 642 689 12,012 Disposals — — — — 5,762 5,762 Reclass — — — — — — Impairment — 683 — — — 683 Amount end of the year 10,182 92,983 47,391 5,216 — 155,772 Net book value Amount beginning of the year 677 8,573 29,861 1,965 56,960 98,036 Amount end of the year 1,029 6,801 21,698 1,323 — 30,851

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Dec. 31, 2022
Goodwill
Schedule of development of goodwill	With respect to the development of goodwill please refer to the following detailed schedules. OAI/Evotec OAI/Evotec Evotec International International Aptuit (US) Just Execute Innovate Execute Execute Execute Total k€ k€ k€ k€ k€ k€ 1 January 2022 84,480 9,204 128,845 4,197 30,843 257,569 Business combination — — 19,622 — — 19,622 Disposal — — — — — — Reclass — — — — — — Foreign currency translation (2,257) (40) (2,243) 260 1,908 (2,372) 31 December 2022 82,223 9,164 146,224 4,457 32,751 274,819 The goodwill addition in financial year 2022 to the Aptuit Execute cash-generating unit was a result of the acquisition of Evotec (Modena) Srl, see (Note 4). Foreign currency translation resulted in a decrease of k€ 2,372. OAI/Evotec OAI/Evotec Evotec International International Aptuit (US) Just Execute Innovate Execute Execute Execute Total k€ k€ k€ k€ k€ k€ 1 January 2021 79,816 9,154 126,059 3,874 28,467 247,370 Business combination — — — — — — Disposal — — — — — — Reclass — — — — — — Foreign currency translation 4,664 50 2,786 323 2,376 10,199 31 December 2021 84,480 9,204 128,845 4,197 30,843 257,569
Schedule of assumptions of cash-generating units	Cash-generating units 2022 OAI/Evotec OAI/Evotec Evotec International International (US) Aptuit Just Execute Innovate Execute Execute Execute Denominated in GBP/EUR GBP/EUR USD GBP/EUR USD Pre-tax discount rate 10.15 % 11.93 % 9.32 % 13.12 % 11.71 % Growth rate for terminal value 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % Cash-generating units 2021 OAI/Evotec OAI/Evotec Evotec International International (US) Aptuit Just Execute Innovate Execute Execute Execute Denominated in GBP/EUR GBP/EUR USD GBP/EUR USD Pre-tax discount rate 8.19 % 11.51 % 7.87 % 9.83 % 9.22 % Growth rate for terminal value 2.0 % 2.0 % 2.0 % 2.0 % 2.0 %

Loan liabilities (Tables)

Loan liabilities (Tables)	12 Months Ended
Loan liabilities (Tables)	Dec. 31, 2022
Loan liabilities
Summary of loan liabilities	31 December 31 December 2022 2022 2021 2021 Nominal interest Maturity Fair Carrying Fair Carrying Country of lender Currency rate until Value amount Value amount k€ k€ k€ k€ Germany EUR fixed interest rate of 0.9% to 3.8% 2024-2029 198,281 214,671 254,911 249,530 Germany EUR 1.60% 2024-2027 71,846 75,000 78,596 75,000 Germany EUR 1.20% 2029 6,358 6,722 8,014 7,797 Germany EUR 1.40% 2031 19,099 20,367 21,332 20,367 Italy EUR fixed interest rate of 1.3% to 3.05% 2026-2027 1,218 1,257 — — France EUR 0.55% 2025 10,038 10,742 8,559 8,650 306,840 328,759 371,412 361,344

Provisions (Tables)

Provisions (Tables)	12 Months Ended
Provisions (Tables)	Dec. 31, 2022
Provisions.
Summary of provisions	The current provisions consist of the following: 31 Dec 31 Dec 2022 2021 k€ k€ Other personnel expenses 47,490 33,983 Pensions 1,730 1,478 Other provisions 5,190 3,799 Total current provisions 54,410 39,260 The non-current provisions consist of the following: 31 Dec 31 Dec 2022 2021 k€ k€ Pensions 12,531 12,950 Other personnel expenses 1,209 2,029 Other provisions 2,687 3,042 Total non-current provisions 16,427 18,021 The following table summarizes the development of total provisions recorded during 2022: Business Foreign 31 Dec 1. Jan. 22 combination Consumption Release exchange Additions 2022 k€ k€ k€ k€ k€ k€ k€ Other personnel expenses 36,012 419 23,105 3,374 (2,525) 41,272 48,699 Pensions 14,428 553 1,629 1,404 (12) 2,325 14,261 Other provisions 6,841 287 1,103 3,182 (63) 5,097 7,877 Total 57,281 1,259 25,837 7,960 (2,600) 48,694 70,837 The following table summarizes the development of total provisions recorded during 2021: Business Foreign 31 Dec 1. Jan. 21 combination Consumption Release exchange Additions 2021 k€ k€ k€ k€ k€ k€ k€ Other personnel expenses 37,005 — 33,018 3,644 636 35,033 36,012 Pensions 14,441 — 463 813 — 1,263 14,428 Other provisions 11,133 — 4,760 7,021 655 6,834 6,841 Total 62,579 — 38,241 11,478 1,291 43,130 57,281

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Dec. 31, 2022
Income taxes
Summary of income tax benefit and expense	2022 2021 2020 k€ k€ k€ Current taxes: - Current tax expense (14,132) (12,309) (12,804) - Adjustment for prior years 156 (4,095) 739 Total current taxes (13,976) (16,404) (12,065) Deferred taxes: - Tax loss carry forwards (10,862) (5,140) (10,319) - Temporary differences 3,140 74 2,822 Total deferred taxes (7,722) (5,066) (7,497) Total income tax expense) (21,698) (21,470) (19,562)
Schedule of effective income tax rate	2022 2021 2020 k€ k€ k€ Income before taxes (153,956) 236,980 25,840 Expected German income tax rate 32.28 % 32.28 % 32.28 % Expected income tax benefit (expense) 49,697 (76,497) (8,341) Non-deductible expenses (59,543) (511) (2,533) Taxable income not recognized in income before tax — — (7,796) R&D tax credits 13,454 6,742 5,983 Tax free income 3,184 71,917 5,485 Permanent differences from GILTI (3,724) (444) (1,401) Tax effects from investments accounted for using the equity method (5,152) (9,300) (2,884) Deviation tax rates to expected tax rate 448 1,815 690 Change in tax rates 636 521 124 Change in recognition of deferred tax assets (19,167) (10,247) (9,317) Non-periodic taxes Current Taxes 156 (4,095) 739 Deferred Taxes (1,348) (570) 203 Other (339) (801) (514) Effective income tax income (expense) (21,698) (21,470) (19,562) Effective income tax rate (14.09 %) 9.06 % 75.70 %
Schedule of deferred income tax assets and liabilities	01 Jan 2022 Recognized in 31 Dec 2022 Recognized other Foreign Deferred Deferred In comprehensive currency tax tax Net balance profit or loss Income translation Acquisition Net assets liabilities k€ k€ k€ k€ k€ k€ k€ Property, plant, and equipment (4,855) (5,140) — 508 30 (9,457) 1,563 (11,020) Intangible assets (22,348) 2,536 — (130) 296 (19,646) 965 (20,611) Right of use assets (21,979) (6,860) — — — (28,839) — (28,839) Financial assets (3,985) 2,539 — — — (1,446) 453 (1,899) Provisions and deferred income 3,965 5,640 (357) 2 — 9,250 12,759 (3,509) Lease obligations 19,927 5,351 — — — 25,278 25,278 — Other 4,949 (727) — 22 — 4,244 5,778 (1,534) Tax credits 1,034 (199) (633) * 71 — 273 273 — Loss carryforward 22,963 (10,862) — 45 — 12,146 12,146 — Total (329) (7,722) (990) 518 326 (8,197) 59,215 (67,412) Set off of tax — — — — — — (48,888) 48,888 Net (329) (7,722) (990) 518 326 (8,197) 10,327 (18,524) * Recorded in Equity without any impact on other comprehensive income 01 Jan 2021 Recognized in 31 Dec 2021 Recognized other Foreign Deferred Deferred in comprehensive currency tax tax Net balance profit or loss Income translation Net assets liabilities k€ k€ k€ k€ k€ k€ k€ Property, plant, and equipment (2,840) (1,969) — (46) (4,855) 1,528 (6,383) Intangible assets (25,314) 3,296 — (330) (22,348) 468 (22,816) Right of use assets (23,535) 1,556 — — (21,979) — (21,979) Financial assets (316) (3,669) — — (3,985) 401 (4,386) Provisions and deferred income 4,801 (768) 7 (75) 3,965 6,516 (2,551) Lease obligations 23,274 (3,347) — — 19,927 20,297 (370) Other (1,309) 6,245 — 13 4,949 5,254 (305) Tax credits 1,521 (1,270) 708 * 75 1,034 1,034 — Loss carryforward 27,711 (5,140) — 392 22,963 22,963 — Total 3,993 (5,066) 715 29 (329) 58,461 (58,790) Set off of tax — — — — — (41,102) 41,102 Net 3,993 (5,066) 715 29 (329) 17,359 (17,688) *
Summary of tax loss, interest carryforwards and tax credits	2022 2021 2020 k€ k€ k€ Tax loss carryforwards (not expiring) 474,989 307,682 272,796 Time-limited tax losses - expiring until 2027 (2021: 2026)(2020: 2025) 13,297 21,409 19,259 - expiring from 2028 to 2032 (2021: 2027-2031) (2020: 2026-2030) 45,696 38,207 45,409 - expiring after 2032 (2021: 2031)(2020: 2030) 57,662 73,811 43,945 Interest carryforward — — — Tax credits 1,313 1,286 1,119 Total 592,957 442,395 382,528

Stock-based compensation (Table

Stock-based compensation (Tables)	12 Months Ended
Stock-based compensation (Tables)	Dec. 31, 2022
Stock-based compensation
Summary of the status of the Share Performance Plans	A summary of the status of the Share Performance Plans as of 31 December 2022 and 2021 and the changes during the year then ended is presented as follows: 31 December 2022 2022 2021 2021 2020 2020 Share Weighted Share Weighted Share Weighted Performance Average Performance Average Performance Average Awards Exercise Awards Exercise Awards Exercise (SPAs) price (SPAs) price (SPAs) price € per share € per share € per share Outstanding at beginning of the year 1,325,450 1.00 1,570,113 1.00 2,149,562 1.00 SPAs granted 468,706 1.00 608,710 1.00 325,612 1.00 SPAs exercised (209,043) 1.00 (701,278) 1.00 (865,687) 1.00 SPAs forfeited (80,475) 1.00 (152,095) 1.00 (39,374) 1.00 Outstanding at end of the year 1,504,638 1.00 1,325,450 1.00 1,570,113 1.00 Thereof exercisable — 1.00 — 1.00 432,450 1.00
Summary of inputs into the Monte-Carlo-Simulation model	27 October 27 May 28 January 2022 2022 2022 Risk-free interest rate in % 2.03 0.57 (0.46) Volatility of Evotec share in % 51.00 45.00 37.00 Volatility of TecDAX index in % — — 17.00 Fluctuation in % 5.00 0.0 – 5.0 0.0 – 5.0 Exercise price in Euro 1.00 1.00 1.00 Share price at grant date in Euro 19.47 25.26 34.90 Market value of TecDAX index at grant date in Euro — — 3,411.87 Fair value according to IFRS 2 at grant date per SPA of the Management Board in Euro — 22.87 31.30 Fair value according to IFRS 2 at grant date per SPA of executives in Euro 18.57 24.29 33.66 22 October 28 May 1 February 2021 2021 2021 Risk-free interest rate in % (0.43) (0.57) (0.78) Volatility of Evotec share in % 35.00 40.00 42.00 Volatility of TecDAX index in % — — 29.00 Fluctuation in % 5.00 0.0 – 5.0 0.0 – 5.0 Exercise price in Euro 1.00 1.00 1.00 Share price at grant date in Euro 44.98 35.49 32.25 Market value of TecDAX index at grant date in Euro — — 3,375.67 Fair value according to IFRS 2 at grant date per SPA of the Management Board in Euro — 33.50 31.34 Fair value according to IFRS 2 at grant date per SPA of executives in Euro 43.96 34.47 36.65 29 October 15 January 2020 2020 Risk-free interest rate in % (0.85) (0.55) Volatility of Evotec share in % 40.0 37.0 Volatility of TecDAX index in % — 18.0 Fluctuation in % 5.00 0.0 – 5.0 Exercise price in Euro 1.00 1.00 Share price at grant date in Euro 22.92 23.39 Market value of TecDAX index at grant date in Euro — 3,099.05 Fair value according to IFRS 2 at grant date per SPA of the Management Board in Euro — 22.69 Fair value according to IFRS 2 at grant date per SPA of executives in Euro 21.89 25.28
Summary of the status of the stock option plans	In the beginning of 2020, there remained a few stock options from the past. A summary of the status of the stock option plans as of 31 December 2020 and the changes during the year then ended is presented as follows: 2020 Weighted 2020 average Options exercise price € per share Outstanding at beginning of the year 32,594 2.79 Options exercised (32,594) 2.79 Options expired — — Options forfeited — — Outstanding at end of the year — — Thereof exercisable — —

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
Stockholders' equity (Tables)	Dec. 31, 2022
Stockholders' equity
Summary of share capital	2022 2021 2020 Shares in Shares in Shares in thousands thousands thousands Issued as of 01 January 176,608 163,915 150,903 Capital increase (cash contribution) — 11,497 11,478 Exercise of share purchase rights 345 1,196 1,534 Issued as of 31 December 176,953 176,608 163,915

Revenues (Tables)

Revenues (Tables)	12 Months Ended
Revenues (Tables)	Dec. 31, 2022
Revenues
Schedule of revenue recognized	The following schedule analyses the revenues Evotec recognized in the financial year 2022: in k€ EVT Execute EVT Innovate Evotec Group Revenues Service fees and FTE-based research payments 498,719 185,268 683,987 Material recharges 38,668 5,768 44,436 Compound access fees 1,464 1,109 2,573 Milestone fees 6,054 12,012 18,066 Licenses 1,813 573 2,386 Total 546,718 204,730 751,448 Timing of revenue recognition At a point in time 44,722 17,780 62,502 Over a period of time 501,996 186,950 688,946 Total 546,718 204,730 751,448 Revenues by region United States 283,755 134,550 418,305 Germany 32,765 26,130 58,895 France 22,546 9,728 32,274 United Kingdom 105,557 9,699 115,256 Rest of the world 102,095 24,623 126,718 Total 546,718 204,730 751,448 The following schedule shows the revenue in the financial year 2021: in k€ EVT Execute EVT Innovate Evotec Group Revenues Service fees and FTE-based research payments 431,184 99,570 530,754 Material recharges 34,104 1,887 35,991 Compound access fees 1,532 43 1,575 Milestone fees 4,232 45,237 49,469 Licenses — 245 245 Total 471,052 146,982 618,034 Timing of revenue recognition At a point in time 38,336 47,124 85,460 Over a period 432,716 99,858 532,574 Total 471,052 146,982 618,034 Revenues by region United States 236,009 101,593 337,602 Germany 24,279 22,573 46,852 France 16,876 13,715 30,591 United Kingdom 98,735 5,905 104,640 Rest of the world 95,153 3,196 98,349 Total 471,052 146,982 618,034 The following schedule shows the revenue in the financial year 2020: in k€ EVT Execute EVT Innovate Evotec Group Revenues Service fees and FTE-based research payments 366,946 93,648 460,594 Material recharges 20,728 1,107 21,835 Compound access fees 1,361 — 1,361 Milestone fees 5,059 12,033 17,092 Licenses — 42 42 Total 394,094 106,830 500,924 Timing of revenue recognition At a certain time 25,787 13,140 38,927 Over a period 368,307 93,690 461,997 Total 394,094 106,830 500,924 Revenues by region United States 189,488 58,360 247,848 Germany 19,529 24,792 44,321 France 21,499 15,561 37,060 United Kingdom 89,258 4,729 93,987 Rest of the world 74,320 3,388 77,708 Total 394,094 106,830 500,924
Schedule of transaction price allocated to the remaining performance obligation	31 Dec 31 Dec 31 Dec 2022 2021 2020 k€ k€ k€ Within one year 405,710 225,061 377,216 After one year 158,068 67,619 69,328

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
Financial instruments (Tables)	Dec. 31, 2022
Disclosure of detailed information about financial instruments [line items]
Schedule of average currency rates	The following table shows the average currency rates as well as the currency rates on 31 December 2022 and 2021 each against the Euro: Average rate 2022 2021 31 December 01 January - 01 January - 31 December 31 December 2022 2021 € € € € USD 0.9496 0.8455 0.9376 0.8829 GBP 1.1727 1.1633 1.1275 1.1901
Currency risks
Disclosure of detailed information about financial instruments [line items]
Schedule of sensitivity analysis	Variance 2022 Variance 2021 Variance 2020 Profit and Profit and Profit and Equity Loss Equity Loss Equity Loss k€ k€ k€ k€ k€ k€ USD (10% strengthening) 31,007 31,007 42,053 42,053 11,321 11,321 USD (10% weakening) (31,007) (31,007) (42,053) (42,053) (11,321) (11,321) GBP (10% strengthening) 3,967 3,967 6,643 6,643 5,702 5,702 GBP (10% weakening) (3,967) (3,967) (6,643) (6,643) (5,702) (5,702) EUR (10% strengthening) 34,974 34,974 48,699 48,699 17,032 17,032 EUR (10% weakening) (34,974) (34,974) (48,699) (48,699) (17,032) (17,032)
Interest rate risks
Disclosure of detailed information about financial instruments [line items]
Schedule of sensitivity analysis	The fair values of the loans and current investments with variable market interest rates as of 31 December 2022 and 2021 would vary by the following amounts: 31 Dec 31 Dec 2022 2021 k€ k€ Variable interest rate +1% point 3,014 2,570 Variable interest rate (1)% point (1,714) (827)

Risks (Tables)

Risks (Tables)	12 Months Ended
Risks (Tables)	Dec. 31, 2022
Risks
Schedule of contractual maturities of financial liabilities	31 Dec 2022 Carrying Contractual Due in Due in More than amount cash flow 1 year 2 - 5 years 5 years k€ k€ k€ k€ k€ Non-derivative financial liabilities Loans (329,851) (345,522) (7,266) (272,749) (65,507) Lease obligations (176,823) (186,894) (19,422) (78,152) (89,320) Contingent consideration (306) (372) (76) (291) (5) Trade accounts payable (97,277) (97,277) (97,277) — — Other financial liabilities (977) (977) (977) — — Total non-derivative financial liabilities (605,234) (631,042) (125,018) (351,192) (154,832) Derivative financial liabilities Interest rate swaps/FX forwards (7,358) (7,358) (6,965) (393) — Total derivative financial liabilities (7,358) (7,358) (6,965) (393) — 31 Dec 2021 Carrying Contractual Due in Due in More than amount cash flow 1 year 2 - 5 years 5 years k€ k€ k€ k€ k€ Non-derivative financial liabilities Loans (362,480) (382,867) (40,467) (253,391) (89,009) Lease obligations (150,437) (175,040) (17,343) (69,396) (88,301) Contingent consideration (1,103) (1,156) (1,156) — — Trade accounts payable (72,598) (72,598) (72,598) — — Other financial liabilities (4,017) (4,017) (4,017) — — Total non-derivative financial liabilities (590,635) (635,678) (135,581) (322,787) (177,310) Derivative financial liabilities Interest rate swaps/FX forwards (9,344) (9,344) (7,423) (1,660) (261) Total derivative financial liabilities (9,344) (9,344) (7,423) (1,660) (261)
Schedule of total assets, equity, equity ratio and net cash	31 Dec 31 Dec 2022 2021 k€ k€ Total assets 2,257,247 2,235,161 Equity attributable to the shareholders of Evotec SE 1,187,184 1,377,685 Equity ratio (in )% 52.6 % 61.6 % Net cash (91,518) 186,409
Schedule of maximum exposure to credit risk for trade receivables	31 Dec 31 Dec 2022 2021 k€ k€ United States 92,034 78,543 France 24,429 17,098 United Kingdom 20,451 12,391 Germany 7,767 6,283 Rest of Europe 13,622 10,363 Rest of the world 10,350 7,400 168,653 132,078
Schedule of reconciliation of cash flows from financing activities to the changes in financial liabilities	Lease Loan liabilities obligations Loan notes k€ k€ k€ As of 1 Jan 2022 362,480 150,437 3 Proceeds from issuance of loans — — — Repayment (34,067) (19,046) — Cashflow from financing activities (34,067) (19,046) — Disposal of finance lease obligation — (232) — Foreign currency translation — (1,120) — Changes in fair value — — — Interest increase 1,438 4,068 — Issue of finance lease obligation — 42,716 — As of 31 Dec 2022 329,851 176,823 3 Lease Loan liabilities obligations Loan notes k€ k€ k€ As of 1 Jan 2021 346,411 145,554 3 Proceeds from issuance of loans 30,791 — — Repayment (16,018) (19,770) — Cashflow from financing activities 14,773 (19,770) — Disposal of finance lease obligation — (58) — Foreign currency translation — 6,691 — Changes in fair value 160 — — Interest increase 1,136 3,728 — Issue of finance lease obligation — 14,292 — As of 31 Dec 2021 362,480 150,437 3

Fair values (Tables)

Fair values (Tables)	12 Months Ended
Fair values (Tables)	Dec. 31, 2022
Fair values
Summary of fair values of financial assets and liabilities other than classified at amortized cost	31 Dec 2022 31 Dec 2021 Classification Carrying Fair Carrying Fair in k€ according to IFRS 9 amount Value amount value Investments Fair value through other comprehensive income 311,899 311,899 158,908 158,908 Long-term investments Fair value through profit and loss 122,477 122,477 268,793 268,793 Assets from derivative financial instruments Fair value through profit and loss 8,215 8,215 0 0 Liabilities from derivative financial instruments Fair value through profit and loss (7,358) (7,358) (9,344) (9,344) Contingent consideration Fair value through profit and loss (306) (306) (1,103) (1,103) 434,927 434,927 417,254 417,254 Unrecognised (gain)/loss — —
Summary of financial assets and financial liabilities to the three levels of the fair value hierarchy	The following table allocates financial assets and financial liabilities to the three levels of the fair value hierarchy as defined in IFRS 13: 31 Dec 2022 in k€ Level 1 Level 2 Level 3 Total Assets at fair value through other comprehensive income 311,899 — — 311,899 Assets at fair value through profit and loss 70,133 8,215 52,344 130,692 Liabilities at fair value through other comprehensive income — — — — Liabilities at fair value through profit and loss — (7,358) (306) (7,664) 31 Dec 2021 in k€ Level 1 Level 2 Level 3 Total Assets at fair value through other comprehensive income 158,908 — — 158,908 Assets at fair value through profit and loss 244,866 — 23,927 268,793 Liabilities at fair value through other comprehensive income — — — — Liabilities at fair value through profit and loss — (9,344) (1,103) (10,447)
Summary of movement of financial assets and liabilities accounted for at fair values at level 3	Other Contingent in k€ Note investments consideration Balance at 1 Jan 2022 23,927 (1,103) Exchange rate differences — — Addition (11);(18) 25,846 (14) Additions due to discontinuation of the use of equity method — — Consumption — — Reclassification to Liabilities — — Net income/expense effected (11) 2,571 811 Balance on 31 Dec 2022 52,344 (306) Other Contingent in k€ Note investments consideration Balance at 1 Jan 2021 19,289 (6,381) Exchange rate differences — (268) Addition (11);(18) 6,647 — Additions due to discontinuation of the use of equity method — — Consumption — 445 Reclassification to Liabilities — 3,571 Net income/expense effected (11) (2,009) 1,530 Balance on 31 Dec 2021 23,927 (1,103)
Summary of sensitivity analysis of fair value measurement to changes in unobservable inputs	2022 2021 Net result Net result in k€ Increase Decrease Increase Decrease Contingent consideration Discount rate (movement of 1.5 %-points) (7) 7 (11) 11 Commercialization success rate (movement of 10 %-points) — — 109 (109) Long-term investments Discount rate (movement of 1.5 %-points) (8,478) 12,539 (4,118) 6,279

Pension plan (Tables)

Pension plan (Tables)	12 Months Ended
Pension plan (Tables)	Dec. 31, 2022
Pension plan
Summary of assumptions used for calculation of defined benefit pension plan obligation	31 Dec 31 Dec 2022 2021 Actuarial interest rate 3.35 % 0.80 % Salary increases 3.00 % 1.90 % Employee turnover 0% - 2.51 % 0% - 1.10 % Retirement age 62 years 62 years Duration 8.7 years 9.2 years
Summary of sensitivity of the actuarial interest rate and the resulting change of the relating pension provision	31 Dec 31 Dec in k€ 2022 2021 Actuarial interest rate +0.50 %-points (550) (626) Actuarial interest rate -0.50 %-points 592 676
Summary of pension provisions	31 Dec 31 Dec in k€ 2022 2021 Pension provision at beginning of the year 14,428 14,441 Addition at acquisition date 553 — Benefit payments from the employer (692) (468) Included in other comprehensive income: Actuarial gains/losses from: Changes in financial assumptions (1,899) (551) Experience adjustments 469 (116) Impact of changes in demographic assumptions 10 3 Included in net income: Current service costs 1,282 1,021 Interest cost 110 98 Pension provision at year-end 14,261 14,428

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
Commitments and contingencies (Tables)	Dec. 31, 2022
Commitments and contingencies
Summary of future minimum lease payments under non-cancellable lease agreements	31 Dec 31 Dec 2022 2021 k€ k€ Less than one year 1,561 801 Between one and five years 16,373 10,595 More than five years 44,979 46,474 Total 62,913 57,870

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
Related party transactions (Tables)	Dec. 31, 2022
Related party transactions
Summary of Related party transactions	Revenues from Cost of Contracts/ revenue/ Trade accounts Other financial Interest income Interest expense receivables assets Other liabilities 1. Jan-31. Dec 2022 1. Jan-31. Dec 2022 31. Dec 2022 31. Dec 2022 31. Dec 2022 Transactions with k EUR k EUR k EUR k EUR k EUR associated companies and joint ventures 36,677 — 3,146 925 — other related party companies — — — — — Revenues from Cost of Contracts/ revenue/ Trade Interest income Interest expense accounts Other financial 1. Jan- 1. Jan- Receivables assets Other liabilities 31. Dec 2021 31. Dec 2021 31. Dec 2021 31. Dec 2021 31. Dec 2021 Transactions with k EUR k EUR k EUR k EUR k EUR associated companies and joint ventures 28,868 146 2,643 153 — other related party companies — — — — — Revenues from Cost of Contracts/ revenue/ Trade Interest income Interest expense accounts Other financial 1. Jan- 1. Jan- receivables assets Other liabilities 31. Dec 2020 31. Dec 2020 31. Dec 2020 31. Dec 2020 31. Dec 2020 Transactions with k EUR k EUR k EUR k EUR k EUR associated companies and joint ventures 35,450 497 2,984 6,435 5,635 other related party companies 32,961 — 6,492 — —

Other disclosures (Tables)

Other disclosures (Tables)	12 Months Ended
Other disclosures (Tables)	Dec. 31, 2022
Remuneration
Schedule of direct and indirect voting rights in subsidiaries and other investments	2022 Company’s voting rights % Subsidiaries Aptuit Global LLC, Princeton, United States 100.00 Aptuit (Verona) SRL, Verona, Italy 100.00 Aptuit (Oxford) Ltd., Abingdon, United Kingdom 100.00 Aptuit (Potters Bar) Ltd., Abingdon, United Kingdom 100.00 Cyprotex Discovery Ltd., Manchester, United Kingdom 100.00 Cyprotex Ltd., Manchester, United Kingdom 100.00 Cyprotex US, LLC., Framingham, United States 100.00 Evotec (France) SAS, Toulouse, France 100.00 Evotec ID (Lyon) SAS, Marcy l’Étoile, France 100.00 Evotec (Hamburg) GmbH, Hamburg, Germany 100.00 Evotec GT GmbH, Orth an der Donau, Austria 100.00 Evotec (India) Private Limited, Thane, India* 100.00 Evotec International GmbH, Hamburg, Germany 100.00 Evotec (München) GmbH, Martinsried, Germany 100.00 Evotec (UK) Ltd., Abingdon, United Kingdom 100.00 Evotec (US), Inc., Princeton, United States 100.00 Just-Evotec Biologics, Inc., Seattle, United States 100.00 Just-Evotec Biologics EU SAS, Toulouse, France 100.00 Evotec Drug Substance (Germany), Halle, Germany 100.00 Evotec (Modena) Srl., Medolla, Italy 100.00 2022 Company’s voting rights % Associates and joint ventures Ananke Therapeutics Inc., Boston, United States 20.09 Autobahn Labs, Palo Alto, United States 35.94 Breakpoint Therapeutics GmbH, Hamburg, Germany 34.12 Celmatix Inc., New York, United States 39.09 Curexsys GmbH, Göttingen, Germany 43.44 Dark Blue Therapeutics Ltd., Oxford, United Kingdom 39.11 Eternygen GmbH, Berlin, Germany 24.97 NephThera GmbH, Hamburg, Germany 50.00 Pancella Inc, Toronto, Canada 12.65 Quantro Therapeutics GmbH, Wien, Austria 38.79 Topas Therapeutics GmbH, Hamburg, Germany 22.14 Tucana Biosciences Inc., Boston, United States 26.92 Other Investments Aeovian Pharmaceuticals Inc., San Francisco, United States 3.79 ArgoBio SAS, Paris, France 10.02 Aurobac Therapeutics SAS, Lyon, France 12.50 Blacksmith Medicines Inc., San Diego, United States 18.00 Cajal Neuroscience Inc., Seattle, United States 1.67 Carma Fund I, Munich, Germany 10.00 Carrick Therapeutics Ltd., Dublin, Ireland 3.48 Centauri Therapeutics Ltd., Sandwich (Kent), United Kingdom 13.17 Curie Bio LLC, Boston, United States 0.11 Curie Bio Seed Fund I L.P., Boston, United States 2.82 Exscientia plc (formely Exscientia Ltd.), Oxford, United Kingdom 11.42 Extend Srl, Rome, Italy 10.00 Fibrocor LLP, Toronto, Canada 16.26 Fibrocor Therapeutics Inc., Toronto, Canada 8.98 IMIDomics Inc., San Francisco, United States 11.77 Immunitas, Therapeutics, Inc., Waltham, United States 6.17 Leon Nanodrugs GmbH, München, Germany 13.24 Mission BioCapital V LP, Cambridge, United States 3.64 OxVax Ltd., Oxford, United Kingdom 12.22 Sernova Corp., Ontario, Canada 5.16 Tubulis GmbH, Munich, Germany 6.90 * in voluntary liquidation
Management Board
Remuneration
Schedule of remuneration granted to the members of the Management Board and remuneration accrued for the members of the Supervisory Board	2022 2022 2022 2022 2022 Fixed Variable Share Performance Fair value of remuneration remuneration and Restricted SPAs and Total (short-term) (short-term) Share Awards RSAs granted remuneration k€ k€ in pcs k€ k€ Dr. Werner Lanthaler 741 578 27,040 1,200 2,519 Dr. Cord Dohrmann 469 335 13,520 600 1,404 Dr. Craig Johnstone 442 270 48,500 1,400 2,112 Enno Spillner 387 216 10,816 480 1,083 Dr. Matthias Evers 304 180 39,353 900 1,384 Total 2,343 1,579 139,229 4,580 8,502 2021 2021 2021 2021 2021 Fixed Variable Share Performance Fair value of remuneration remuneration and Restricted SPAs and Total (short-term) (short-term) Share Awards RSAs granted remuneration k€ k€ in pcs k€ k€ Dr. Werner Lanthaler 711 590 100,769 3,313 4,614 Dr. Cord Dohrmann 451 275 40,956 1,348 2,074 Dr. Craig Johnstone 382 234 9,439 296 912 Enno Spillner 384 220 8,884 278 882 Total 1,928 1,319 160,048 5,235 8,482
Supervisory Board
Remuneration
Schedule of remuneration granted to the members of the Management Board and remuneration accrued for the members of the Supervisory Board	2022 2021 Remuneration Remuneration k€ k€ Prof. Dr. Iris Löw-Friedrich 150.0 113.6 Roland Sackers 95.0 90.5 Dr. Mario Polywka 60.0 55.5 Dr. Elaine Sullivan 65.3 60.0 Kasim Kutay 28.4 60.0 Dr. Constanze Ulmer-Eilfort 73.2 32.7 Prof. Dr. Wolfgang Plischke — 68.2 Camilla Macapili Languille 31.6 — Total 503.5 480.5

Summary of significant accoun_4

Summary of significant accounting policies (Details)	12 Months Ended
Summary of significant accounting policies (Details)	Dec. 31, 2022
Buildings and leasehold improvements
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	30 years
Buildings and leasehold improvements \| Minimum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	3 years
Plant, machinery and equipment
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	15 years
Plant, machinery and equipment \| Minimum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	4 years
Furniture and fixtures
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	15 years
Furniture and fixtures \| Minimum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	3 years

Summary of significant accoun_5

Summary of significant accounting policies - Leases (Details) - Right-of use assets	12 Months Ended
	Dec. 31, 2022
Buildings \| Minimum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	1 year
Buildings \| Maximum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	20 years
Plant and machinery \| Minimum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	2 years
Plant and machinery \| Maximum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	7 years
Motor vehicles \| Minimum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	3 years
Motor vehicles \| Maximum
Disclosure of detailed information about property, plant and equipment
Estimated useful lives (in years)	4 years

Summary of significant accoun_6

Summary of significant accounting policies - Intangible assets, excluding goodwill (Details)	12 Months Ended
	Dec. 31, 2022
Trademarks \| Minimum
Disclosure of detailed information about intangible assets
Useful lives of intangible assets, excluding goodwill (in years)	2 years
Trademarks \| Maximum
Disclosure of detailed information about intangible assets
Useful lives of intangible assets, excluding goodwill (in years)	10 years
Developed technology \| Minimum
Disclosure of detailed information about intangible assets
Useful lives of intangible assets, excluding goodwill (in years)	6 years
Developed technology \| Maximum
Disclosure of detailed information about intangible assets
Useful lives of intangible assets, excluding goodwill (in years)	18 years
Patents and licences \| Maximum
Disclosure of detailed information about intangible assets
Useful lives of intangible assets, excluding goodwill (in years)	15 years

Summary of significant accoun_7

Summary of significant accounting policies - Income taxes (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement
Tax rate	32.28%	32.28%	32.28%
Minimum \| Domestic
Statement
Tax rate	27%	27%	27%
Minimum \| Foreign
Statement
Tax rate	19%	19%	19%
Maximum \| Domestic
Statement
Tax rate	32%	32%	32%
Maximum \| Foreign
Statement
Tax rate	31%	28%	31%

Summary of significant accoun_8

Summary of significant accounting policies - Net income per share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Summary of significant accounting policies
Number of shares issued	176,952,653	176,608,195	163,915,000		150,903,000
Treasury shares	(249,915)	(249,915)	(250,000)		(250,000)
Effect of weighted average share capital increase	316,000	1,953,000	2,508,000
Effect of weighted average share options exercised		788,000	591,000
Weighted average number of ordinary shares 31 December	176,674,341	166,405,926	153,752,241	[1]
Number of potentially dilutive shares to be issued from stock options and Share Performance Awards	463,415	722,286	1,172,673

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Segment information (Details)

Segment information (Details) - EUR (€) € in Thousands	12 Months Ended
Segment information (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segments
Revenues	€ 751,448	€ 618,034	€ 500,924	[1]
Operating income (loss)	20,850	40,996	48,556	[1]
EVT Execute
Segments
Revenues	546,718	471,052	394,094
EVT Execute \| Contributions
Segments
Revenues	10,551	8,565	4,648
EVT Innovate
Segments
Revenues	204,730	146,982	106,830
Operating segments \| EVT Execute
Segments
Revenues	735,635	610,168	509,870
Operating income (loss)	32,523	63,109	77,362
Operating segments \| EVT Execute \| Contributions
Segments
Revenues	10,551	8,565	4,648
Operating segments \| EVT Innovate
Segments
Revenues	204,730	146,982	106,830
Operating income (loss)	(11,673)	(22,113)	(28,806)
Intersegment eliminations
Segments
Revenues	€ (188,917)	€ (139,116)	€ (115,776)

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Segment information - Non curre

Segment information - Non current assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Geographical areas
Non-current Assets	€ 1,042,206	€ 848,069
United States
Geographical areas
Non-current Assets	231,439	209,508
United Kingdom
Geographical areas
Non-current Assets	211,115	196,543
Italy
Geographical areas
Non-current Assets	227,113	188,858
France
Geographical areas
Non-current Assets	205,749	129,178
Germany
Geographical areas
Non-current Assets	160,970	105,283
Switzerland
Geographical areas
Non-current Assets		14,089
Austria
Geographical areas
Non-current Assets	3,914	2,697
Canada
Geographical areas
Non-current Assets	€ 1,906	€ 1,913

Acquisitions (Details)

Acquisitions (Details) - EUR (€)		2 Months Ended	6 Months Ended	12 Months Ended
Acquisitions (Details) - EUR (€)	Nov. 01, 2022	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2022	Jul. 01, 2022	Dec. 31, 2021
Acquisitions
Earn-out provision		€ 306,000	€ 306,000	€ 306,000		€ 1,103,000
Gain recognised in bargain purchase transaction				4,908,000
Evotec (Modena) Srl., Medolla, Italy
Acquisitions
Ownership interest acquired (in percent)					100%
Purchase price in cash					€ 23,000,000
Contingent consideration					14,000
Earn-out provision		14,000	14,000	14,000
Intangible assets					727,000
Goodwill					19,622,000
Net profit (loss) since acquisition date			159,000
Revenue since acquisition date			€ 1,715,000
Revenue, combined entity				1,781,000
Net profit (loss), combined entity				(889,000)
Transaction costs				773,000
Evotec (Modena) Srl., Medolla, Italy \| Developed technology for cell-based gene therapy product
Acquisitions
Intangible assets					120,000
Evotec (Modena) Srl., Medolla, Italy \| Two other developed technologies
Acquisitions
Intangible assets					€ 0
Evotec Drug Substance (Germany), Halle, Germany
Acquisitions
Ownership interest acquired (in percent)	100%
Purchase price in cash	€ 1
Intangible assets	23,000
Order backlog	(2,200,000)
Fair value adjustment of inventories	(981,000)
Gain recognised in bargain purchase transaction	€ 4,909,000
Net profit (loss) since acquisition date		(559,000)
Revenue since acquisition date		€ 2,097,000
Revenue, combined entity				5,396,000
Net profit (loss), combined entity				(5,261,000)
Transaction costs				€ 943,000

Acquisitions - Fair Value at th

Acquisitions - Fair Value at the date of acquisition (Details) - EUR (€) € in Thousands			12 Months Ended
	Nov. 01, 2022	Jul. 01, 2022	Dec. 31, 2022	Dec. 31, 2020	[1]
Fair values at date of acquisition
Bargain Purchase			€ (4,908)
Cash outflow on acquisition			€ 20,859	€ 10,929
Evotec (Modena) Srl., Medolla, Italy
Fair values at date of acquisition
Cash and cash equivalents		€ 263
Trade accounts receivables		244
Inventories		29
Property, plant and equipment		3,809
Intangible assets		727
Deferred tax asset		344
Other assets		374
Trade accounts payable		(382)
Current liabilities		(564)
Non-current liabilities		(1,009)
Other liabilities		(370)
Other accrued liabilities		(73)
Net assets acquired		3,392
Goodwill		19,622
Cost of acquisition / Consideration transferred		23,014
Contingent consideration		(14)
Cash and cash equivalents acquired		(263)
Cash outflow on acquisition		€ 22,737
Evotec Drug Substance (Germany), Halle, Germany
Fair values at date of acquisition
Cash and cash equivalents	€ 16,099
Trade accounts receivables	1,210
Inventories	2,903
Prepaid expenses	77
Property, plant and equipment	6,213
Intangible assets	23
Deferred tax asset	725
Trade accounts payable	(43)
Current provisions	(609)
Contract liabilities	(705)
Current tax payables	(76)
Other payables	(7)
Non-current provisions	(553)
Non-current lease liabilities	(3,940)
Order intake	(2,200)
Net assets acquired	19,117
Bargain Purchase	(4,909)
Cost of acquisition / Consideration transferred	14,208
Cash and cash equivalents acquired	(16,099)
Purchase price for shareholder loan	(14,208)
Cash outflow on acquisition	€ (1,891)

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Cash, cash equivalents and in_2

Cash, cash equivalents and investments (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents and investments \| Accumulated impairment
Financial instruments
Financial assets	€ (225)	€ (239)
Corporate bonds
Financial instruments
Unrealized gains of assets recognized in other comprehensive income	12,064	1,448
Cash balances with credit institutions
Financial instruments
Restricted cash balances	€ 14,458	€ 7,736

Trade accounts receivables (Det

Trade accounts receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Trade receivables
Trade accounts receivables	€ 168,653	€ 132,078
Minimum
Trade receivables
Expected credit loss rate	0.078%	0.024%
Maximum
Trade receivables
Expected credit loss rate	16.758%	21.80%
Gross/Acquisition and manufacturing costs \| Not past due
Trade receivables
Trade accounts receivables	€ 136,372	€ 95,556
Gross/Acquisition and manufacturing costs \| 1-30 days
Trade receivables
Trade accounts receivables	24,425	31,222
Gross/Acquisition and manufacturing costs \| 31-120 days
Trade receivables
Trade accounts receivables	6,301	5,164
Gross/Acquisition and manufacturing costs \| More than 120 days
Trade receivables
Trade accounts receivables	4,778	2,236
Accumulated impairment
Trade receivables
Trade accounts receivables	(3,223)	(2,100)
Accumulated impairment \| Specific default risk
Trade receivables
Trade accounts receivables	(2,312)	(1,584)
Accumulated impairment \| Expected credit risk in accordance with IFRS 9
Trade receivables
Trade accounts receivables	(911)	(516)
Accumulated impairment \| 1-30 days
Trade receivables
Trade accounts receivables	(67)	(30)
Accumulated impairment \| 31-120 days
Trade receivables
Trade accounts receivables	(323)	(89)
Accumulated impairment \| More than 120 days
Trade receivables
Trade accounts receivables	€ (2,833)	€ (1,981)

Inventories (Details)

Inventories (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventories
Raw materials	€ 27,917	€ 25,043
Work-in-progress	1,908	750
Total inventories	29,825	25,793
Accumulated impairment
Inventories
Total inventories	€ (1,679)	€ (595)

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid expenses and other current assets
Prepaid expenses	€ 16,948	€ 19,210
Other	40,178	20,685
Total prepaid expenses and other current assets	57,126	39,895
VAT-related receivables	19,035	€ 14,943
Positive fair values of forward exchange contracts	€ 8,215

Long-term Investments account_3

Long-term Investments accounted for using the equity method (Details) € in Thousands				12 Months Ended
	Dec. 31, 2021 EUR (€)	Jun. 30, 2021	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 EUR (€) item	Dec. 31, 2021 EUR (€)
Investments
Equity book value limit				€ 10,000
Evotec's share of earnings limit				€ 2,000
Number of investments classified as significant \| item				5
Number of investments classified as insignificant \| item				8
Balance at beginning				€ 13,068	€ 39,710
Additions				18,940	10,911
Pro rata net result				(15,965)	(16,570)
Loss against other current assets					977
Impairment					(2,497)
Discontinued use of equity method					(19,463)
Net book value at end	€ 13,068		€ 39,710	16,043	13,068
NephThera GmbH
Investments
Balance at beginning					486
Pro rata net result					(486)
Net book value at end			486
Autobahn Labs LLC
Investments
Additions				3,634
Pro rata net result				(2,263)
Net book value at end				1,371
Exscientia plc
Investments
Balance at beginning					21,040
Pro rata net result					(1,577)
Discontinued use of equity method					(19,463)
Net book value at end			€ 21,040
Proportion of ownership interest held (in percent)	11.70%	14.84%	20.32%
Breakpoint Therapeutics GmbH
Investments
Balance at beginning				2,774	1,918
Additions					3,667
Pro rata net result				(2,774)	(2,811)
Net book value at end	€ 2,774		€ 1,918		2,774
Curexsys GmbH
Investments
Balance at beginning				4,212
Additions				2,564
Pro rata net result				(2,809)
Net book value at end	4,212			3,967	4,212
Dark Blue Therapeutics Ltd
Investments
Balance at beginning				405
Additions				7,167
Pro rata net result				(3,550)
Net book value at end	405			4,022	405
Topas Therapeutics GmbH
Investments
Balance at beginning				1,497
Additions				1,821
Pro rata net result				(2,913)
Net book value at end	1,497			405	1,497
Tucana Biosciences Inc.
Investments
Additions				2,504
Insignificant Investments
Investments
Balance at beginning				4,180
Additions				3,754
Pro rata net result				(1,656)
Net book value at end	4,180			6,278	4,180
Insignificant investments
Investments
Balance at beginning				€ 10,294	16,266
Additions					7,244
Pro rata net result					(11,696)
Loss against other current assets					977
Impairment					(2,497)
Net book value at end	€ 10,294		€ 16,266		€ 10,294

Long-term Investments account_4

Long-term Investments accounted for using the equity method - Financial Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	[1]
Investments
Current assets	€ 1,073,671	€ 1,100,940
Non-current assets	1,183,576	1,134,221
Current liabilities	337,706	324,516
Non-current liabilities	732,357	532,960
Revenues from 01 Jan to 31 Dec	751,448	618,034	€ 500,924
Net result from 01 Jan to 31 Dec	(175,655)	215,510	€ 6,278
Autobahn Labs LLC
Investments
Current assets	4,029
Non-current assets	6
Current liabilities	672
Net result from 01 Jan to 31 Dec	(6,144)
Breakpoint Therapeutics GmbH
Investments
Current assets	7,204	18,501
Non-current assets	2	2
Current liabilities	1,068	719
Non-current liabilities	143
Net result from 01 Jan to 31 Dec	(11,789)	(8,283)
Curexsys GmbH
Investments
Current assets	3,409
Non-current assets	484
Current liabilities	302
Non-current liabilities	85
Revenues from 01 Jan to 31 Dec	15
Net result from 01 Jan to 31 Dec	(6,940)
Dark Blue Therapeutics Ltd
Investments
Current assets	14,244
Non-current assets	32
Current liabilities	1,065
Non-current liabilities	8,208
Net result from 01 Jan to 31 Dec	1,025
Topas Therapeutics GmbH
Investments
Current assets	6,795
Current liabilities	843
Net result from 01 Jan to 31 Dec	€ (9,340)
NephThera GmbH
Investments
Current assets		8,013
Non-current assets		10
Current liabilities		525
Net result from 01 Jan to 31 Dec		€ (5,769)

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Other long-term investments (De

Other long-term investments (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Investments other than equity method investments
Balance at 1 January	€ 268,793	€ 19,289
Additions	46,137	6,647
Additions due to discontinue use of equity method		19,463
Adjustments at fair value, affecting net income	(172,159)	223,394
Adjustments at fair value, affecting OCI	(11,729)
Net book value 31 December	131,042	€ 268,793
Exscientia plc
Investments other than equity method investments
Adjustments at fair value, affecting net income	€ (174,729)

Property, plant and equipment_2

Property, plant and equipment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	€ 484,597	€ 337,297
Amount end of the year	650,201	484,597
Gross/Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	686,086	481,879
Foreign currency translation	4,894	17,755
Additions	228,565	190,816
Business combination	10,044
Disposals	8,779	4,364
Amount end of the year	920,810	686,086
Depreciation, amortisation and write-downs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	(201,489)	(144,582)
Foreign currency translation	719	(5,167)
Additions	(72,677)	(55,596)
Disposals	(2,838)	(3,856)
Amount end of the year	(270,609)	(201,489)
Buildings and leasehold improvements
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	315,088	174,583
Amount end of the year	364,603	315,088
Buildings and leasehold improvements \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	378,467	215,055
Foreign currency translation	3,234	9,099
Additions	61,673	83,535
Business combination	6,534
Disposals	3,573	3,022
Reclass	16,727	73,800
Amount end of the year	463,062	378,467
Buildings and leasehold improvements \| Depreciation, amortisation and write-downs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	(63,379)	(40,472)
Foreign currency translation	196	(1,919)
Additions	(33,126)	(23,463)
Disposals	(44)	(2,552)
Reclass	(2,194)	(77)
Amount end of the year	(98,459)	(63,379)
Plant, machinery and equipment
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	113,710	81,176
Amount end of the year	149,629	113,710
Plant, machinery and equipment \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	227,611	168,224
Foreign currency translation	839	4,576
Additions	59,611	36,082
Business combination	3,309
Disposals	3,101	443
Reclass	1,667	19,172
Amount end of the year	289,936	227,611
Plant, machinery and equipment \| Depreciation, amortisation and write-downs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	(113,901)	(87,048)
Foreign currency translation	355	(2,628)
Additions	(30,490)	(24,826)
Disposals	(1,563)	(424)
Reclass	2,166	177
Amount end of the year	(140,307)	(113,901)
Furniture and fixtures
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	15,449	10,383
Amount end of the year	19,588	15,449
Furniture and fixtures \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	39,658	27,445
Foreign currency translation	(62)	718
Additions	11,663	7,546
Business combination	107
Disposals	1,243	860
Reclass	1,308	4,809
Amount end of the year	51,431	39,658
Furniture and fixtures \| Depreciation, amortisation and write-downs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	(24,209)	(17,062)
Foreign currency translation	168	(620)
Additions	(9,061)	(7,307)
Disposals	(1,231)	(880)
Reclass	28	(100)
Amount end of the year	(31,843)	(24,209)
Assets under construction
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	40,350	71,155
Amount end of the year	116,381	40,350
Assets under construction \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about property, plant and equipment
Amount beginning of the year	40,350	71,155
Foreign currency translation	883	3,362
Additions	95,618	63,653
Business combination	94
Disposals	862	39
Reclass	(19,702)	(97,781)
Amount end of the year	€ 116,381	€ 40,350

Property, plant and equipment -

Property, plant and equipment - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment
Right-of-use assets	€ 168,327	€ 145,038
Increase in property, plant and equipment	165,604
Just-Evotec Biologics EU SAS, Toulouse, France
Disclosure of detailed information about property, plant and equipment
Increase in property, plant and equipment	€ 55,705

Leases - Right of use assets (D

Leases - Right of use assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Amount beginning of the year	€ 484,597	€ 337,297
Amount end of the year	650,201	484,597
Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	686,086	481,879
Foreign currency translation	4,894	17,755
Additions	228,565	190,816
Business combination	10,044
Disposals	8,779	4,364
Amount end of the year	920,810	686,086
Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(201,489)	(144,582)
Foreign currency translation	719	(5,167)
Additions	(72,677)	(55,596)
Disposals	(2,838)	(3,856)
Amount end of the year	(270,609)	(201,489)
Plant, machinery and equipment
Leases
Amount beginning of the year	113,710	81,176
Amount end of the year	149,629	113,710
Plant, machinery and equipment \| Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	227,611	168,224
Foreign currency translation	839	4,576
Additions	59,611	36,082
Business combination	3,309
Disposals	3,101	443
Reclass	1,667	19,172
Amount end of the year	289,936	227,611
Plant, machinery and equipment \| Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(113,901)	(87,048)
Foreign currency translation	355	(2,628)
Additions	(30,490)	(24,826)
Disposals	(1,563)	(424)
Reclass	2,166	177
Amount end of the year	(140,307)	(113,901)
Furniture and Fixtures
Leases
Amount beginning of the year	15,449	10,383
Amount end of the year	19,588	15,449
Furniture and Fixtures \| Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	39,658	27,445
Foreign currency translation	(62)	718
Additions	11,663	7,546
Business combination	107
Disposals	1,243	860
Reclass	1,308	4,809
Amount end of the year	51,431	39,658
Furniture and Fixtures \| Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(24,209)	(17,062)
Foreign currency translation	168	(620)
Additions	(9,061)	(7,307)
Disposals	(1,231)	(880)
Reclass	28	(100)
Amount end of the year	(31,843)	(24,209)
Right-of use assets
Leases
Amount beginning of the year	145,038	142,110
Amount end of the year	168,325	145,038
Right-of use assets \| Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	186,676	167,365
Foreign currency translation	(936)	7,472
Additions	39,037	14,292
Business combination	3,962
Disposals		2,453
Amount end of the year	228,739	186,676
Right-of use assets \| Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(41,638)	(25,255)
Foreign currency translation	(117)	(2,717)
Additions	(18,659)	(15,829)
Disposals		(2,163)
Amount end of the year	(60,414)	(41,638)
Right-of use assets \| Buildings
Leases
Amount beginning of the year	141,880	137,285
Amount end of the year	166,955	141,880
Right-of use assets \| Buildings \| Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	177,602	158,454
Foreign currency translation	(919)	7,442
Additions	38,393	14,077
Business combination	3,940
Disposals		2,453
Reclass	3,718	82
Amount end of the year	222,734	177,602
Right-of use assets \| Buildings \| Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(35,722)	(21,169)
Foreign currency translation	(8)	(2,573)
Additions	(17,855)	(14,160)
Disposals		(2,163)
Reclass	(2,194)	17
Amount end of the year	(55,779)	(35,722)
Right-of use assets \| Plant, machinery and equipment
Leases
Amount beginning of the year	2,693	4,443
Amount end of the year	786	2,693
Right-of use assets \| Plant, machinery and equipment \| Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	8,077	8,382
Foreign currency translation	(17)	30
Additions	306
Reclass	(3,678)	(335)
Amount end of the year	4,688	8,077
Right-of use assets \| Plant, machinery and equipment \| Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(5,384)	(3,939)
Foreign currency translation	(109)	(120)
Additions	(575)	(1,462)
Reclass	2,166	137
Amount end of the year	(3,902)	(5,384)
Right-of use assets \| Furniture and Fixtures
Leases
Amount beginning of the year	465	382
Amount end of the year	584	465
Right-of use assets \| Furniture and Fixtures \| Gross/Acquisition and manufacturing costs
Leases
Amount beginning of the year	997	529
Additions	338	215
Business combination	22
Reclass	(40)	253
Amount end of the year	1,317	997
Right-of use assets \| Furniture and Fixtures \| Depreciation, amortisation and write-downs
Leases
Amount beginning of the year	(532)	(147)
Foreign currency translation		(24)
Additions	(229)	(207)
Reclass	28	(154)
Amount end of the year	€ (733)	€ (532)

Leases - Carrying amounts of le

Leases - Carrying amounts of lease liabilities and the movements (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Amount beginning of the year	€ 150,437	€ 145,554
Foreign currency translation	(923)	6,691
Additions	38,784	14,292
Business combination	3,962
Disposals	(232)	(58)
Accretion of interest	3,841	3,728	€ 3,125
Payments	(19,046)	(19,770)
Amount end of the year	€ 176,823	€ 150,437	€ 145,554

Leases - Lease liabilities (Det

Leases - Lease liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Current portion of lease obligations	€ 14,825	€ 14,473
Long-term lease obligations	161,998	135,964
Total lease liabilities	€ 176,823	€ 150,437	€ 145,554

Leases - Amounts recognised in

Leases - Amounts recognised in profit and loss (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Depreciation expense of right-of-use assets	€ 18,659	€ 15,829	€ 16,035
Interest expense on lease liability	3,841	3,728	3,125
Expense relating to short-term leases	476	839	807
Expense relating to leases of low-value assets	50	56	33
Total amount recognised in profit and loss	23,026	20,452	20,000
Cash outflows for leases	€ 19,046	€ 20,665	€ 21,014

Intangible assets, excluding _3

Intangible assets, excluding goodwill (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about intangible assets
Amount beginning of the year	€ 30,851	€ 98,036
Impairment of intangible assets		(683)	€ (3,244)	[1]
Amount end of the year	23,819	30,851	98,036
Gross/Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets
Amount beginning of the year	186,623	245,836
Foreign currency translation	34	2,381
Additions	917	439
Business combination	1,672
Disposals		62,033
Amount end of the year	189,246	186,623	245,836
Depreciation, amortisation and write-downs
Disclosure of detailed information about intangible assets
Amount beginning of the year	(155,772)	(147,800)
Foreign currency translation	393	(1,039)
Additions	(10,048)	(12,012)
Disposals		(5,762)
Impairment of intangible assets		(683)
Amount end of the year	(165,427)	(155,772)	(147,800)
Patents and licences
Disclosure of detailed information about intangible assets
Amount beginning of the year	1,029	677
Amount end of the year	1,534	1,029	677
Patents and licences \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets
Amount beginning of the year	11,211	10,772
Additions		439
Business combination	1,672
Amount end of the year	12,883	11,211	10,772
Patents and licences \| Depreciation, amortisation and write-downs
Disclosure of detailed information about intangible assets
Amount beginning of the year	(10,182)	(10,095)
Additions	(1,223)	(87)
Reclass	56
Amount end of the year	(11,349)	(10,182)	(10,095)
Developed technology
Disclosure of detailed information about intangible assets
Amount beginning of the year	6,801	8,573
Impairment of intangible assets		(683)
Amount end of the year	6,575	6,801	8,573
Developed technology \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets
Amount beginning of the year	99,784	98,845
Foreign currency translation	34	939
Additions	917
Amount end of the year	100,735	99,784	98,845
Developed technology \| Depreciation, amortisation and write-downs
Disclosure of detailed information about intangible assets
Amount beginning of the year	(92,983)	(90,272)
Foreign currency translation	438	(348)
Additions	(1,559)	(1,680)
Reclass	(56)
Impairment of intangible assets		(683)
Amount end of the year	(94,160)	(92,983)	(90,272)
Customer related
Disclosure of detailed information about intangible assets
Amount beginning of the year	21,698	29,861
Additions	(6,969)
Amount end of the year	14,684	21,698	29,861
Customer related \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets
Amount beginning of the year	69,089	67,647
Foreign currency translation		1,442
Amount end of the year	69,089	69,089	67,647
Customer related \| Depreciation, amortisation and write-downs
Disclosure of detailed information about intangible assets
Amount beginning of the year	(47,391)	(37,786)
Foreign currency translation	(45)	(691)
Additions	(6,969)	(8,914)
Amount end of the year	(54,405)	(47,391)	(37,786)
Trademarks
Disclosure of detailed information about intangible assets
Amount beginning of the year	1,323	1,965
Amount end of the year	1,026	1,323	1,965
Trademarks \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets
Amount beginning of the year	6,539	6,539
Amount end of the year	6,539	6,539	6,539
Trademarks \| Depreciation, amortisation and write-downs
Disclosure of detailed information about intangible assets
Amount beginning of the year	(5,216)	(4,574)
Additions	(297)	(642)
Amount end of the year	€ (5,513)	(5,216)	(4,574)
Favorable Contract
Disclosure of detailed information about intangible assets
Amount beginning of the year		56,960
Amount end of the year			56,960
Favorable Contract \| Gross/Acquisition and manufacturing costs
Disclosure of detailed information about intangible assets
Amount beginning of the year		62,033
Disposals		62,033
Amount end of the year			62,033
Favorable Contract \| Depreciation, amortisation and write-downs
Disclosure of detailed information about intangible assets
Amount beginning of the year		(5,073)
Additions		(689)
Disposals		€ (5,762)
Amount end of the year			€ (5,073)

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Intangible assets, excluding _4

Intangible assets, excluding goodwill - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about intangible assets
Decrease in intangible assets other than goodwill	€ (7,032)
Intangible assets, excluding goodwill	23,819	€ 30,851	€ 98,036
Impairment amount		683	3,244	[1]
Customer related
Disclosure of detailed information about intangible assets
Intangible assets, excluding goodwill	14,684	21,698	29,861
Amortization	6,969
Aptuit customer base
Disclosure of detailed information about intangible assets
Amortization	5,557
Developed technology
Disclosure of detailed information about intangible assets
Intangible assets, excluding goodwill	€ 6,575	6,801	€ 8,573
Impairment amount		€ 683

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Goodwill - Development of goodw

Goodwill - Development of goodwill (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill
Goodwill at beginning of period	€ 257,569	€ 247,370
Business combination	19,622
Foreign currency translation	(2,372)	10,199
Goodwill at end of period	274,819	257,569
OAI/Evotec International Execute
Goodwill
Goodwill at beginning of period	84,480	79,816
Foreign currency translation	(2,257)	4,664
Goodwill at end of period	82,223	84,480
OAI/Evotec International Innovate
Goodwill
Goodwill at beginning of period	9,204	9,154
Foreign currency translation	(40)	50
Goodwill at end of period	9,164	9,204
Aptuit Execute
Goodwill
Goodwill at beginning of period	128,845	126,059
Business combination	19,622
Foreign currency translation	(2,243)	2,786
Goodwill at end of period	146,224	128,845
Evotec (US) Execute
Goodwill
Goodwill at beginning of period	4,197	3,874
Foreign currency translation	260	323
Goodwill at end of period	4,457	4,197
Just Execute
Goodwill
Goodwill at beginning of period	30,843	28,467
Foreign currency translation	1,908	2,376
Goodwill at end of period	€ 32,751	€ 30,843

Goodwill - Cash-generating unit

Goodwill - Cash-generating units (Details)	12 Months Ended
Goodwill - Cash-generating units (Details)	Dec. 31, 2022	Dec. 31, 2021
Cash generating units except for Just Execute
Impairment
Cash flow projection period based on strategic/detailed plan	5 years
Cash flow projection period including simplified transition period	10 years
OAI/Evotec International Execute
Impairment
Pre-tax discount rate	10.15%	8.19%
Growth rate for terminal value	2%	2%
OAI/Evotec International Innovate
Impairment
Pre-tax discount rate	11.93%	11.51%
Growth rate for terminal value	2%	2%
Evotec (US) Execute
Impairment
Pre-tax discount rate	9.32%	7.87%
Growth rate for terminal value	2%	2%
Aptuit Execute
Impairment
Pre-tax discount rate	13.12%	9.83%
Growth rate for terminal value	2%	2%
Just Execute
Impairment
Cash flow projection period based on strategic/detailed plan	10 years
Pre-tax discount rate	11.71%	9.22%
Growth rate for terminal value	2%	2%

Goodwill - Changes in the key a

Goodwill - Changes in the key assumptions (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Impairment
Impairment loss	€ 0	€ 0
Future cash flows
Impairment
Percentage of reasonably possible increase (decrease) in key assumption	(10.00%)
Impairment loss due to reasonably possible increase (decrease) in key assumption	€ 0
Discount rate
Impairment
Percentage of reasonably possible increase (decrease) in key assumption	10%
Impairment loss due to reasonably possible increase (decrease) in key assumption	€ 0
Terminal sustainable growth rate
Impairment
Percentage of reasonably possible increase (decrease) in key assumption	(1.00%)
Impairment loss due to reasonably possible increase (decrease) in key assumption	€ 0
Just Execute \| Scenario analysis
Impairment
Impairment loss due to reasonably possible increase (decrease) in key assumption	€ 0

Loan liabilities (Details)

Loan liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Borrowings
Accrued short-term interest	€ 1,092	€ 1,136
Unutilized lines of credit	245,509	€ 99,601
Facility with European Investment Bank
Borrowings
Unutilized lines of credit	€ 150,000

Loan liabilities - Details (Det

Loan liabilities - Details (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Borrowings
Loans, excluding accrued interest	€ 328,759	€ 361,344
Fair value disclosed
Borrowings
Loans, excluding accrued interest	306,840	371,412
Germany 0.9-3.8%
Borrowings
Loans, excluding accrued interest	€ 214,671	€ 249,530
Germany 0.9-3.8% \| Minimum
Borrowings
Nominal interest rate	0.90%	0.90%
Germany 0.9-3.8% \| Maximum
Borrowings
Nominal interest rate	3.80%	3.80%
Germany 0.9-3.8% \| Fair value disclosed
Borrowings
Loans, excluding accrued interest	€ 198,281	€ 254,911
Germany 1.60%
Borrowings
Nominal interest rate	1.60%	1.60%
Loans, excluding accrued interest	€ 75,000	€ 75,000
Germany 1.60% \| Fair value disclosed
Borrowings
Loans, excluding accrued interest	€ 71,846	€ 78,596
Germany 1.20%
Borrowings
Nominal interest rate	1.20%	1.20%
Loans, excluding accrued interest	€ 6,722	€ 7,797
Germany 1.20% \| Fair value disclosed
Borrowings
Loans, excluding accrued interest	€ 6,358	€ 8,014
Germany 1.40%
Borrowings
Nominal interest rate	1.40%	1.40%
Loans, excluding accrued interest	€ 20,367	€ 20,367
Germany 1.40% \| Fair value disclosed
Borrowings
Loans, excluding accrued interest	19,099	€ 21,332
Italy 1.3-3.05%
Borrowings
Loans, excluding accrued interest	€ 1,257
Italy 1.3-3.05% \| Minimum
Borrowings
Nominal interest rate	1.30%
Italy 1.3-3.05% \| Maximum
Borrowings
Nominal interest rate	3.05%
Italy 1.3-3.05% \| Fair value disclosed
Borrowings
Loans, excluding accrued interest	€ 1,218
France 0.55%
Borrowings
Nominal interest rate	0.55%	0.55%
Loans, excluding accrued interest	€ 10,742	€ 8,650
France 0.55% \| Fair value disclosed
Borrowings
Loans, excluding accrued interest	€ 10,038	€ 8,559

Provisions (Details)

Provisions (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Provisions
Current provisions	€ 54,410	€ 39,260
Non-current provisions	16,427	18,021
Other personnel expenses
Provisions
Current provisions	47,490	33,983
Non-current provisions	1,209	2,029
Pensions
Provisions
Current provisions	1,730	1,478
Non-current provisions	12,531	12,950
Other provisions
Provisions
Current provisions	5,190	3,799
Non-current provisions	€ 2,687	€ 3,042

Provisions - Development of Tot

Provisions - Development of Total Provisions (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Provisions
Balance at beginning of period	€ 57,281	€ 62,579
Business combination	1,259
Consumption	25,837	38,241
Release	7,960	11,478
Foreign exchange	(2,600)	1,291
Additions	48,694	43,130
Balance at end of period	70,837	57,281
Other personnel expenses
Provisions
Balance at beginning of period	36,012	37,005
Business combination	419
Consumption	23,105	33,018
Release	3,374	3,644
Foreign exchange	(2,525)	636
Additions	41,272	35,033
Balance at end of period	48,699	36,012
Pensions
Provisions
Balance at beginning of period	14,428	14,441
Business combination	553
Consumption	1,629	463
Release	1,404	813
Foreign exchange	(12)
Additions	2,325	1,263
Balance at end of period	14,261	14,428
Other provisions
Provisions
Balance at beginning of period	6,841	11,133
Business combination	287
Consumption	1,103	4,760
Release	3,182	7,021
Foreign exchange	(63)	655
Additions	5,097	6,834
Balance at end of period	€ 7,877	€ 6,841

Provisions Additional Informati

Provisions Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Provisions.
Bonus accrual	€ 26,704	€ 22,396
Accrued vacation	16,637	13,904
Provisions to address the risk of a potential divergent interpretation of selected contracts by the tax authorities	2,139	2,139
Earn-out provision	306	1,103
Audit fee provision	2,111	878
Maintenance fee provision	€ 1,483	€ 1,598

Contract liabilities (Details)

Contract liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Customers
Current contract liabilities	€ 122,922	€ 112,061
BMS
Customers
Contract liabilities	235,652	94,988
Current contract liabilities	€ 42,506	€ 62,568

Income Taxes - Amounts recognis

Income Taxes - Amounts recognised in consolidated income statement (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Tax
Net deferred tax assets	€ 10,327	€ 17,359
Current taxes:
Current tax expense	(14,132)	(12,309)	€ (12,804)
Adjustment for prior years	156	(4,095)	739
Total current taxes	(13,976)	(16,404)	(12,065)	[1]
Deferred taxes:
Tax loss carry forwards	(10,862)	(5,140)	(10,319)
Temporary differences	3,140	74	2,822
Total deferred taxes	(7,722)	(5,066)	(7,497)	[1]
Total taxes	€ (21,698)	€ (21,470)	(19,562)	[1]
Impact of applying IFRIC agenda decision on IAS 19
Tax
Net deferred tax assets			€ (558)

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of effective tax rates (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Tax
Income before taxes	€ (153,956)	€ 236,980	€ 25,840
Expected German income tax rate	32.28%	32.28%	32.28%
Expected income tax benefit (expense)	€ 49,697	€ (76,497)	€ (8,341)
Non-deductible expenses	(59,543)	(511)	(2,533)
Taxable income not recognised in income before tax			(7,796)
R&D tax credits	13,454	6,742	5,983
Tax free income	3,184	71,917	5,485
Permanent differences from GILTI	(3,724)	(444)	(1,401)
Tax effects from investments accounted for using the equity method	(5,152)	(9,300)	(2,884)
Deviation tax rates to expected tax rate	448	1,815	690
Change in tax rates	636	521	124
Change in recognition of deferred tax assets	(19,167)	(10,247)	(9,317)
Current Taxes	156	(4,095)	739
Deferred Taxes	(1,348)	(570)	203
Other	(339)	(801)	(514)
Total taxes	€ (21,698)	€ (21,470)	€ (19,562)	[1]
Effective income tax rate	(14.09%)	9.06%	75.70%
Solidarity surcharge rate	15.825%
Minimum
Tax
Trade tax rate	10.85%
Maximum
Tax
Trade tax rate	16.625%

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Income Taxes - Deferred income

Income Taxes - Deferred income tax assets and liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Tax
Net, Balance at beginning of period	€ (329)	€ 3,993
Recognised in profit or loss	(7,722)	(5,066)	€ (7,497)	[1]
Recognised in other comprehensive income	(990)	715
Foreign currency translation	518	29
Acquisition	326
Net, Balance at end of period	(8,197)	(329)	3,993
Deferred tax asset	59,215	58,461
Deferred tax liabilities	(67,412)	(58,790)
Deferred tax liabilities offset against assets	(48,888)	(41,102)
Deferred tax assets offset against liabilities	48,888	41,102
Net deferred tax assets	10,327	17,359
Net deferred tax liabilities	(18,524)	(17,688)
Property, plant and equipment
Tax
Net, Balance at beginning of period	(4,855)	(2,840)
Recognised in profit or loss	(5,140)	(1,969)
Foreign currency translation	508	(46)
Acquisition	30
Net, Balance at end of period	(9,457)	(4,855)	(2,840)
Deferred tax asset	1,563	1,528
Deferred tax liabilities	(11,020)	(6,383)
Intangible assets other than goodwill
Tax
Net, Balance at beginning of period	(22,348)	(25,314)
Recognised in profit or loss	2,536	3,296
Foreign currency translation	(130)	(330)
Acquisition	296
Net, Balance at end of period	(19,646)	(22,348)	(25,314)
Deferred tax asset	965	468
Deferred tax liabilities	(20,611)	(22,816)
Right-of use assets
Tax
Net, Balance at beginning of period	(21,979)	(23,535)
Recognised in profit or loss	(6,860)	1,556
Net, Balance at end of period	(28,839)	(21,979)	(23,535)
Deferred tax liabilities	(28,839)	(21,979)
Financial assets
Tax
Net, Balance at beginning of period	(3,985)	(316)
Recognised in profit or loss	2,539	(3,669)
Net, Balance at end of period	(1,446)	(3,985)	(316)
Deferred tax asset	453	401
Deferred tax liabilities	(1,899)	(4,386)
Provisions and deferred income
Tax
Net, Balance at beginning of period	3,965	4,801
Recognised in profit or loss	5,640	(768)
Recognised in other comprehensive income	(357)	7
Foreign currency translation	2	(75)
Net, Balance at end of period	9,250	3,965	4,801
Deferred tax asset	12,759	6,516
Deferred tax liabilities	(3,509)	(2,551)
Lease obligations
Tax
Net, Balance at beginning of period	19,927	23,274
Recognised in profit or loss	5,351	(3,347)
Net, Balance at end of period	25,278	19,927	23,274
Deferred tax asset	25,278	20,297
Deferred tax liabilities		(370)
Other
Tax
Net, Balance at beginning of period	4,949	(1,309)
Recognised in profit or loss	(727)	6,245
Foreign currency translation	22	13
Net, Balance at end of period	4,244	4,949	(1,309)
Deferred tax asset	5,778	5,254
Deferred tax liabilities	(1,534)	(305)
Tax credits
Tax
Net, Balance at beginning of period	1,034	1,521
Recognised in profit or loss	(199)	(1,270)
Recognised in other comprehensive income	(633)	708
Foreign currency translation	71	75
Net, Balance at end of period	273	1,034	1,521
Deferred tax asset	273	1,034
Tax loss carryforwards
Tax
Net, Balance at beginning of period	22,963	27,711
Recognised in profit or loss	(10,862)	(5,140)
Foreign currency translation	45	392
Net, Balance at end of period	12,146	22,963	€ 27,711
Deferred tax asset	€ 12,146	€ 22,963

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Income Taxes - Unrecognized def

Income Taxes - Unrecognized deferred tax (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income taxes
Unrecognized deferred tax liabilities	€ 20,576	€ 12,009

Income Taxes - Unrecognized d_2

Income Taxes - Unrecognized deferred tax assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Tax
Unused tax losses, interest carryforwards and tax credits for which no deferred tax asset recognised	€ 592,957	€ 442,395	€ 382,528
Unrecognized deferred tax assets for temporary differences	11,354	6,346	2,707
Tax loss carryforwards \| Not expiring
Tax
Unused tax losses, interest carryforwards and tax credits for which no deferred tax asset recognised	474,989	307,682	272,796
Tax loss carryforwards \| Not later than five years
Tax
Unused tax losses, interest carryforwards and tax credits for which no deferred tax asset recognised	13,297	21,409	19,259
Tax loss carryforwards \| Later than five years and not later than ten years
Tax
Unused tax losses, interest carryforwards and tax credits for which no deferred tax asset recognised	45,696	38,207	45,409
Tax loss carryforwards \| Later than ten years
Tax
Unused tax losses, interest carryforwards and tax credits for which no deferred tax asset recognised	57,662	73,811	43,945
Tax credits
Tax
Unused tax losses, interest carryforwards and tax credits for which no deferred tax asset recognised	€ 1,313	€ 1,286	€ 1,119

Other current financial liabi_2

Other current financial liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial instruments
Other current financial liabilities	€ 7,087	€ 12,115
Foreign currency forward contracts
Financial instruments
Other current financial liabilities	€ 7,087	8,565
Other liabilities
Financial instruments
Other current financial liabilities		€ 3,550

Stock-based compensation - Shar

Stock-based compensation - Share Performance Awards (Details)	12 Months Ended
	Dec. 31, 2022 Y item € / shares shares
Share-based payments
Contribution per share \| € / shares	€ 1
Restricted Share Awards
Share-based payments
Number of subscription rights to shares \| item	1
Restricted Share Awards \| Restricted Share Plan 2020
Share-based payments
Number of bearer shares that may be granted	1,200,000
Vesting period for share-based payments	4 years
Maximum exercise period for share-based payments	5 years
Threshold number of consecutive calendar years for achievement of targets \| Y	4
Share Performance Awards
Share-based payments
Number of subscription rights to shares \| item	2
Number of shares to which one subscription right entitles	1
Share Performance Awards \| Share Performance Plan 2017 and 2022
Share-based payments
Number of trading days for exercise of shares	10 days
Holding period for share-based payments	4 years
Number of key performance indicators in share-based payments \| item	2
Threshold number of consecutive calendar years for achievement of targets \| Y	4
Share Performance Awards \| Share Performance Plan 2017
Share-based payments
Number of bearer shares that may be granted	6,000,000
Share Performance Awards \| Share Performance Plan 2022
Share-based payments
Number of bearer shares that may be granted	6,000,000

Stock-based compensation - Stat

Stock-based compensation - Status of the Share Performance Plans (Details)	12 Months Ended
	Dec. 31, 2022 EquityInstruments € / shares shares	Dec. 31, 2021 EquityInstruments € / shares shares	Dec. 31, 2020 EquityInstruments € / shares shares
Share-based payments
SPAs exercised	€ 1	€ 1
Share Performance Awards
Share-based payments
Outstanding at beginning of the year \| EquityInstruments	1,325,450	1,570,113	2,149,562
SPAs granted \| EquityInstruments	468,706	608,710	325,612
SPAs exercised \| EquityInstruments	(209,043)	(701,278)	(865,687)
SPAs forfeited \| EquityInstruments	(80,475)	(152,095)	(39,374)
Outstanding at end of the year \| EquityInstruments	1,504,638	1,325,450	1,570,113
Thereof exercisable \| EquityInstruments			432,450
Outstanding at beginning of the year	€ 1	€ 1	€ 1
SPAs granted	1	1	1
SPAs exercised	1	1	1
SPAs forfeited	1	1	1
Outstanding at the end of the year	1	1	1
Thereof exercisable	1	1	1
Weighted average share price	€ 34.27	€ 37.97	€ 24.26
Number of shares issued on exercise of awards \| shares	344,458	1,195,954	1,501,254
Share Performance Awards \| Management Board
Share-based payments
SPAs granted \| EquityInstruments	139,229	160,048	77,214

Stock-based compensation - The

Stock-based compensation - The fair value of the grant of Share Performance Awards was estimated on the date of grant (Details) - EUR (€)									12 Months Ended
	Oct. 27, 2022	May 27, 2022	Jan. 28, 2022	Oct. 22, 2021	May 28, 2021	Feb. 01, 2021	Oct. 29, 2020	Jan. 15, 2020	Dec. 31, 2022
Share Performance Awards
Share-based payments
Risk free interest rate, share-based payments	2.03%	0.57%	(0.46%)	(0.43%)	(0.57%)	(0.78%)	(0.85%)	(0.55%)
Expected volatility of share, share based-payments	51%	45%	37%	35%	40%	42%	40%	37%
Expected volatility of index, share based-payments			17%			29%		18%
Fluctuation, share based-payments	5%			5%			5%
Exercise price, share-based payments	€ 1	€ 1	€ 1	€ 1	€ 1	€ 1	€ 1	€ 1
Share price at grant date, share based-payments	19.47	25.26	€ 34.90	44.98	35.49	€ 32.25	22.92	€ 23.39
Market value of index, share based-payments			€ 3,411.87			€ 3,375.67		€ 3,099.05
Fair value for Management Board, share based-payments		22.87	€ 31.30		33.50	€ 31.34		€ 22.69
Fair value for executives, share based-payments	€ 18.57	€ 24.29	€ 33.66	€ 43.96	€ 34.47	€ 36.65	€ 21.89	€ 25.28
Expected dividend as percentage, share-based payments									0%
Share Performance Awards \| Minimum
Share-based payments
Fluctuation, share based-payments		0%	0%		0%	0%		0%
Share Performance Awards \| Maximum
Share-based payments
Fluctuation, share based-payments		5%	5%		5%	5%		5%
Vesting periods starting in January
Share-based payments
Expected life, share based-payments									4 years
Vesting eriods starting in May and October
Share-based payments
Expected life, share based-payments									5 years

Stock-based compensation - Sh_2

Stock-based compensation - Share option plans (Details)	12 Months Ended
Stock-based compensation - Share option plans (Details)	Dec. 31, 2020 EquityInstruments € / shares
Stock-based compensation
Outstanding at beginning of the year \| EquityInstruments	32,594
Options exercised \| EquityInstruments	(32,594)
Outstanding at beginning of the year	€ 2.79
Options exercised	2.79
Weighted average share price, share options granted	€ 25.17

Stock-based compensation - Addi

Stock-based compensation - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Performance Awards and Restricted Share Awards Plans
Share-based payments
Stock compensation expense	€ 9,919	€ 7,805	€ 5,285
Option Plans
Share-based payments
Stock compensation expense	0	0	0
Management Board \| Share Performance Awards
Share-based payments
Stock compensation expense	€ 2,791	€ 2,002	€ 1,902

Stockholders' equity - Share ca

Stockholders' equity - Share capital (Details) - shares	12 Months Ended
Stockholders' equity - Share capital (Details) - shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' equity
Beginning balance (Shares)	176,608,195	163,915,000	150,903,000
Capital increase (cash contribution)		11,497,000	11,478,000
Exercise of share purchase rights	345,000	1,196,000	1,534,000
Ending balance (Shares)	176,952,653	176,608,195	163,915,000

Stockholders' equity - Raised C

Stockholders' equity - Raised Capital (Details) - € / shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stockholders' equity
Number of shares issued	176,952,653	176,608,195	163,915,000	150,903,000
Number of shares outstanding	176,952,653	176,608,195
Nominal amount per share	€ 1

Stockholders' equity - Addition

Stockholders' equity - Additional information (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity
Exercise price for SPAs exercised	€ 1	€ 1
Shares available to issue	42,732,865
Additional capital authorised	€ 35,321,639
Number of shares in entity held by entity or by its subsidiaries or associates	249,915	249,915	250,000	250,000
Proportion of treasury shares to total share capital	0.10%	0.10%
Share Performance Plans and the Stock Option Plans
Equity
Shares available to issue	12,773,576
Owners or creditors, participation rights and/or income bonds
Equity
Shares available to issue	29,959,289

Revenues - Recognised Revenues

Revenues - Recognised Revenues (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue
Revenues	€ 751,448	€ 618,034	€ 500,924	[1]
United States
Revenue
Revenues	418,305	337,602	247,848
Germany
Revenue
Revenues	58,895	46,852	44,321
France
Revenue
Revenues	32,274	30,591	37,060
United Kingdom
Revenue
Revenues	115,256	104,640	93,987
Rest of the world
Revenue
Revenues	126,718	98,349	77,708
At a point in time
Revenue
Revenues	62,502	85,460	38,927
Over a period of time
Revenue
Revenues	688,946	532,574	461,997
Service fees and FTE-based research payments
Revenue
Revenues	683,987	530,754	460,594
Material recharges
Revenue
Revenues	44,436	35,991	21,835
Compound access fees
Revenue
Revenues	2,573	1,575	1,361
Milestone fees
Revenue
Revenues	18,066	49,469	17,092
Licences
Revenue
Revenues	2,386	245	42
EVT Execute
Revenue
Revenues	546,718	471,052	394,094
EVT Execute \| United States
Revenue
Revenues	283,755	236,009	189,488
EVT Execute \| Germany
Revenue
Revenues	32,765	24,279	19,529
EVT Execute \| France
Revenue
Revenues	22,546	16,876	21,499
EVT Execute \| United Kingdom
Revenue
Revenues	105,557	98,735	89,258
EVT Execute \| Rest of the world
Revenue
Revenues	102,095	95,153	74,320
EVT Execute \| At a point in time
Revenue
Revenues	44,722	38,336	25,787
EVT Execute \| Over a period of time
Revenue
Revenues	501,996	432,716	368,307
EVT Execute \| Service fees and FTE-based research payments
Revenue
Revenues	498,719	431,184	366,946
EVT Execute \| Material recharges
Revenue
Revenues	38,668	34,104	20,728
EVT Execute \| Compound access fees
Revenue
Revenues	1,464	1,532	1,361
EVT Execute \| Milestone fees
Revenue
Revenues	6,054	4,232	5,059
EVT Execute \| Licences
Revenue
Revenues	1,813
EVT Innovate
Revenue
Revenues	204,730	146,982	106,830
EVT Innovate \| United States
Revenue
Revenues	134,550	101,593	58,360
EVT Innovate \| Germany
Revenue
Revenues	26,130	22,573	24,792
EVT Innovate \| France
Revenue
Revenues	9,728	13,715	15,561
EVT Innovate \| United Kingdom
Revenue
Revenues	9,699	5,905	4,729
EVT Innovate \| Rest of the world
Revenue
Revenues	24,623	3,196	3,388
EVT Innovate \| At a point in time
Revenue
Revenues	17,780	47,124	13,140
EVT Innovate \| Over a period of time
Revenue
Revenues	186,950	99,858	93,690
EVT Innovate \| Service fees and FTE-based research payments
Revenue
Revenues	185,268	99,570	93,648
EVT Innovate \| Material recharges
Revenue
Revenues	5,768	1,887	1,107
EVT Innovate \| Compound access fees
Revenue
Revenues	1,109	43
EVT Innovate \| Milestone fees
Revenue
Revenues	12,012	45,237	12,033
EVT Innovate \| Licences
Revenue
Revenues	€ 573	€ 245	€ 42

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Revenues - Additional informati

Revenues - Additional information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Transaction price
Revenues	€ 751,448	€ 618,034	€ 500,924	[1]
EVT Execute
Transaction price
Revenues	546,718	471,052	394,094
Contributions \| EVT Execute
Transaction price
Revenues	10,551	8,565	4,648
BMS
Transaction price
Revenue from contracts with customers	€ 138,737	€ 98,616	62,561
BMS \| Minimum
Transaction price
Percentage of entity's revenue	10%	10%
Within one year
Transaction price
Transaction price allocated to the remaining performance obligation	€ 405,710	€ 225,061	377,216
After one year
Transaction price
Transaction price allocated to the remaining performance obligation	€ 158,068	€ 67,619	€ 69,328

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Research and Development (Detai

Research and Development (Details) - EUR (€) € in Thousands	12 Months Ended
Research and Development (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Expenses
Research and development expenses relating to overhead expenses	€ 12,198	€ 8,136	€ 9,341
EVT Innovate
Expenses
Research and development expenses relating to own projects	62,100	64,064	55,992
EVT Execute
Expenses
Research and development expenses relating to own projects	2,345	2,528	3,636
Research and development expense
Expenses
Depreciation and amortisation expense	€ 471	€ 1,042	€ 789

Selling, general and administ_2

Selling, general and administrative expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Expenses
Sales and marketing expense	€ 13,491	€ 9,422	€ 9,503
Other administrative expenses	142,699	96,023	67,356
Selling, general and administrative expense
Expenses
Depreciation and amortisation expense	€ 38,025	€ 24,957	€ 19,840

Other operating income (Details

Other operating income (Details) - EUR (€) € in Thousands	12 Months Ended
Other operating income (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
France
Other operating income
Refunds related to tax development programmes	€ 25,068	€ 22,691	€ 19,308
Italy
Other operating income
Refunds related to tax development programmes	7,342	2,784	124
United Kingdom
Other operating income
Refunds related to tax development programmes	7,250	6,502	4,337
Germany
Other operating income
Refunds related to tax development programmes	3,280	0	0
Sanofi
Other operating income
Refunds related to development of portfolios	€ 34,174	€ 35,762	€ 43,398

Financial instruments - Currenc

Financial instruments - Currency risks (Details)	12 Months Ended
Financial instruments - Currency risks (Details)	Dec. 31, 2022 € / $	Dec. 31, 2022 € / £ € / $	Dec. 31, 2021 € / $	Dec. 31, 2021 € / $ € / £	Dec. 31, 2022 € / £	Dec. 31, 2021 € / £
Financial instruments
Average currency rates	0.9496	1.1727	0.8455	1.1633
Currency rates	0.9376	0.9376	0.8829	0.8829	1.1275	1.1901

Financial instruments - Analysi

Financial instruments - Analysis of financial instruments (Details) - Currency risks - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
USD
Financial instruments
Percentage strengthening in rate	10%	10%	10%
Percentage weakening in rate	10%	10%	10%
Variance in equity from strengthening in rate	€ 31,007	€ 42,053	€ 11,321
Variance in equity from weakening in rate	(31,007)	(42,053)	(11,321)
Variance in profit and loss from strengthening in rate	31,007	42,053	11,321
Variance in profit and loss from weakening in rate	€ (31,007)	€ (42,053)	€ (11,321)
GBP
Financial instruments
Percentage strengthening in rate	10%	10%	10%
Percentage weakening in rate	10%	10%	10%
Variance in equity from strengthening in rate	€ 3,967	€ 6,643	€ 5,702
Variance in equity from weakening in rate	(3,967)	(6,643)	(5,702)
Variance in profit and loss from strengthening in rate	3,967	6,643	5,702
Variance in profit and loss from weakening in rate	€ (3,967)	€ (6,643)	€ (5,702)
EUR
Financial instruments
Percentage strengthening in rate	10%	10%	10%
Percentage weakening in rate	10%	10%	10%
Variance in equity from strengthening in rate	€ 34,974	€ 48,699	€ 17,032
Variance in equity from weakening in rate	(34,974)	(48,699)	(17,032)
Variance in profit and loss from strengthening in rate	34,974	48,699	17,032
Variance in profit and loss from weakening in rate	€ (34,974)	€ (48,699)	€ (17,032)

Financial instruments (Details)

Financial instruments (Details) - Currency risks - Foreign currency forward contracts € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Financial instruments
Gains and losses from the fair value accounting related to foreign currency derivatives \| €	€ 9,424	€ (12,410)	€ (20)
Cash flows economically hedged, amount				$ 394,039	$ 344,830	$ 70,500
EUR
Financial instruments
Cash flows economically hedged, amount				349,639	300,430	45,000
GBP
Financial instruments
Cash flows economically hedged, amount	€ 8,400			$ 44,400	$ 44,400	$ 25,500

Financial instruments - Interes

Financial instruments - Interest rate risks (Details) - Variable interest rates - Interest rate risks - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial instruments
Variable interest rate increase	1%	1%
Variable interest rate decrease	1%	1%
Impact on income before taxes from increase in assumption	€ 3,014	€ 2,570	€ 415
Impact on income before taxes from decrease in assumption	(1,714)	(827)	€ (415)
Impact on fair value of instrument from increase in assumption	3,014	2,570
Impact on fair value of instrument from decrease in assumption	€ (1,714)	€ (827)

Financial instruments - Inter_2

Financial instruments - Interest rate swaps hedge (Details) - Interest rate risks € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€) item	Jun. 30, 2019 EUR (€) item
Interest rate swap
Financial instruments
Number of swaps entered \| item		2	2
Notional amount		€ 22,500	€ 48,250
Net gain (loss) on redemption of swaps	€ (4,683)
Interest rate swap one
Financial instruments
Borrowings, swapped fixed rate			0.17%
Interest rate swap two
Financial instruments
Borrowings, swapped fixed rate			0.24%

Risks (Details)

Risks (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Carrying amount
Loans	€ (329,851)	€ (362,480)
Lease obligations	(176,823)	(150,437)	€ (145,554)
Contingent consideration	(306)	(1,103)
Trade accounts payable	(97,277)	(72,598)
Other financial liabilities	(977)	(4,017)
Total non-derivative financial liabilities	(605,234)	(590,635)
Interest rate swaps/FX forwards	(7,358)	(9,344)
Total derivative financial liabilities	(7,358)	(9,344)
Non-derivative financial liabilities
Loans	(345,522)	(382,867)
Lease obligations	(186,894)	(175,040)
Contingent consideration	(372)	(1,156)
Trade accounts payable	(97,277)	(72,598)
Other financial liabilities	(977)	(4,017)
Total non-derivative financial liabilities	(631,042)	(635,678)
Derivative financial liabilities
Interest rate swaps/FX forwards	(7,358)	(9,344)
Total derivative financial liabilities	(7,358)	(9,344)
Due in 1 year
Non-derivative financial liabilities
Loans	(7,266)	(40,467)
Lease obligations	(19,422)	(17,343)
Contingent consideration	(76)	(1,156)
Trade accounts payable	(97,277)	(72,598)
Other financial liabilities	(977)	(4,017)
Total non-derivative financial liabilities	(125,018)	(135,581)
Derivative financial liabilities
Interest rate swaps/FX forwards	(6,965)	(7,423)
Total derivative financial liabilities	(6,965)	(7,423)
Due in 2 - 5 years
Non-derivative financial liabilities
Loans	(272,749)	(253,391)
Lease obligations	(78,152)	(69,396)
Contingent consideration	(291)
Total non-derivative financial liabilities	(351,192)	(322,787)
Derivative financial liabilities
Interest rate swaps/FX forwards	(393)	(1,660)
Total derivative financial liabilities	(393)	(1,660)
More than 5 years
Non-derivative financial liabilities
Loans	(65,507)	(89,009)
Lease obligations	(89,320)	(88,301)
Contingent consideration	(5)
Total non-derivative financial liabilities	€ (154,832)	(177,310)
Derivative financial liabilities
Interest rate swaps/FX forwards		(261)
Total derivative financial liabilities		€ (261)

Risks - Capital management risk

Risks - Capital management risk (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Risks
Total assets	€ 2,257,247	€ 2,235,161
Equity attributable to the shareholders of Evotec SE	€ 1,187,184	€ 1,377,685
Equity ratio (in %)	52.60%	61.60%
Net cash	€ (91,518)	€ 186,409

Risks - Credit risks (Details)

Risks - Credit risks (Details) - EUR (€) € in Thousands	12 Months Ended
Risks - Credit risks (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
One customer
Credit risk
Receivables percentage	22%	23%
Trade accounts receivables
Credit risk
Maximum exposure to credit risk	€ 168,653	€ 132,078
Trade accounts receivables \| United States
Credit risk
Maximum exposure to credit risk	92,034	78,543
Trade accounts receivables \| France
Credit risk
Maximum exposure to credit risk	24,429	17,098
Trade accounts receivables \| United Kingdom
Credit risk
Maximum exposure to credit risk	20,451	12,391
Trade accounts receivables \| Germany
Credit risk
Maximum exposure to credit risk	7,767	6,283
Trade accounts receivables \| Rest of Europe
Credit risk
Maximum exposure to credit risk	13,622	10,363
Trade accounts receivables \| Rest of the world
Credit risk
Maximum exposure to credit risk	10,350	7,400
Contract assets
Credit risk
Maximum exposure to credit risk	€ 30,516	€ 18,614

Risks - Reconciliation of cash

Risks - Reconciliation of cash flows from financing activities to the changes in financial liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liabilities from financing activities
Proceeds from issuance of loans		€ 30,791	€ 21,539	[1]
Repayment	€ (34,067)	(16,018)	(6,520)	[1]
Loan liabilities
Liabilities from financing activities
As of 1 January	362,480	346,411
Proceeds from issuance of loans		30,791
Repayment	(34,067)	(16,018)
Cashflow from financing activities	(34,067)	14,773
Changes in fair value		160
Interest increase	1,438	1,136
As of 31 December	329,851	362,480	346,411
Lease obligations
Liabilities from financing activities
As of 1 January	150,437	145,554
Repayment	(19,046)	(19,770)
Cashflow from financing activities	(19,046)	(19,770)
Disposal of finance lease obligation	(232)	(58)
Foreign currency translation	(1,120)	6,691
Interest increase	4,068	3,728
Issue of finance lease obligation	42,716	14,292
As of 31 December	176,823	150,437	145,554
Loan notes
Liabilities from financing activities
As of 1 January	3	3
As of 31 December	€ 3	€ 3	€ 3

[1]Includes the impacts of the IFRIC final agenda decisions of April 2021 of benefits to periods of service, as described in Note 2 “First time adoption of new accounting standards in the financial year 2021”

Fair values (Details)

Fair values (Details) € in Thousands	12 Months Ended
Fair values (Details) € in Thousands	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Fair values
Transfer of assets from level 1 to level 2	€ 0	€ 0
Transfer of assets from level 2 to level 1	0	0
Transfer of assets into level 3	0	0
Transfer of assets out of level 3	0	0
Transfer of liabilities from level 1 to level 2	0	0
Transfer of liabilities from level 2 to level 1	0	0
Transfer of liabilities into level 3	0	0
Transfer of liabilities out of level 3	€ 0	€ 0
Long-term credit liabilities \| Discount rate
Fair values
Significant unobservable input, liabilities	0.0306

Fair values - Summary of fair v

Fair values - Summary of fair values of financial assets and liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
At fair value
Financial instruments
Financial assets (liabilities)	€ 434,927	€ 417,254
Financial assets (liabilities) at fair value	434,927	417,254
Amortised cost, liabilities \| Non-current loan liabilities \| Level 3
Financial instruments
Financial liabilities	328,295	326,344
Financial liabilities, at fair value	306,574	336,412
Fair value through profit and loss, liabilities
Financial instruments
Financial liabilities, at fair value	(7,664)	(10,447)
Fair value through profit and loss, liabilities \| Level 2
Financial instruments
Financial liabilities, at fair value	(7,358)	(9,344)
Fair value through profit and loss, liabilities \| Level 3
Financial instruments
Financial liabilities, at fair value	(306)	(1,103)
Fair value through profit and loss, liabilities \| Derivative financial instruments, liabilities \| At fair value
Financial instruments
Financial liabilities	(7,358)	(9,344)
Financial liabilities, at fair value	(7,358)	(9,344)
Fair value through profit and loss, liabilities \| Contingent consideration \| At fair value
Financial instruments
Financial liabilities	(306)	(1,103)
Financial liabilities, at fair value	(306)	(1,103)
Fair value through other comprehensive income
Financial instruments
Financial assets, at fair value	311,899	158,908
Fair value through other comprehensive income \| Level 1
Financial instruments
Financial assets, at fair value	311,899	158,908
Fair value through other comprehensive income \| Investments \| At fair value
Financial instruments
Financial assets	311,899	158,908
Financial assets, at fair value	311,899	158,908
Fair value through profit and loss, assets
Financial instruments
Financial assets, at fair value	130,692	268,793
Fair value through profit and loss, assets \| Level 1
Financial instruments
Financial assets, at fair value	70,133	244,866
Fair value through profit and loss, assets \| Level 2
Financial instruments
Financial assets, at fair value	8,215
Fair value through profit and loss, assets \| Level 3
Financial instruments
Financial assets, at fair value	52,344	23,927
Fair value through profit and loss, assets \| Long-term investments \| At fair value
Financial instruments
Financial assets	122,477	268,793
Financial assets, at fair value	122,477	268,793
Fair value through profit and loss, assets \| Derivative financial instruments, assets \| At fair value
Financial instruments
Financial assets	8,215	0
Financial assets, at fair value	€ 8,215	€ 0

Fair values - Summary of moveme

Fair values - Summary of movement of financial assets and liabilities accounted for at fair values at level 3 (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Other investments
Balance at the beginning	€ 2,235,161
Balance at the end	2,257,247	€ 2,235,161
Level 3 \| Contingent consideration
Contingent consideration
Balance at the beginning	(1,103)	(6,381)
Exchange rate differences		(268)
Addition	(14)
Consumption		445
Reclassification to Liabilities		3,571
Net income/expense effected	811	1,530
Balance at the end	(306)	(1,103)
Level 3 \| Long-term investments
Other investments
Balance at the beginning	23,927	19,289
Addition	25,846	6,647
Net income/expense effected	2,571	(2,009)
Balance at the end	€ 52,344	€ 23,927

Fair values - Summary for the f

Fair values - Summary for the fair value of the level 3 hierarchy, possible alternative assumptions of significant unobservable inputs (Details) - Level 3 - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Discount rate \| Contingent consideration
Fair values
Increase in input	1.50%	1.50%
Decrease in input	1.50%	1.50%
Increase (decrease) in net result due to increase in input	€ (7)	€ (11)
Increase (decrease) in net result due to decrease in input	€ 7	€ 11
Discount rate \| Long-term investments
Fair values
Increase in input	1.50%	1.50%
Decrease in input	1.50%	1.50%
Increase (decrease) in net result due to increase in input	€ (8,478)	€ (4,118)
Increase (decrease) in net result due to decrease in input	€ 12,539	€ 6,279
Commercialization success rate \| Contingent consideration
Fair values
Increase in input	10%	10%
Decrease in input	10%	10%
Increase (decrease) in net result due to increase in input		€ 109
Increase (decrease) in net result due to decrease in input		€ (109)

Pension plan - Group Personal P

Pension plan - Group Personal Pension Plan (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
United Kingdom
Pension plan
Pension charge for the year	€ 3,346	€ 4,519
Contributions payable	379	152
United States
Pension plan
Pension charge for the year	€ 575	€ 646

Pension plan - Pension Benefit

Pension plan - Pension Benefit Plan Obligation (Details) - France	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension plan
Actuarial interest rate	3.35%	0.80%
Salary increase	3%	1.90%
Retirement age	62 years	62 years
Duration	8 years 8 months 12 days	9 years 2 months 12 days
Minimum
Pension plan
Employee turnover	0%	0%
Maximum
Pension plan
Employee turnover	2.51%	1.10%

Pension plan - actuarial intere

Pension plan - actuarial interest rate and the resulting change of the relating pension provision (Details) - France - Interest rate - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Pension plan
Increase in assumption	0.50%	0.50%
Decrease in assumption	0.50%	0.50%
Change of relating pension provision due to increase in assumption	€ (550)	€ (626)
Change of relating pension provision due to decrease in assumption	€ 592	€ 676

Pension plan - Additional Infor

Pension plan - Additional Information (Details) - Germany	Dec. 31, 2022	Dec. 31, 2021
Evotec DS
Pension plan
Assumed pension increases	2%
Discount rate	3.70%
Former member of the Management Board of Evotec SE
Pension plan
Assumed pension increases	2%	1.50%
Discount rate	3.51%	1.06%

Pension plan - Pension Provisio

Pension plan - Pension Provisions Development (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension plan
Pension provision at beginning of the year	€ 14,428	€ 14,441
Addition at acquisition date	553
Benefit payments from the employer	(692)	(468)
Actuarial gains/losses from:
Changes in financial assumptions	(1,899)	(551)
Experience adjustments	469	(116)
Impact of changes in demographic assumptions	10	3
Included in net income:
Current service costs	1,282	1,021
Interest cost	110	98
Pension provision at year-end	14,261	14,428
Within one year
Included in net income:
Expected payments of undiscounted benefits	1,751
Germany
Pension plan
Pension provision at beginning of the year	189
Included in net income:
Pension provision at year-end	722	€ 189
France
Included in net income:
Pension provision at year-end	€ 13,539

Commitments and contingencies -

Commitments and contingencies - Operating lease obligations (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases
Future minimum lease payments for leases signed but not yet recognised	€ 62,913	€ 57,870
Less than one year
Leases
Future minimum lease payments for leases signed but not yet recognised	1,561	801
Between one and five years
Leases
Future minimum lease payments for leases signed but not yet recognised	16,373	10,595
More than five years
Leases
Future minimum lease payments for leases signed but not yet recognised	€ 44,979	€ 46,474

Commitments and contingencies_2

Commitments and contingencies - Other commitments and contingency (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Commitments and contingencies
Future minimum payments for miscellaneous long-term commitments	€ 22,111	€ 9,459
Purchase commitments	€ 152,289	€ 66,154

Related party transactions (Det

Related party transactions (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related parties
Expenses for allowances on outstanding balances	€ 1,477	€ 8,969
Associated companies and joint ventures
Related parties
Revenues from Contracts/ Interest income	36,677	28,868	€ 35,450
Cost of revenue/ Interest expense		146	497
Other liabilities			5,635
Associated companies and joint ventures \| Trade accounts receivables
Related parties
Receivables	3,146	2,643	2,984
Associated companies and joint ventures \| Other financial assets
Related parties
Receivables	€ 925	€ 153	6,435
Other related party companies
Related parties
Revenues from Contracts/ Interest income			32,961
Other related party companies \| Trade accounts receivables
Related parties
Receivables			€ 6,492

Personnel expenses and cost o_2

Personnel expenses and cost of material (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Personnel expenses and cost of material
Personnel expenses	€ 388,050	€ 319,353	€ 250,082
Statutory retirement insurance expenses	15,106	12,407	10,065
Cost of materials	120,568	107,837	92,827
Foreign
Personnel expenses and cost of material
Personnel expenses	284,452	240,947	187,677
Statutory retirement insurance expenses	9,066	7,566	6,292
Cost of materials	€ 90,901	€ 83,275	€ 73,064

Other disclosures - Subsidiarie

Other disclosures - Subsidiaries and other Investments (Details)	Dec. 31, 2022
Aeovian Pharmaceuticals Inc., San Francisco, United States
Interests in other entities
Voting rights % held in other investments	3.79%
AgroBio SAS, Paris, France
Interests in other entities
Voting rights % held in other investments	10.02%
Aurobac Therapeutics SAS, Lyon, France
Interests in other entities
Voting rights % held in other investments	12.50%
Blacksmith Medicines Inc. San Diego, USA
Interests in other entities
Voting rights % held in other investments	18%
Cajal Neuroscience Inc., Seattle, USA
Interests in other entities
Voting rights % held in other investments	1.67%
Carma Fund I, Munich, Germany
Interests in other entities
Voting rights % held in other investments	10%
Carrick Therapeutics Ltd., Dublin, Ireland
Interests in other entities
Voting rights % held in other investments	3.48%
Centauri Therapeutics Ltd., Sandwich (Kent), United Kingdom
Interests in other entities
Voting rights % held in other investments	13.17%
Curie Bio LLC, Boston, United States
Interests in other entities
Voting rights % held in other investments	0.11%
Curie Bio Seed Fund I L.P., Boston, United States
Interests in other entities
Voting rights % held in other investments	2.82%
Exscientia plc (before: Exscientia Ltd.), Oxford, United Kingdom
Interests in other entities
Voting rights % held in other investments	11.42%
Extend Srl, Rome, Italy
Interests in other entities
Voting rights % held in other investments	10%
Fibrocor LLP, Toronto, Canada
Interests in other entities
Voting rights % held in other investments	16.26%
Fibrocor Therapeutics Inc., Toronto, Canada
Interests in other entities
Voting rights % held in other investments	8.98%
IMIDomics Inc., San Francisco, United States
Interests in other entities
Voting rights % held in other investments	11.77%
Immunitas, Therapeutics, Inc., Waltham, United States
Interests in other entities
Voting rights % held in other investments	6.17%
Leon Nanodrugs GmbH, Mnchen, Germany
Interests in other entities
Voting rights % held in other investments	13.24%
Mission BioCapital V LP, Cambridge, United States
Interests in other entities
Voting rights % held in other investments	3.64%
OxVax Limited, Oxford, United Kingdom
Interests in other entities
Voting rights % held in other investments	12.22%
Sernova Corp., Ontario, Canada
Interests in other entities
Voting rights % held in other investments	5.16%
Tubulis GmbH, Munich, Germany
Interests in other entities
Voting rights % held in other investments	6.90%
Ananke Therapeutics Inc, Boston, United States
Interests in other entities
Voting rights % held in associates and joint ventures	20.09%
Autobahn Labs, Palo Alto, United States
Interests in other entities
Voting rights % held in associates and joint ventures	35.94%
Breakpoint Therapeutics GmbH, Hamburg, Germany
Interests in other entities
Voting rights % held in associates and joint ventures	34.12%
Celmatix Inc., New York, United States
Interests in other entities
Voting rights % held in associates and joint ventures	39.09%
Curexsys GmbH, Gttingen, Germany
Interests in other entities
Voting rights % held in associates and joint ventures	43.44%
Dark Blue Therapeutics LTD, Oxford, United Kingdom
Interests in other entities
Voting rights % held in associates and joint ventures	39.11%
Eternygen GmbH, Berlin, Germany
Interests in other entities
Voting rights % held in associates and joint ventures	24.97%
NephThera GmbH, Hamburg, Germany
Interests in other entities
Voting rights % held in associates and joint ventures	50%
Pancella Inc, Toronto, Canada
Interests in other entities
Voting rights % held in associates and joint ventures	12.65%
Quantro Therapeutics GmbH, Wien, Austria
Interests in other entities
Voting rights % held in associates and joint ventures	38.79%
Topas Therapeutics GmbH, Hamburg, Germany
Interests in other entities
Voting rights % held in associates and joint ventures	22.14%
Tucana Biosciences Inc., Boston, United States
Interests in other entities
Voting rights % held in associates and joint ventures	26.92%
Aptuit Global LLC, Princeton, United States
Interests in other entities
Voting rights % held in subsidiary	100%
Aptuit (Verona) SRL, Verona, Italy
Interests in other entities
Voting rights % held in subsidiary	100%
Aptuit (Oxford) Ltd., Abingdon, United Kingdom
Interests in other entities
Voting rights % held in subsidiary	100%
Aptuit (Potters Bar) Ltd, Abingdon, United Kingdom
Interests in other entities
Voting rights % held in subsidiary	100%
Cyprotex Discovery Ltd., Manchester, United Kingdom
Interests in other entities
Voting rights % held in subsidiary	100%
Cyprotex Ltd., Manchester, United Kingdom
Interests in other entities
Voting rights % held in subsidiary	100%
Cyprotex US, LLC., Framingham, United States
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (France) SAS, Toulouse, France
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec ID (Lyon) SAS, Marcy l'Etoile, France
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (Hamburg) GmbH, Hamburg, Germany
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec GT GmbH, Orth an der Donau, Austria
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (India) Private Limited, Thane, India*
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec International GmbH, Hamburg, Germany
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (Munchen) GmbH, Martinsried, Germany
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (UK) Ltd., Abingdon, United Kingdom
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (US), Inc., Princeton, United States
Interests in other entities
Voting rights % held in subsidiary	100%
Just-Evotec Biologics, Inc, Seattle, United States
Interests in other entities
Voting rights % held in subsidiary	100%
Just-Evotec Biologics EU SAS, Toulouse, France
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec Drug Substance (Germany), Halle, Germany
Interests in other entities
Voting rights % held in subsidiary	100%
Evotec (Modena) Srl., Medolla, Italy
Interests in other entities
Voting rights % held in subsidiary	100%

Other disclosures - Management

Other disclosures - Management Board Remunerations (Details) - Management Board € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) EquityInstruments item	Dec. 31, 2021 EUR (€) EquityInstruments item
Remuneration
Number of strategic goals/targets \| item	9	8
Percentage of achievement of company-related targets	50%	40%
Percentage of achievement of corporate financial targets	50%	60%
Number of share-based programs \| item	2
Vesting period	4 years	4 years
Fixed remuneration (short-term)	€ 2,343	€ 1,928
Variable remuneration (short-term)	€ 1,579	€ 1,319
Share Performance and Restricted Share Awards \| EquityInstruments	139,229	160,048
Fair values of SPAs and RSAs granted	€ 4,580	€ 5,235
Total remuneration	€ 8,502	8,482
Percentage of shares assumed by third party for change-of-control	30%
Dr. Werner Lanthaler
Remuneration
Fixed remuneration (short-term)	€ 741	711
Variable remuneration (short-term)	€ 578	€ 590
Share Performance and Restricted Share Awards \| EquityInstruments	27,040	100,769
Fair values of SPAs and RSAs granted	€ 1,200	€ 3,313
Total remuneration	€ 2,519	4,614
Term of base salary for calculating severance payment	2 years
Dr. Cord Dohrmann
Remuneration
Fixed remuneration (short-term)	€ 469	451
Variable remuneration (short-term)	€ 335	€ 275
Share Performance and Restricted Share Awards \| EquityInstruments	13,520	40,956
Fair values of SPAs and RSAs granted	€ 600	€ 1,348
Total remuneration	€ 1,404	2,074
Term of base salary for calculating severance payment	18 months
Dr. Craig Johnstone
Remuneration
Fixed remuneration (short-term)	€ 442	382
Variable remuneration (short-term)	€ 270	€ 234
Share Performance and Restricted Share Awards \| EquityInstruments	48,500	9,439
Fair values of SPAs and RSAs granted	€ 1,400	€ 296
Total remuneration	€ 2,112	912
Term of base salary for calculating severance payment	18 months
Enno Spillner
Remuneration
Fixed remuneration (short-term)	€ 387	384
Variable remuneration (short-term)	€ 216	€ 220
Share Performance and Restricted Share Awards \| EquityInstruments	10,816	8,884
Fair values of SPAs and RSAs granted	€ 480	€ 278
Total remuneration	1,083	€ 882
Dr. Matthias Evers
Remuneration
Fixed remuneration (short-term)	304
Variable remuneration (short-term)	€ 180
Share Performance and Restricted Share Awards \| EquityInstruments	39,353
Fair values of SPAs and RSAs granted	€ 900
Total remuneration	€ 1,384

Other disclosures - Supervisory

Other disclosures - Supervisory Board Remuneration (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Remuneration
Supervisory Board share-based compensation	€ 0	€ 0
Supervisory Board
Remuneration
Remuneration	503,500	480,500
Supervisory Board \| Prof. Dr. Iris Lw-Friedrich
Remuneration
Remuneration	150,000	113,600
Supervisory Board \| Roland Sackers
Remuneration
Remuneration	95,000	90,500
Supervisory Board \| Dr. Mario Polywka
Remuneration
Remuneration	60,000	55,500
Supervisory Board \| Dr. Elaine Sullivan
Remuneration
Remuneration	65,300	60,000
Supervisory Board \| Kasim Kutay
Remuneration
Remuneration	28,400	60,000
Supervisory Board \| Dr. Constanze Ulmer-Eilfort
Remuneration
Remuneration	73,200	32,700
Supervisory Board \| Prof. Dr. Wolfgang Plischke
Remuneration
Remuneration		68,200
Supervisory Board \| Camilla Macapili Languille
Remuneration
Remuneration	31,600
Supervisory Board \| Members of Supervisory Board
Remuneration
Remuneration	50,000	50,000
Supervisory Board \| Chairperson of Supervisory Board
Remuneration
Remuneration	125,000	125,000
Supervisory Board \| Deputy Chairperson of Supervisory Board
Remuneration
Remuneration	60,000	60,000
Supervisory Board \| Members of Supervisory Board committees
Remuneration
Remuneration	10,000	10,000
Supervisory Board \| Chairperson of Supervisory Board committee
Remuneration
Remuneration	€ 25,000	€ 25,000